[go: up one dir, main page]

US20200148650A1 - Isoxazole carboxamide compounds - Google Patents

Isoxazole carboxamide compounds Download PDF

Info

Publication number
US20200148650A1
US20200148650A1 US16/588,209 US201916588209A US2020148650A1 US 20200148650 A1 US20200148650 A1 US 20200148650A1 US 201916588209 A US201916588209 A US 201916588209A US 2020148650 A1 US2020148650 A1 US 2020148650A1
Authority
US
United States
Prior art keywords
alkyl
optionally substituted
cancer
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/588,209
Inventor
Megan Alene Cloonan FOLEY
Kevin Wayne Kuntz
James Edward John MILLS
Lorna Helen Mitchell
Michael John Munchhof
Darren Martin Harvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Priority to US16/588,209 priority Critical patent/US20200148650A1/en
Publication of US20200148650A1 publication Critical patent/US20200148650A1/en
Assigned to Epizyme, Inc. reassignment Epizyme, Inc. TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Assignors: BIOPHARMA CREDIT PLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present disclosure provides substituted isoxazole carboxamides as SMYD protein inhibitors, such as SMYD3 and SMYD2 inhibitors, and therapeutic methods of treating conditions and diseases wherein inhibition of SMYD proteins such as SMYD3 and SMYD2 provides a benefit.
  • Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases.
  • Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence.
  • epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin.
  • methyltransferases e.g., SMYD proteins such as SMYD3 and SMYD2
  • the present disclosure provides substituted isoxazole carboxamide compounds represented by Formulae I-XVII below, and the pharmaceutically acceptable salts and solvates thereof, collectively referred to herein as “Compounds of the Disclosure.”
  • the present disclosure provides a Compound of the Disclosure and one or more pharmaceutically acceptable carriers.
  • the present disclosure provides a method of inhibiting SMYD proteins, such as SMYD3 or SMYD2, or both, in a mammal, comprising administering to the mammal an effective amount of at least one Compound of the Disclosure.
  • SMYD proteins such as SMYD3 or SMYD2
  • the present disclosure provides methods for treating a disease, disorder, or condition, e.g., cancer, responsive to inhibition of SMYD proteins, such as SMYD3 or SMYD2, or both, comprising administering a therapeutically effective amount of a Compound of the Disclosure.
  • a disease, disorder, or condition e.g., cancer
  • SMYD proteins such as SMYD3 or SMYD2
  • the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD3.
  • the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD2.
  • the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD proteins.
  • the present disclosure provides a pharmaceutical composition for treating a disease, disorder, or condition responsive to inhibition of SMYD proteins, such as SMYD3 or SMYD2, or both, wherein the pharmaceutical composition comprises a therapeutically effective amount of a Compound of the Disclosure in a mixture with one or more pharmaceutically acceptable carriers.
  • the present disclosure provides Compounds of the Disclosure for use in treating cancer in a mammal, e.g., breast, cervical, colon, kidney, liver, head and neck, skin, pancreatic, ovary, esophageal, lung, and prostate cancer.
  • a mammal e.g., breast, cervical, colon, kidney, liver, head and neck, skin, pancreatic, ovary, esophageal, lung, and prostate cancer.
  • the present disclosure provides a Compound of the Disclosure for use in the manufacture of a medicament for treating cancer in a mammal.
  • the present disclosure provides kit comprising a Compound of the Disclosure.
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD proteins.
  • the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions, e.g., cancer, responsive to inhibition of SMYD proteins.
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD3.
  • the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions. e.g., cancer, responsive to inhibition of SMYD3.
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD2.
  • the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions, e.g., cancer, responsive to inhibition of SMYD2.
  • Compounds of the Disclosure are compounds having Formula I:
  • R 1 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-4 alkenyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, and hydroxyalkyl;
  • R 2 is selected from the group consisting of hydrogen, halo, and carboxamido
  • A is selected from the group consisting of C 1-10 alkylenyl, (cycloalkylenyl)alkyl, optionally substituted C 3-12 cycloalkylenyl, optionally substituted C 6-14 arylenyl, optionally substituted 5- to 14-membered heteroarylenyl, optionally substituted 4- to 14-membered heterocyclenyl, and —C(H)R 3 R 4 ;
  • R 1 is ethyl, n-propyl, isopropyl, isobutyl, or cyclopropyl; and R 2 is hydrogen, then A is not optionally substituted, optionally bridged piperidinenyl;
  • R 1 is ethyl or cyclopropyl
  • R 2 is hydrogen
  • X is —N(R 7 )S(—O) 2 —, —N(R 7 )C( ⁇ O)—, or —N(R 7 )C( ⁇ O)C(R 8 )(H)—
  • A is not optionally substituted 1,4-cyclohexylenyl
  • R 1 is ethyl or cyclopropyl
  • R 2 is hydrogen
  • X is absent
  • Z is amino, alkylamino, dialkylamino, or heterocycloamino, then A is not optionally substituted 1,4-cyclohexylenyl
  • R 1 is hydrogen. C 1-6 alkyl, or Cm cycloalkyl; and R 2 is hydrogen, then A is not optionally substituted pyrrolidinenyl;
  • R 3 is selected from the group consisting of hydrogen, C 1-6 alkyl. (hydroxy)(aryl)alkyl, (amino)alkyl. (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, optionally substituted C 3-12 cycloalkyl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted C 6-14 aryl, aralkyl, alkoxycarbonyl, and —C( ⁇ O)N(R 5 )(R 6 );
  • R 4 is selected from the group consisting of C 1-6 alkyl, hydroxyalkyl, optionally substituted C 3-12 cycloalkyl, optionally substituted C 6-14 aryl, optionally substituted 5- to 14-membered heteroaryl, optionally substituted 4- to 14-membered heterocyclo, and (heteroaryl)alkyl;
  • R 5 is selected from the from the group consisting of hydrogen and C 1-4 alkyl
  • R 6 is selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, fluoroalkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(carboxamido)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl, (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C 6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C 3-12 cycloalkyl
  • X is selected from the group consisting of —S( ⁇ O) 2 —, —S( ⁇ O) 2 N(R 7 )—, —N(R 7 )S( ⁇ O) 2 —, —S( ⁇ O) 2 C(R 8 )(H)—, —C( ⁇ O)—, —C( ⁇ O)N(R 7 )—, —N(R 7 )C( ⁇ O)—, —C( ⁇ O)O—, —OC( ⁇ O)—, —C( ⁇ O)C(R 8 )(H)N(R 7 )—, —N(R 7 )C( ⁇ O)C(R 8 )(H)—, —C(R 8 )(H)C( ⁇ O)N(R 7 )—, —C(R 8 )(H)N(R 7 )—, —C(R 8 )(H)N(R 7 )—, and —C( ⁇ O)C(R 8
  • Z is selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, fluoroalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, heterocycloamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C 6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C 3-12 cyclo
  • —X—Z is attached to any available carbon or nitrogen atom of A, R 3 , R 4 , or R 6 ; e.g., when R 4 is C 1-6 alkyl. e.g., ethyl, a hydrogen atom of that ethyl group is replaced with —X—Z to give —CH 2 CH 2 —X—Z or
  • R 4 is optionally substituted C 3-12 cycloalkyl, e.g., cyclohexyl, a hydrogen atom of the cyclohexyl group is replaced with —X—Z to give:
  • R 4 is optionally substituted 4- to 14-membered heterocyclo, e.g., piperidinyl
  • the hydrogen atom attached to the piperidinyl nitrogen atom is replaced with —X—Z to give:
  • R 4 is optionally substituted C 6-14 aryl, e.g., phenyl, a hydrogen atom on that phenyl group is replaced with —X—Z to give:
  • R 7 is selected from the group consisting of hydrogen and C 1-4 alkyl
  • R 8 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and hydroxyalkyl.
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is C 1-10 alkylenyl.
  • Compounds of the Disclosure are compounds having Formula II:
  • R 9a and R 9b are independently selected from the group consisting of hydrogen and C 1-4 alkyl
  • R 9c and R 9d are independently selected from the group consisting of hydrogen and C 1-4 alkyl; or
  • R 9c and R 9d taken together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl
  • R 9e is selected from the group consisting of hydrogen and C 1-4 alkyl
  • n 0 or 1:
  • X is selected from the group consisting of —N(R 7 )C( ⁇ O)—, —N(R 7 )C( ⁇ O)C(R 8 )(H)—, and —N(R 7 )S( ⁇ O) 2 —;
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino;
  • Z is selected from the group consisting of C 1-6 alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted 4- to 14-membered heterocyclo, and optionally substituted C 1-4 , cycloalkyl, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted C 6-14 arylenyl.
  • Compounds of the Disclosure are compounds having Formula III:
  • R 10a is selected from the group consisting of hydrogen, halo, C 1-6 alkyl, alkoxy, hydroxyalkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C( ⁇ O)N(R 7 )—, —N(R 7 )C( ⁇ O)—, —C( ⁇ O)C(R 8 )(H)N(R 7 )—, —C(R 8 )(H)C( ⁇ O)N(R 7 )— and —S( ⁇ O) 2 N(R 7 )—; or X is absent;
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino;
  • Z is selected from the group consisting of hydrogen, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, heteroalkyl, (amino)(hydroxy)alkyl, (heterocyclo)alkyl, optionally substituted C 3-12 cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula IV:
  • R 10a is selected from the group consisting of hydrogen, halo. C 1-6 alkyl, alkoxy, hydroxyalkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C( ⁇ O)N(R 7 )—, —N(R 7 )C( ⁇ O)—, —C( ⁇ O)C(R 8 )(H)N(R 7 )—, —C(R 8 )(H)C( ⁇ O)N(R 7 )— and —S( ⁇ O) 2 N(R 7 )—; or X is absent;
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino;
  • Z is selected from the group consisting of hydrogen, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, heteroalkyl, (amino)hydroxy)alkyl, (heterocyclo)alkyl, optionally substituted C 3-12 cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted C 3-12 cycloalkylenyl.
  • Compounds of the Disclosure are compounds having Formula V:
  • R 10a and R 10b are independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • X is selected from the group consisting of —S( ⁇ O) 2 —, —S( ⁇ O) 2 N(R 7 )—, —N(R 7 )C( ⁇ O)—, —C( ⁇ O)N(R 7 )—, —N(R 7 )S( ⁇ O)—, and —OC( ⁇ O)—; or X is absent;
  • Z is selected from the group consisting of amino, alkylamino, dialkylamino, heterocycloamino. (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and (hydroxyalkylamino)alkyl; n is 0 or 1; and p is 0 or 1, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted 4- to 14-membered heterocyclenyl.
  • Compounds of the Disclosure are compounds having Formula VI:
  • R 11a and R 11b are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C( ⁇ O)—, —S( ⁇ O) 2 —, and —C( ⁇ O)C(R 8 )(H)—;
  • Z is selected from the group consisting of (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted C 3-12 cycloalkyl, and aralkyl; and
  • r is 0 or 1
  • R 1 , R 2 , and R 8 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula XVI:
  • R 11c and R 11d are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • X is selected from the group consisting of —C( ⁇ O)— and —S( ⁇ O) 2 ; or X is absent; and
  • R 1 , and R 2 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula XVI, and the pharmaceutically acceptable salts or solvates. e.g., hydrates, thereof, wherein R 11c and R 11d are hydrogen; X is absent; Z is selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, fluoroalkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl. (dialkylamino)alkyl.
  • R 2 is hydrogen; and R 1 is as defined above in connection with Formula I.
  • Z is selected from the group consisting of aralkyl, and (heteroaryl)alkyl.
  • Z is (heteroaryl)alkyl that is substituted with an aralkyl, e.g.,
  • R 1 is selected from the group consisting of C 1-4 alkyl and C 3-6 cycloalkyl.
  • Compounds of the Disclosure are compounds having Formula XVII:
  • R′′ is selected from the group consisting of aralkyl and (heteroaryl)alkyl
  • R 1 is as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula XVII, wherein R 1 is selected from the group consisting of C 1-6 alkyl and C 3-6 cycloalkyl.
  • R′′ is aralkyl.
  • R′′ is (heteroaryl)alkyl.
  • R′′ is benzyl wherein the phenyl group is optionally substituted with one or two substituents, e.g., —CH 2 (4-Cl-Ph), —CH 2 (3-Cl-Ph), —CH 2 (3,4-di-Cl-Ph), and —CH 2 (4-CF 3 -Ph).
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is —C(H)R 3 R 4 .
  • R 3 is selected from the group consisting of C 1-6 alkyl and optionally substituted C 3-12 cycloalkyl; and R 4 is selected from the group consisting of optionally substituted C 3-12 cycloalkyl and optionally substituted C 6-14 aryl.
  • R 4 is optionally substituted 4- to 14-membered heterocyclo.
  • R 3 is C 1-4 alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, optionally substituted C 6-14 aryl, and aralkyl.
  • —X—Z replaces a hydrogen atom on the R 4 substituent.
  • —X—Z can be hydrogen, when X is absent and Z is hydrogen.
  • Compounds of the Disclosure are compounds having Formula VII, Formula VIII, or Formula IX:
  • R 3 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted C 6-14 aryl, aryloxyalkyl, and aralkyl;
  • X is selected from the group consisting of —S( ⁇ O) 2 —, —S( ⁇ O) 2 N(R 7 )—, —S( ⁇ O) 2 C(R 8 )(H)—, —C( ⁇ O)—, —C( ⁇ O)N(R 7 )—, —C( ⁇ O)O—, —OC( ⁇ O)—, and —C( ⁇ O)C(R 8 )(H)—; or X is absent;
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino;
  • Z is selected from the group consisting of C 1-6 alkyl, (amino)alkyl. (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, hydroxyalkyl, optionally substituted C 3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • R 3 is selected from the group consisting of hydrogen and methyl.
  • Compounds of the Disclosure are compounds having Formula X, Formula XI, or Formula XII:
  • R 12 is selected from the group consisting of hydrogen, halo, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, (aralkyloxy)alkyl, alkoxyalkyl, heteroalkyl, (hydroxyalkylamino)alkyl, (heterocycloamino)alkyl, and carboxamido, and R 1 , R 2 , X, and Z are as defined above in connection with Formula I.
  • X is selected from the group consisting of —C( ⁇ O)N(R 7 )— and —S( ⁇ O) 2 N(R 7 )—;
  • Z is optionally substituted C 1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl.
  • heterocyclo alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C 6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C 3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl; and R 12 is hydrogen.
  • X is absent;
  • Z is hydrogen; and R 12 is selected from the group consisting of halo, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, (aralkyloxy)alkyl, alkoxyalkyl, heteroalkyl, (hydroxyalkylamino)alkyl, (hetcrocycloamino)alkyl, and carboxamido.
  • Compounds of the Disclosure are compounds having Formula XIII, Formula XIV, or Formula XV:
  • R 6 is selected from the group consisting of optionally substituted C 1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C 6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C 3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
  • X is selected from the group consisting of —C( ⁇ O)N(R 7 )—, —C( ⁇ O)C(R 8 )(H)—, and —S( ⁇ O) 2 N(R 7 )—; or X is absent;
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino:
  • Z is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)heteroaryl)alkyl, and (amino)(hydroxy)alkyl, and R 1 , R 2 , and R 7 are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • X is selected from the group consisting of:
  • R 8 is selected from the group consisting of C 1-4 alkyl, amino, alkylamino, and dialkylamino, and R 1 , R 2 , A, and Z are as defined above in connection with Formula I.
  • Compounds of the Disclosure are compounds having any one of Formulae I-XVII, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein R 1 is selected from the group consisting of C 1 0.4 alkyl and C 3-6 cycloalkyl. In another embodiment, R 1 is cyclopropyl. In another embodiment, R 2 is hydrogen.
  • a Compound of the Disclosure is not 5-cyclopropyl-N-(pyridin-3-yl)-1,2-oxazole-3-carboxamide.
  • Compounds of the Disclosure are compounds of Table 1, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • the chemical names of the compounds of Table 1 are provided in Table 1A.
  • Compounds of the Disclosure are compounds of Table 1A, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof.
  • Compounds of the Disclosure are compounds of Table 2, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • Compounds of the Disclosure is the compound of Table 3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof.
  • Compounds of the Disclosure are compounds of Tables 1 and 2, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • Compounds of the Disclosure are compounds of Tables 1-3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • Compounds of the Disclosure are compounds of Table 1, Table 1A, Table 2, and Table 3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof
  • alkyl refers to a straight- or branched-chain aliphatic hydrocarbon containing one to twelve carbon atoms (i.e., C 1-12 alkyl) or the number of carbon atoms designated (i.e., a C 1 alkyl such as methyl, a C 2 alkyl such as ethyl, a C 3 alkyl such as propyl or isopropyl, etc.).
  • the alkyl group is chosen from a straight chain C 1-10 alkyl group.
  • the alkyl group is chosen from a branched chain C 3-10 alkyl group.
  • the alkyl group is chosen from a straight chain C 1-6 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C 3-6 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain C 1-4 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C 3-4 alkyl group. In another embodiment, the alkyl group is chosen from a straight or branched chain C 3-4 alkyl group. In another embodiment, the alkyl group is partially or completely deuterated, i.e., one or more hydrogen atoms of the alkyl group are replaced with deuterium atoms.
  • Non-limiting exemplary C 1-10 alkyl groups include methyl (including —CD 3 ), ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
  • Non-limiting exemplary C 1-4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and iso-butyl.
  • Non-limiting exemplary C 1-4 groups include methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • the term “optionally substituted alkyl” as used by itself or as part of another group means that the alkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, alkoxycarbonyl, and carboxyalkyl.
  • the alkyl is a C 1-6 alkyl.
  • the alkyl is a C 1-4 alkyl.
  • the optionally substituted alkyl is substituted with two substituents.
  • the optionally substituted alkyl is substituted with one substituent.
  • Non-limiting exemplary optionally substituted alkyl groups include —CH 2 CH 2 NO 2 , —CH 2 CH 2 CO 2 H, —CH 2 CH 2 SO 2 CH 3 , —CH 2 CH 2 COPh, and —CH 2 C 6 H 11 .
  • alkylenyl refers to a divalent form of an alkyl group as defined above.
  • the alkylenyl is a divalent form of a C 1-6 alkyl.
  • the alkylenyl is a divalent form of a C 1-4 alkyl.
  • Non-limiting exemplary alkylenyl groups include —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH(CH 3 )CH 2 —, and —CH 2 C(CH 3 ) 2 CH 2 —.
  • cycloalkyl refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C 3-12 cycloalkyl) or the number of carbons designated.
  • the cycloalkyl group has two rings.
  • the cycloalkyl group has one ring.
  • the cycloalkyl group is chosen from a C 3-8 cycloalkyl group.
  • the cycloalkyl group is chosen from a C 3-6 cycloalkyl group.
  • Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, spiro[3.3]heptane, and bicyclo[3.3.1]nonane.
  • the term “optionally substituted cycloalkyl” as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted ary
  • the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent. In one embodiment, the optionally substituted cycloalkyl is an (amino)cycloalkyl.
  • the term “(amino)cycloalkyl” as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is substituted with one amino or alkylamino group, and optionally one or two additional substituents.
  • the optionally substituted cycloalkyl is an (amino)cyclohexyl.
  • the term “(amino)cyclohexyl” as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is a cyclohexyl group substituted with one amino or alkylamino group, and optionally one or two additional substituents.
  • Non-limiting exemplary optionally substituted cycloalkyl groups include:
  • Non-limiting exemplary (amino)cycloalkyl groups include:
  • Non-limiting exemplary (amino)cyclohexyl groups include:
  • optionally substituted cyclohexyl as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is an optionally substituted cyclohexyl group.
  • cycloalkylenyl as used herein by itself or part of another group refers to a divalent form of an optionally substituted cycloalkyl group as defined above.
  • the cycloalkylenyl is a “cyclohexylenyl.”
  • Non-limiting exemplary cycloalkylenyl groups include:
  • 1,4-cyclohexylenyl as used herein by itself or part of another group refers to a cyclohexylenyl as defined above wherein the radicals are in the 1 and 4 positions of the cyclohexyl ring.
  • Non-limiting exemplary 1,4-cyclohexylenyl groups include:
  • (cycloalkylenyl)alkyl refers to an alkyl group substituted with a divalent form of an optionally substituted cycloalkyl group.
  • the cycloalkylenyl is a divalent form of optionally substituted cyclohexyl.
  • the alkyl is C 1-4 alkyl.
  • Non-limiting exemplary (cycloalkylenyl)alkyl groups include:
  • cycloalkenyl as used by itself or part of another group refers to a partially unsaturated cycloalkyl group as defined above.
  • the cycloalkenyl has one carbon-to-carbon double bond.
  • the cycloalkenyl group is chosen from a C 4-8 cycloalkenyl group.
  • Exemplary cycloalkenyl groups include cyclopentenyl and cyclohexenyl.
  • the term “optionally substituted cycloalkenyl” as used by itself or as part of another group means that the cycloalkenyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, monohydroxyalkyl, dihydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted hetero
  • the optionally substituted cycloalkenyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkenyl is substituted with one substituent. In another embodiment, the cycloalkenyl is unsubstituted.
  • alkenyl refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds.
  • the alkenyl group is chosen from a C 2-6 alkenyl group.
  • the alkenyl group is chosen from a C 2-4 alkenyl group.
  • Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.
  • the term “optionally substituted alkenyl” as used herein by itself or as part of another group means the alkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclo.
  • alkynyl refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds.
  • the alkynyl has one carbon-to-carbon triple bond.
  • the alkynyl group is chosen from a C 2-6 alkynyl group.
  • the alkynyl group is chosen from a C 2-4 alkynyl group.
  • Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
  • alkynyl as used herein by itself or as part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
  • haloalkyl as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine, chlorine, bromine and/or iodine atoms.
  • the alkyl group is substituted by one, two, or three fluorine and/or chlorine atoms.
  • the haloalkyl group is chosen from a C 1-4 haloalkyl group.
  • Non-limiting exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.
  • fluoroalkyl as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine atoms.
  • the alkyl group is substituted by one, two, or three fluorine atoms.
  • the fluoroalkyl group is chosen from a C 1-4 fluoroalkyl group.
  • Non-limiting exemplary fluoroalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, and 4,4,4-trifluorobutyl.
  • hydroxyalkyl refers to an alkyl group substituted with one or more, e.g., one, two, or three, hydroxy groups.
  • the hydroxyalkyl group is a monohydroxyalkyl group, i.e., substituted with one hydroxy group.
  • the hydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with two hydroxy groups.
  • the hydroxyalkyl group is chosen from a C 1-4 hydroxyalkyl group.
  • Non-limiting exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as I-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl.
  • alkoxy refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom.
  • the alkoxy group is chosen from a C 1-4 alkoxy group.
  • the alkoxy group is chosen from a C 1-4 alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, tert-butoxy, —OCH 2 C ⁇ CH, —OCH 2 C ⁇ CCH 3 , and —OCH 2 CH 2 CH 2 C ⁇ CH.
  • alkylthio refers to a sulfur atom substituted by an optionally substituted alkyl group.
  • the alkylthio group is chosen from a C 1-4 alkylthio group.
  • Non-limiting exemplary alkylthio groups include —SCH 3 , and —SCH 2 CH 3 .
  • alkoxyalkyl refers to an alkyl group substituted with an alkoxy group.
  • Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sc-butoxymethyl, pentyloxymethyl, —CH 2 OCH 2 C ⁇ CH and —CH 2 OCH 2 CH 2 CH 2 C ⁇ CH.
  • haloalkoxy as used by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen atom.
  • Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.
  • heteroalkyl refers to a stable straight or branched chain hydrocarbon radical containing 1 to 10 carbon atoms and at least two heteroatoms, which can be the same or different, selected from O, N, or S, wherein: 1) the nitrogen atom(s) and sulfur atom(s) can optionally be oxidized; and/or 2) the nitrogen atom(s) can optionally be quaternized.
  • the heteroatoms can be placed at any interior position of the heteroalkyl group or at a position at which the heteroalkyl group is attached to the remainder of the molecule.
  • the heteroalkyl group contains two oxygen atoms.
  • the heteroalkyl contains one oxygen and one nitrogen atom, e.g., a (hydroxyalkylamino)alkyl group, e.g., —CH 2 N(CH 3 )CH 2 CH 2 CH 2 OH. In one embodiment, the heteroalkyl contains two nitrogen atoms.
  • Non-limiting exemplary heteroalkyl groups include —CH 2 OCH 2 CH 2 OCH 3 , —OCH 2 CH 2 OCH 2 CH 2 OCH 3 , —CH— 2 NHCH 2 CH 2 OCH 2 , —OCH 2 CH 2 NH 2 , —NHCH 2 CH 2 N(H)CH 7 , —NHCH 2 CH 2 OCH 3 , —CH 2 OCH 2 CH 2 NH 2 , —CH 2 OCH 2 CH 2 N(H)CH 2 CH 3 , and —OCH 2 CH 2 OCH 3 .
  • aryl refers to a monocyclic or bicyclic aromatic ring system having from six to fourteen carbon atoms (i.e., C 6-14 aryl).
  • Non-limiting exemplary aryl groups include phenyl (abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups.
  • the aryl group is chosen from phenyl or naphthyl.
  • the aryl group is phenyl.
  • the term “optionally substituted aryl” as used herein by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkyl aralkyloxy, (aralkyloxy)alkyl, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, heteroalkyl optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl,
  • the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent.
  • the optionally substituted phenyl has at least one amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl. (amino)(heteroaryl)alkyl, or (amino)(hydroxy)alkyl substituent.
  • Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, 3-chloro-4-fluorophenyl, and 2-phenylpropan-2-amine.
  • arylenyl as used herein by itself or part of another group refers to a divalent form of an optionally substituted aryl group as defined above.
  • the arylenyl is a divalent form of an optionally substituted phenyl.
  • the arylenyl is a divalent form of phenyl.
  • Non-limiting exemplary alkylenyl groups include:
  • aryloxy as used by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom.
  • a non-limiting exemplary aryloxy group is PhO—.
  • heteroaryloxy as used by itself or as part of another group refers to an optionally substituted heteroaryl attached to a terminal oxygen atom.
  • aralkyloxy or “arylalkyloxy” as used by itself or as part of another group refers to an aralkyl group attached to a terminal oxygen atom.
  • a non-limiting exemplary aralkyloxy group is PhCH 2 O—.
  • (aralkyloxy)alkyl refers to an alkyl group substituted with an aralkyloxy group.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary “(aralkyloxy)alkyl” groups include —CH 4 OCH 1 (3-F-Ph) and —CH 2 OCH 2 CH 2 CH 2 (2-OMe-Ph).
  • heteroaryl refers to monocyclic and bicyclic aromatic ring systems having 5 to 14 ring members (i.e., a 5- to 14-membered heteroaryl) and 1, 2, 3, or 4 heteroatoms independently chosen from oxygen, nitrogen or sulfur.
  • the heteroaryl has three heteroatoms.
  • the heteroaryl has two heteroatoms.
  • the heteroaryl has one heteroatom.
  • the heteroaryl has 5 ring atoms, e.g., thienyl.
  • the heteroaryl has 6 ring atoms, e.g., pyridyl.
  • Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, ⁇ -carboliny
  • the heteroaryl is chosen from thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.
  • the term “optionally substituted heteroaryl” as used by itself or as part of another group means that the heteroaryl as defined above is either unsubstituted or substituted with one to four substituents, e.g., one or two substituents, independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aralkyl, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally
  • R 43 is hydrogen or C 1-4 alkyl
  • R 44 is alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, (alkylamino)alkyl, or (dialkylamino)alkyl
  • R 45 is alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • the optionally substituted heteroaryl has one substituent.
  • the substituent is amino, alkylamino, dialkylamino, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, —N(R 43 )(R 44 ), or —N(H)C( ⁇ O)—R 45 .
  • the substituent is aralkyl or (heteroaryl)alkyl. Examples include:
  • the optionally substituted heteroaryl is an optionally substituted pyridyl, i.e., 2-, 3-, or 4-pyridyl. Any available carbon or nitrogen atom can be substituted.
  • the term optionally substituted heteroaryl is meant to include heteroaryl groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include:
  • heteroarylenyl as used herein by itself or part of another group refers to a divalent form of an optionally substituted heteroaryl group as defined above.
  • the heteroarylenyl is a divalent form of an optionally substituted pyridyl.
  • Non-limiting exemplary heteroarylenyl groups include:
  • heterocycle or “heterocyclo” as used by itself or as part of another group refers to saturated and partially unsaturated (e.g., containing one or two double bonds) cyclic groups containing one, two, or three rings having from three to fourteen ring members (i.e., a 3- to 14-membered heterocyclo) and at least one heteroatom.
  • Each heteroatom is independently selected from the group consisting of oxygen, sulfur, including sulfoxide and sulfone, and/or nitrogen atoms, which can be quaternized.
  • heterocyclo is meant to include cyclic ureido groups such as imidazolidinyl-2-one, cyclic amide groups such as ⁇ -lactam, ⁇ -lactam, ⁇ -lactam and ⁇ -lactam, and cyclic carbamate groups such as oxazolidinyl-2-one.
  • heterocyclo is also meant to include groups having fused optionally substituted aryl groups, e.g., indolinyl, indolinyl-2-one, benzo[d]oxazolyl-2(3H)one.
  • the heterocyclo group is chosen from a 4-, 5-, 6-, 7- or 8-membered cyclic group containing one ring and one or two oxygen and/or nitrogen atoms. In one embodiment, the heterocyclo group is chosen from a 5- or 6-membered cyclic group containing one ring and one or two nitrogen atoms. In one embodiment, the heterocyclo group is chosen from a 8-, 9-, 10-, 11-, or 12-membered cyclic group containing two rings and one or two nitrogen atoms. The heterocyclo can be optionally linked to the rest of the molecule through a carbon or nitrogen atom.
  • Non-limiting exemplary heterocyclo groups include 2-oxopyrrolidin-3-yl, 2-imidazolidinone, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, 8-azabicyclo[3.2.1]octane (nortropane), 6-azaspiro[2.5]octane, 6-azaspiro[3.4]octane, indolinyl, indolinyl-2-one, 1,3-dihydro-2H-benzo[d]imidazol-2-one
  • the term “optionally substituted heterocyclo” as used herein by itself or part of another group means the heterocyclo as defined above is either unsubstituted or substituted with one to four substituents independently selected from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl,
  • substitution may occur on any available carbon or nitrogen atom, and may form a spirocycle.
  • the optionally substituted heterocyclo is substituted with at least one amino, alkylamino, or dialkylamino group.
  • Non-limiting exemplary optionally substituted heterocyclo groups include:
  • heterocyclenyl refers to a divalent form of an optionally substituted heterocyclo group as defined above.
  • the heterocyclenyl is a divalent form of an optionally substituted azetidine.
  • the heterocyclenyl is a divalent form of an optionally substituted piperidinyl.
  • Non-limiting exemplary heterocyclenyl groups include:
  • optionally substituted pyrrolidinyl as used by itself or as part of another group means that the optionally substituted heterocyclo as defined above is an optionally substituted pyrrolidinyl group.
  • optionally substituted pyrrolidinonyl refers to a divalent form of an optionally substituted pyrrolidinyl group as defined above.
  • optionally substituted pyrrolidinenyl groups include:
  • the term “optionally substituted, optionally bridged piperidinenyl” as used by itself or as part of another group refers to a divalent form having the following structure:
  • R 2′a , R 2′b , R 3′a , R 3′b , R 4′a , R 4′b , R 5′a , and R 5′b are each independently selected from the group consisting of hydrogen, halo, C 1-6 alkyl, C 3-12 cycloalkyl, haloalkyl, hydroxyalkyl, optionally substituted C 6-14 aryl, aralkyl, and alkoxycarbonyl; or
  • R 2′a and R 2′b taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl; and R 3′a , R 3′b , R 4′a , R 4′b R 5′a , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 3′a and R 3′b taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl; and R 2′a , R 2′b , R 4′a , R 4′b , R 5′a , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 4a and R 4b taken together with the carbon atom to which they are attached form a Cu cycloalkyl; and R 2′a , R 2′b , R 3′a , R 3′b , R 4′a , and R 4′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 5′a and R 5′b taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl; and R 2′a , R 2′b , R 3′a , R 3′b , R 4′a , and R 4′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 2′a and R 5′a taken together form a C 1-4 bridge; and R 2′b , R 3′a , R 3′b , R 4′a , R 4′b , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl, or
  • R 3′a and R 4′a taken together form a C 1-4 bridge; and R 2′a , R 2′b , R 3′b , R 4′a , R 5′a , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 2′a and R 4′a taken together form a C 1-4 bridge; and R 2′b , R 3′a , R 3′b , R 4′b , R 5′a , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl; or
  • R 3′a and R 5′a taken form a C 1-4 bridge; and R 2′a , R 2′b , R 3′b , R 4′a , R 4′b , and R 5′b are each independently selected from the group consisting of hydrogen, halo, and C 1-4 alkyl;
  • R 6′ is selected from the group consisting of hydrogen and C 1-4 alkyl
  • amino as used by itself or as part of another group refers to —NH 2 .
  • alkylamino as used by itself or as part of another group refers to —NHR 22 , wherein R 22 is C 1-6 alkyl. In one embodiment, R 22 is C 1-4 alkyl.
  • Non-limiting exemplary alkylamino groups include —N(H)CH 3 and —N(H)CH 2 CH 3 .
  • dialkylamino as used by itself or as part of another group refers to —NR 23a R 23b , wherein R 23a and R 23b are each independently C 1-6 alkyl. In one embodiment, R 23a and R 23b are each independently C 1-4 alkyl.
  • Non-limiting exemplary dialkylamino groups include —N(CH 3 ) 2 and —N(CH 3 )CH 2 CH(CH 3 ) 2 .
  • hydroxyalkylamino as used by itself or as part of another group refers to —NR 24a R 24b , wherein R 24a is hydrogen or C 1-4 alkyl, and R 24b is hydroxyalkyl.
  • Non-limiting exemplary hydroxyalkylamino groups include —N(H)CH 2 CH 2 OH, —N(H)CH 2 CH 2 CH 2 OH, —N(CH 3 )CH 2 CH 2 OH, and —N(CH 3 )CH 2 CH 2 CH 2 OH
  • (hydroxyalkylamino)alkyl refers to an alkyl group substituted with an hydroxyalkylamino group.
  • the alkyl is a C 1-4 alkyl.
  • a non-limiting exemplary (hydroxyalkylamino)alkyl group is —CH 2 N(CH 3 )CH 2 CH 2 CH 2 OH.
  • cycloalkylamino as used by itself or as part of another group refers to —NR 25a R 25b , wherein R 25a is optionally substituted cycloalkyl and R 25b is hydrogen or C 1-4 alkyl.
  • heterocycloamino as used by itself or as part of another group refers to —NR 25c R 25d , wherein R 25c is optionally substituted heterocyclo and R 25d is hydrogen or C 1-4 alkyl.
  • Non-limiting exemplary heterocycloamino groups include:
  • heterocycloaminoalkyl refers to an alkyl group substituted with an heterocycloamino group.
  • the alkyl is a C 1-4 alkyl.
  • aralkylamino as used by itself or as part of another group refers to —NR 26a R 26b , wherein R 26a is aralkyl and R 26b is hydrogen or C 1-4 alkyl.
  • Non-limiting exemplary aralkylamino groups include —N(H)CH 2 Ph and —N(CH 3 )CH 2 Ph.
  • (amino)alkyl refers to an alkyl group substituted with an amino group.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary (amino)alkyl groups include —CH 2 NH 2 , —C(NH 2 )(H)CH 3 , —CH 2 CH 2 NH 2 , —CH 2 C(NH 2 )(H)CH 3 , —CH 2 CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 CH 2 NH 2 , and —CH 2 C(CH 3 ) 2 CH 2 NH 2 .
  • (alkylamino)alkyl refers to an alkyl group substituted with an alkylamino group.
  • the alkyl is a C 1-4 alkyl.
  • a non-limiting exemplary (alkylamino)alkyl group is —CH 2 CH 2 N(H)CH 3 .
  • dialkylamino)alkyl refers to an alkyl group substituted by a dialkylamino group.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary (dialkylamino)alkyl groups are —CH 2 CH 2 N(CH 3 ) 2 .
  • (cycloalkylamino)alkyl refers to an alkyl group substituted by a cycloalkylamino group.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary (cycloalkylamino)alkyl groups include —CH 2 N(H)cyclopropyl, —CH 2 N(H)cyclobutyl, and —CH 2 N(H)cyclohexyl.
  • (aralkylamino)alkyl refers to an alkyl group substituted with an aralkylamino group.
  • the alkyl is a C 1-4 alkyl.
  • a non-limiting exemplary (aralkylamino)alkyl group is —CH 2 CH 2 CH 2 N(H)CH 2 Ph.
  • (hydroxyalkylamino)alkyl refers to an alkyl group substituted with an hydroxyalkylamino group.
  • a non-limiting exemplary (hydroxyalkylamino)alkyl group is —CH 2 CH 2 NHCH 2 CH 2 OH
  • (cyano)alkyl refers to an alkyl group substituted with one or more cyano, e.g., —CN, groups.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary (cyano)alkyl groups include —CH 2 CH 2 CN, —CH 2 CH 2 CH 2 CN, and —CH 2 C 2 CH 2 CH 2 CH 2 CN.
  • (amino)(hydroxy)alkyl refers to an alkyl group substituted with one amino, alkylamino, dialkylamino, or heterocyclo group and one hydroxy group.
  • the alkyl is a C 1-6 alkyl.
  • the alkyl is a C 1-4 alkyl.
  • Non-limiting exemplary (amino)(hydroxy)alkyl groups include:
  • (amino)(carboxamido)alkyl refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino, and one carboxamido group.
  • the alkyl is a C 1-6 alkyl.
  • Non-limiting exemplary (amino)(carboxamido)alkyl groups include:
  • (amino)(aryl)alkyl refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino group and one optionally substituted aryl group.
  • the alkyl is a C 1-6 alkyl.
  • the optionally substituted aryl group is an optionally substituted phenyl.
  • Non-limiting exemplary (amino)(aryl)alkyl groups include:
  • (amino)(heteroaryl)alkyl refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino group and one optionally substituted heteroaryl group.
  • the alkyl is a C 1-6 alkyl.
  • the alkyl is a C 1-4 alkyl.
  • the optionally substituted heteroaryl group is an optionally substituted pyridyl.
  • Non-limiting exemplary (amino)(heteroaryl)alkyl groups include:
  • (cycloalkyl)alkyl refers to an alkyl group substituted with one optionally substituted cycloalkyl group.
  • the alkyl is a C 1-4 alkyl.
  • the cycloalkyl is a C 3-6 cycloalkyl.
  • the optionally substituted cycloalkyl group is substituted with an amino or (amino)alkyl group.
  • Non-limiting exemplary (cycloalkyl)alkyl groups include:
  • (hydroxy)(aryl)alkyl refers to an alkyl group substituted with one hydroxy group and one optionally substituted aryl group.
  • the alkyl is a C 1-6 alkyl.
  • the optionally substituted aryl group is an optionally substituted phenyl.
  • Non-limiting exemplary (hydroxy)(aryl)alkyl groups include:
  • the term “carboxamido” as used by itself or as part of another group refers to a radical of formula —C( ⁇ O)NR 26a R 26b , wherein R 26a and R 26b are each independently hydrogen, optionally substituted alkyl, optionally substituted aryl, aralkyl, (heteroaryl)alkyl, or optionally substituted heteroaryl, or R 26a and R 26b taken together with the nitrogen to which they are attached from a 3- to 8-membered heterocyclo group. In one embodiment, R 26a and R 26b are each independently hydrogen or optionally substituted alkyl.
  • Non-limiting exemplary carboxamido groups include —CONH 2 , —CON(H)CH 3 , CON(CH 3 ) 2 , and —CON(H)Ph.
  • (carboxamido)alkyl refers to an alkyl group substituted with a carboxamido group.
  • Non-limiting exemplary (carboxamido)alkyl groups include —CH 2 CONH 2 , —C(H)CH 3 —CONH 2 , and —CH 2 CON(H)CH 3 .
  • sulfonamido refers to a radical of the formula —SO 2 NR 27a R 27b , wherein R 27a and R 27b are each independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, or R 27a and R 27b taken together with the nitrogen to which they are attached from a 3- to 8-membered heterocyclo group.
  • Non-limiting exemplary sulfonamido groups include —SO 2 NH 2 , —SO 2 N(H)CH 3 , and —SO 2 N(H)Ph.
  • alkylcarbonyl as used by itself or as part of another group refers to a carbonyl group, i.e., —C( ⁇ O)—, substituted by an alkyl group.
  • a non-limiting exemplary alkylcarbonyl group is —COCH 3 .
  • arylcarbonyl as used by itself or as part of another group refers to a carbonyl group, i.e., —C( ⁇ O)—, substituted by an optionally substituted aryl group.
  • a non-limiting exemplary arylcarbonyl group is —COPh.
  • alkylsulfonyl as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO 2 —, substituted by any of the above-mentioned optionally substituted alkyl groups.
  • a non-limiting exemplary alkylsulfobnyl group is —SO 2 CH 3 .
  • arylsulfonyl as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO 2 —, substituted by any of the above-mentioned optionally substituted aryl groups.
  • a non-limiting exemplary arylsulfonyl group is —SO 2 Ph.
  • mercaptoalkyl as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted by a —SH group.
  • carboxy as used by itself or as part of another group refers to a radical of the formula —COOH.
  • carboxyalkyl as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with a —COOH.
  • a non-limiting exemplary carboxyalkyl group is —CH 2 CO 2 H.
  • alkoxycarbonyl as used by itself or as part of another group refers to a carbonyl group, i.e., —C( ⁇ O)—, substituted by an alkoxy group.
  • Non-limiting exemplary alkoxycarbonyl groups are —CO 2 Me and —CO 2 Et.
  • aralkyl or “arylalkyl” as used by itself or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted aryl groups.
  • the aralkyl group is a C 1-4 alkyl substituted with one optionally substituted aryl group.
  • Non-limiting exemplary aralkyl groups include benzyl, phenethyl, —CHPh 2 , —CH 2 (4-OH-Ph), and —CH(4-F-Ph) 2 .
  • ureido refers to a radical of the formula —NR 30a —C( ⁇ O)—NR 30b R 30c , wherein R 22a is hydrogen, alkyl, or optionally substituted aryl, and R 30b and R 30c are each independently hydrogen, alkyl, or optionally substituted aryl, or R 30b and R 30c taken together with the nitrogen to which they are attached form a 4- to 8-membered heterocyclo group.
  • Non-limiting exemplary ureido groups include —NH—C(C ⁇ O)—NH 2 and —NH—C(C ⁇ O)—NHCH 3 .
  • the term “guanidino” as used by itself or as part of another group refers to a radical of the formula —NR 28a —C( ⁇ NR 29 )—NR 28b R 28c , wherein R 28a , R 28b , and R 28c are each independently hydrogen, alkyl, or optionally substituted aryl, and R 29 is hydrogen, alkyl, cyano, alkylsulfonyl, alkylcarbonyl, carboxamido, or sulfonamido.
  • Non-limiting exemplary guanidino groups include —NH—C(C ⁇ NH)—NH 2 , —NH—C(C ⁇ NCN)—NH 2 , and —NH—C(C ⁇ NH)—NHCH 3 .
  • the term “(heterocyclo)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted heterocyclo groups.
  • the (heterocyclo)alkyl is a C 1-4 alkyl substituted with one optionally substituted heterocyclo group.
  • the heterocyclo can be linked to the alkyl group through a carbon or nitrogen atom.
  • Non-limiting exemplary (heterocyclo)alkyl groups include:
  • (heteroaryl)alkyl refers to an alkyl group substituted with one, two, or three optionally substituted heteroaryl groups.
  • the (heteroaryl)alkyl group is a C 1-4 alkyl substituted with one optionally substituted heteroaryl group.
  • Non-limiting exemplary (heteroaryl)alkyl groups include:
  • alkylcarbonylamino as used by itself or as part of another group refers to an alkylcarbonyl group attached to an amino.
  • a non-limiting exemplary alkylcarbonylamino group is —NHCOCH 3 .
  • C 1-4 bridge refers to a —CH 2 —, —(CH 2 ) 2 —, —(CH 2 ) 3 —, or —(CH 2 ) 4 — group that joins two carbon atoms of a piperidine to form an azabicyclo group.
  • R 3a and R 4a of B can be taken together to form a 6-azabicyclo[3.1.1]heptane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, or 10-azabicyclo[4.3.1]decane group.
  • Each methylene unit of the C 1-4 bridge can be optionally substituted with one or two substituents independently selected from the group consisting of C 1-4 alkyl and halo.
  • the present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number.
  • isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H (or deuterium (D)), 3 H, 11 C, 13 C, 14 C, 5 N, 13 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively, e.g., 3 H, 11 C, and 14 C.
  • compositions wherein substantially all of the atoms at a position within the Compound of the Disclosure are replaced by an atom having a different atomic mass or mass number.
  • Isotopically-labelled Compounds of the Disclosure can be prepared by methods known in the art.
  • Compounds of the Disclosure may contain one or more asymmetric centers and may thus give rise to enantiomers, diasteromers, and other stereoisomeric forms.
  • the present disclosure is meant to encompass the use of all such possible forms, as well as their racemic and resolved forms and mixtures thereof.
  • the individual enantiomers can be separated according to methods known in the art in view of the present disclosure.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present disclosure as well.
  • stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • chiral center or “asymmetric carbon atom” refers to a carbon atom to which four different groups are attached.
  • enantiomer and “enantiomeric” refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
  • racemic refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.
  • absolute configuration refers to the spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description, e.g., R or S.
  • enantiomeric excess refers to a measure for how much of one enantiomer is present compared to the other.
  • percent enantiomeric excess is defined as
  • *100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R+S 1.
  • the percent enantiomeric excess is defined as ([ ⁇ ] obs /[ ⁇ ] max )*100, where [ ⁇ ] obs is the optical rotation of the mixture of enantiomers and [ ⁇ ] max is the optical rotation of the pure enantiomer. Determination of enantiomeric excess is possible using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography or optical polarimetry.
  • enantiomerically pure or “enantiopure” refer to a sample of a chiral substance all of whose molecules (within the limits of detection) have the same chirality sense.
  • enantiomerically enriched or “enantioenriched” refer to a sample of a chiral substance whose enantiomeric ratio is greater than 50:50. Enantiomerically enriched compounds may be enantiomerically pure.
  • the present disclosure encompasses the preparation and use of salts of the Compounds of the Disclosure, including non-toxic pharmaceutically acceptable salts.
  • pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts.
  • the pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like
  • pharmaceutically acceptable salt refers to any salt, e.g., obtained by reaction with an acid or a base, of a Compound of the Disclosure that is physiologically tolerated in the target patient (e.g., a mammal, e.g., a human).
  • Acid addition salts can be formed by mixing a solution of the particular Compound of the Disclosure with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like.
  • Basic salts can be formed by mixing a solution of the compound of the present disclosure with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.
  • solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents.
  • solvate as used herein is a combination, physical association and/or solvation of a compound of the present disclosure with a solvent molecule such as, e.g. a desolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively.
  • This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
  • solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid.
  • “solvate” encompasses both solution-phase and isolatable solvates.
  • Compounds of the Disclosure can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure.
  • a pharmaceutically acceptable solvent such as water, methanol, ethanol, and the like
  • solvate is a hydrate.
  • a “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water.
  • Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M.
  • Compounds of the Disclosure are inhibitors of SMYD proteins, such as SMYD3 and SMYD2, a number of diseases, conditions, or disorders mediated by SMYD proteins, such as SMYD3 and SMYD2, can be treated by employing these compounds.
  • the present disclosure is thus directed generally to a method for treating a disease, condition, or disorder responsive to the inhibition of SMYD proteins, such as SMYD3 and SMYD2, in an animal suffering from, or at risk of suffering from, the disorder, the method comprising administering to the animal an effective amount of one or more Compounds of the Disclosure.
  • the present disclosure is further directed to a method of inhibiting SMYD proteins in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • the present disclosure is further directed to a method of inhibiting SMYD3 in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • the present disclosure is further directed to a method of inhibiting SMYD2 in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • the terms “treat,” “treating,” “treatment,” and the like refer to eliminating, reducing, or ameliorating a disease or condition, and/or symptoms associated therewith. Although not precluded, treating a disease or condition does not require that the disease, condition, or symptoms associated therewith be completely eliminated.
  • the terms “treat.” “treating.” “treatment,” and the like may include “prophylactic treatment,” which refers to reducing the probability of redeveloping a disease or condition, or of a recurrence of a previously-controlled disease or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or condition or a recurrence of the disease or condition.
  • the term “treat” and synonyms contemplate administering a therapeutically effective amount of a Compound of the Disclosure to an individual in need of such treatment.
  • treatment also includes relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions.
  • the treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
  • terapéuticaally effective amount refers to an amount of the active ingredient(s) that is(are) sufficient, when administered by a method of the disclosure, to efficaciously deliver the active ingredient(s) for the treatment of condition or disease of interest to an individual in need thereof.
  • the therapeutically effective amount of the agent may reduce (i.e., retard to some extent and preferably stop) unwanted cellular proliferation; reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., retard to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., retard to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; modulate protein methylation in the target cells; and/or relieve, to some extent, one or more of the symptoms associated with the cancer.
  • the administered compound or composition prevents growth and/or kills existing cancer cells, it may be cytostatic and/or cytotoxic.
  • tainer means any receptacle and closure therefore suitable for storing, shipping, dispensing, and/or handling a pharmaceutical product.
  • insert means information accompanying a pharmaceutical product that provides a description of how to administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and patient to make an informed decision regarding use of the product.
  • the package insert generally is regarded as the “label” for a pharmaceutical product.
  • disease or “condition” or “disorder” denotes disturbances and/or anomalies that as a rule are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and/or malfunctions.
  • Compounds of the Disclosure inhibit SMYD proteins, such as SMYD3 and SMYD2 and can be used in treating diseases and conditions such as proliferative diseases, wherein inhibition of SMYD proteins, such as SMYD3 and SMYD2 provides a benefit.
  • the Compounds of the Disclosure can be used to treat a “SMYD protein mediated disorder” (e.g., a SMYD3-mediated disorder or a SMYD2-mediated disorder).
  • a SMYD protein mediated disorder is any pathological condition in which a SMYD protein is know to play a role.
  • a SMYD-mediated disorder is a proliferative disease.
  • inhibiting SMYD proteins is the inhibition of the activity of one or more activities of SMYD proteins such as SMYD3 and SMYD2.
  • the activity of the SMYD proteins such as SMYD3 and SMYD2 is the ability of the SMYD protein such as SMYD3 or SMYD2 to transfer a methyl group to a target protein (e.g., histone). It should be appreciated that the activity of the one or more SMYD proteins such as SMYD3 and SMYD2 may be inhibited in vitro or in vivo.
  • Examplary levels of inhibition of the activity one or more SMYD proteins such as SMYD3 and SMYD2 include at least 10% inhibition, at least 20% inhibition, at least 30% inhibition, at least 40% inhibition, at least 50% inhibition, at least 60% inhibition, at least 70% inhibition, at least 80% inhibition, at least 90%/0 inhibition, and up to 100% inhibition.
  • the family of human SMYD proteins consists of SMYD1, SMYD2, SMYD3. SMYD4 and SMYD5.
  • SMYD1, SMYD2, and SMYD3 share a high degree of sequence homology and, with the exception of SMYD5, human SMYD proteins harbor at least one C-terminal tetratrico peptide repeat (TPR) domain.
  • TPR C-terminal tetratrico peptide repeat
  • the SMYD proteins have been found to be linked to various cancers (See e.g., Hamamoto et al. Nat Cell. Biol. 2004, 6: 731-740), Hu et al. Cancer Research 2009, 4067-4072, and Komatsu et al. Carcinogenesis 2009, 301139-1146.)
  • SMYD3 is a protein methyltransferase found to be expressed at high levels in a number of different cancers (Hamamoto, R., et al., Nat. Cell Biol., 6(8):731-40 (2004)). SMYD3 likely plays a role in the regulation of gene transcription and signal transduction pathways critical for survival of breast, liver, prostate and lung cancer cell lines (Hamamoto, R., et al., Nat. Cell Biol., 6(8):731-40 (2004); Hamamoto, R., et al., Cancer Sci., 97(2):113-8 (2006); Van Aller, G. S., et al., Epigenetics, 7(4):340-3 (2012); Liu, C., et al., J. Natl. Cancer Inst., 105(22):1719-28 (2013): Mazur, P. K., et al., Nature, 510(7504):283-7 (2014)).
  • RNAi-based technologies have shown that ablation of SMYD3 in hepatocellular carcinoma cell lines greatly reduces cell viability and that its pro-survival role is dependent on its catalytic activity (Hamamoto. R., et al., Nat. Cell Biol., 6(8):731-40 (2004); Van Aller, G. S., et al., Epigenetics, 7(4):340-3 (2012)).
  • SMYD3 has also been shown to be a critical mediator of transformation resulting from gain of function mutations in the oncogene, KRAS for both pancreatic and lung adenocarcinoma in mouse models.
  • SMYD3 function has also been shown to play a role in immunology and development. For instance, de Almeida reported that SMYD3 plays a role in generation of inducible regulatory T cells (iTreg) cells.
  • iTreg inducible regulatory T cells
  • SMYD3 ⁇ / ⁇ mice demonstrated exacerbation of RSV-induced disease related to enhanced proinflammatory responses and worsened pathogenesis within the lung (de Almeida et al. Mucosal Immunol. 2015 Feb. 11. doi: 10.1038/mi.2015.4. [Epub ahead of print]).
  • SMYD2 (SET and MYND domain-containing protein 2) was first characterized as protein that is a member of a sub-family of SET domain containing proteins which catalyze the site-specific transfer of methyl groups onto substrate proteins.
  • SMYD2 was initially shown to have methyltransferase activity towards lysine 36 on histone H3 (H3K36) but has subsequently been shown to have both histone and non-histone methyltrasferase activity.
  • SMYD2 has been implicated in the pathogenesis of multiple cancers. It has been shown to be over-expressed, compared to matched normal samples, in tumors of the breast, cervix, colon, kidney, liver, head and neck, skin, pancreas, ovary, esophagus and prostate, as well as hematologic malignancies such as AML, B- and T-ALL, CLL and MCL, suggesting a role for SMYD2 in the biology of these cancers. More specifically, studies using genetic knock-down of SMYD2 have demonstrated anti-proliferative effects in esophageal squamous cell carcinoma (ESCC), bladder carcinoma and cervical carcinoma cell lines.
  • ESCC esophageal squamous cell carcinoma
  • SMYD2 has also been implicated in immunology. For instance, Xu et al. have shown that SMYD2 is a negative regulator of macrophage activation by suppressing Interleukin-6 and TNF-alpha production. (Xu et al., J Biol Chem. 2015 Feb. 27; 290(9):5414-23).
  • the present disclosure provides a method of treating cancer in a patient comprising administering a therapeutically effective amount of a Compound of the Disclosure.
  • Compounds of the Disclosure can treat cancer by inhibiting SMYD proteins, such as SMYD3 and SMYD2.
  • treatable cancers include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentigious melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell
  • Schwannomatosis seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma.
  • Sezary's disease small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor.
  • the cancer is breast, cervix, colon, kidney, liver, head and neck, skin, pancreas, ovary, esophagus, or prostate cancer.
  • the cancer is a hematologic malignancy such as acute myeloid leukemia (AML), B- and T-acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or mantle cell lymphoma (MCL).
  • AML acute myeloid leukemia
  • ALL B- and T-acute lymphoblastic leukemia
  • CLL chronic lymphocytic leukemia
  • MCL mantle cell lymphoma
  • the cancer is esophageal squamous cell carcinoma (ESCC), bladder carcinoma, or cervical carcinoma.
  • ESCC esophageal squamous cell carcinoma
  • bladder carcinoma esophageal squamous cell carcinoma
  • cervical carcinoma esophageal squamous cell carcinoma
  • the cancer is a leukemia, for example a leukemia selected from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukemia (MLL).
  • the cancer is NUT-midline carcinoma.
  • the cancer is multiple myeloma.
  • the cancer is a lung cancer such as small cell lung cancer (SCLC).
  • SCLC small cell lung cancer
  • the cancer is a neuroblastoma.
  • the cancer is Burkitt's lymphoma.
  • the cancer is cervical cancer.
  • the cancer is esophageal cancer.
  • the cancer is ovarian cancer.
  • the cancer is colorectal cancer.
  • the cancer is prostate cancer.
  • the cancer is breast cancer.
  • the present disclosure provides a therapeutic method of modulating protein methylation, gene expression, cell proliferation, cell differentiation and/or apoptosis in vivo in the cancers mentioned above by administering a therapeutically effective amount of a Compound of the Disclosure to a subject in need of such therapy.
  • Compounds of the Disclosure can be administered to a mammal in the form of a raw chemical without any other components present.
  • Compounds of the Disclosure can also be administered to a mammal as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier.
  • a suitable pharmaceutically acceptable carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 19th ed. 1995.
  • compositions within the scope of the present disclosure include all compositions where a Compound of the Disclosure is combined with one or more pharmaceutically acceptable carriers.
  • the Compound of the Disclosure is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art.
  • a Compound of the Disclosure can be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof, per day to treat the particular disorder.
  • a useful oral dose of a Compound of the Disclosure administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt or solvate thereof.
  • the dose is typically about one-half of the oral dose.
  • a unit oral dose may comprise from about 0.01 mg to about 1 g of the Compound of the Disclosure, e.g., about 0.01 mg to about 500 mg, about 0.01 mg to about 250 mg, about 0.01 mg to about 100 mg, 0.01 mg to about 50 mg, e.g., about 0.1 mg to about 10 mg, of the compound.
  • the unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 mg to about 1 g of the compound, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof.
  • a pharmaceutical composition of the present disclosure can be administered to any patient that may experience the beneficial effects of a Compound of the Disclosure.
  • mammals e.g., humans and companion animals, although the disclosure is not intended to be so limited.
  • the patient is a human.
  • a pharmaceutical composition of the present disclosure can be administered by any means that achieves its intended purpose.
  • administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation.
  • the dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, gender, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • a pharmaceutical composition of the present disclosure can be administered orally.
  • a pharmaceutical composition of the present disclosure can be administered orally and is formulated into tablets, dragees, capsules, or an oral liquid preparation.
  • the oral formulation comprises extruded multiparticulates comprising the Compound of the Disclosure.
  • a pharmaceutical composition of the present disclosure can be administered rectally, and is formulated in suppositories.
  • composition of the present disclosure can be administered by injection.
  • composition of the present disclosure can be administered transdermally.
  • composition of the present disclosure can be administered by inhalation or by intranasal or transmucosal administration.
  • composition of the present disclosure can be administered by the intravaginal route.
  • a pharmaceutical composition of the present disclosure can contain from about 0.01 to 99 percent by weight, e.g., from about 0.25 to 75 percent by weight, of a Compound of the Disclosure, e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or about 75% by weight of a Compound of the Disclosure.
  • a Compound of the Disclosure e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or about 75% by weight of a Compound of the Disclosure.
  • a pharmaceutical composition of the present disclosure is manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes.
  • pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • saccharides for example, lactose, sucrose, mannitol or sorbitol
  • cellulose preparations for example, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate)
  • binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethyl
  • one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Dragee cores are provided with suitable coatings that are resistant to gastric juices.
  • suitable coatings that are resistant to gastric juices.
  • concentrated saccharide solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate can be used.
  • Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain a compound in the form of granules, which can be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin.
  • stabilizers can be added.
  • Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base.
  • Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution.
  • a suspension of the active compound can be prepared as an oily suspension.
  • Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400).
  • An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may optionally contain stabilizers.
  • kits which comprise a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a manner that facilitates their use to practice methods of the present disclosure.
  • the kit includes a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure.
  • the compound or composition is packaged in a unit dosage form.
  • the kit further can include a device suitable for administering the composition according to the intended route of administration.
  • Compound A is converted to compound B (i.e, a compound having Formula VII, wherein X is —S( ⁇ O) 2 —) by coupling with a suitable sulfonyl chloride (Z—SO 2 Cl) in the presence of a suitable base such as TEA or DIPEA in a suitable solvent such as dichloromethane, acetonitrile, or DMF.
  • a suitable base such as TEA or DIPEA
  • a suitable solvent such as dichloromethane, acetonitrile, or DMF.
  • Compound A was converted to compound C by coupling with a suitable carboxylic acid (ZCO 2 H) in the presence of a suitable coupling reagent such as HATU or HOBT in the presence of a suitable base such as TEA or DIPEA in a suitable solvent such as DMF.
  • a suitable coupling reagent such as HATU or HOBT
  • a suitable base such as TEA or DIPEA
  • a suitable solvent such as DMF.
  • Compound A can also be converted to compound C by coupling with a suitable acid chloride (ZCOCl) in the presence of a suitable base such as TEA or DIPEA in the presence of a suitable solvent such as dichloromethane, acetonitrile or DMF.
  • Compound purification was carried out as needed using a variety of traditional methods including, but not limited to, preparative chromatography under acidic, neutral, or basic conditions using either normal phase or reverse phase HPLC or flash columns or Prep-TLC plates.
  • Compound purity and mass confirmations were conducted using standard HPLC and/or UPLC and/or MS spectrometers and/or LCMS and/or GC equipment (i.e., including, but not limited to the following instrumentation: Waters Alliance 2695 with 2996 PDA detector connected with ZQ detector and ESI source: Shimadzu LDMS-2020; Waters Acquity H Class with PDA detector connected with SQ detector and ESI source; Agilent 1100 Series with PDA detector; Waters Alliance 2695 with 2998 PDA detector; AB SCIEX API 2000 with ESI source; Agilent 7890 GC).
  • Step 4 Synthesis of Tert-Butyl 4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidine-1-carboxylate
  • tert-Butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate was added (0.070 g, 0.41 mmol) in DCM (5 mL) followed by triethylamine (0.23 mL, 0.17 mmol). The reaction was stirred at RT for 1 hr. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with sodium bicarbonate and, extracted with DCM.
  • Step 1 Synthesis of Tert-Butyl ((2S)-1-(4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate
  • Step 2 Synthesis of N-1-(1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)piperidin-4-yl)ethyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 1 Synthesis of tert-butyl ((S)-1-(4-((S)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate and tert-butyl ((S)-1-(4-((R)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate
  • Step 2 Synthesis of N—((S)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 2 Synthesis of N—((R)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 2 Synthesis of tert-butyl 4-(3-(methoxycarbonyl)benzoyl)piperidine-1-carboxylate
  • Step 4 Synthesis of tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate
  • Step 5 Synthesis of 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(5-cyclopropylisoxazole-3-carboxamido)methyl)benzoic Acid
  • Step 6 Synthesis of Tert-Butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidine-1-carboxylate
  • Step 7 Synthesis of 5-cyclopropyl-N-(piperidin-4-yl(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)isoxazole-3-carboxamide Hydrochloride
  • Step 8 Synthesis of Tert-butyl ((2S)-1-(4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate
  • Step 9 Synthesis of N-((1-((S)-2-aminopropanoyl)piperidin-4-yl)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 1 Synthesis of (S)-tert-butyl (1-(4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidin-1l-yl)-3-methyl-1-oxobutan-2-yl)carbamate
  • Step 2 Synthesis of (S)—N-((1-(2-amino-3-methylbutanoyl)piperidin-4-yl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 1 Synthesis of (E)-1-(4-aminophenyl)-3-(pyridin-3-yl)prop-2-en-1-one
  • Step 3 Synthesis of 5-cyclopropyl-N-(4-(3-(pyridin-3-yl)propanoyl)phenyl)isoxazole-3-carboxamide
  • Triethylamine (0.35 mL, 2.61 mmol) and a solution of 1-(4-aminophenyl)-3-(pyridin-3-yl)propan-1-one (0.354 g, 1.56 mmol) in DCM (1 mL) was added at 0° C. to the reaction mixture. The mixture was stirred at rt for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was quenched with saturated NaHCO 3 solution and extracted with DCM.
  • Step 4 Synthesis of N-(4-(1-amino-3-(pyridin-3-yl)propyl)phenyl)-5-cyclopropylisoxazole-3-carboxamide
  • Step 1 Synthesis of (S)-Tert-butyl (1-((4-(5-cyclopropylisoxazole-3-carboxamido)butyl) amino)-1-oxopropan-2-yl)carbamate
  • Step 2 Synthesis of (S)—N-(4-(2-aminopropanamido)butyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 4 Synthesis of Tert-Butyl ((1r,4r)-4-(5-(2-hydroxyethyl)isoxazole-3-carboxamido)cyclohexyl)carbamate
  • Step 5 Synthesis of N-((1r,4r)-4-aminocyclohexyl)-5-(2-hydroxyethyl)isoxazole-3-carboxamide Hydrochloride
  • Step 3 Synthesis of Tert-Butyl ((1r,4r)-4-(5-cyclopropyl-4-iodoisoxazole-3-carboxamido)cyclohexyl)carbamate
  • Step 4 Synthesis of N-((1r,4r)-4-aminocyclohexyl-5-cyclopropyl-4-iodoisoxazole-3-carboxamide Hydrochloride
  • Step 1 Synthesis of 3-(((r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylic Acid
  • Step 2 Synthesis of Pentafluorophenyl 3-(((1r,4r)-4-((tert-butoxycarbonyl)amino) cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylate
  • Step 3 Synthesis of Tert-Butyl ((1r,4r)-4-(4-carbamoyl-5-cyclopropylisoxazole-3-carboxamido)cyclohexyl)carbamate
  • the material was purified by trituration with hexane and diethyl ether to obtain tert-butyl ((1 r,4r)-4-4-carbamoyl-5-cyclopropylisoxazole-3-carboxamido)cyclohexyl) carbamate (0.040 g, 71%.).
  • Step 4 Synthesis of N3-((1r,4r)-4-aminocyclohexyl)-5-cyclopropylisoxazole-3,4-dicarboxamide Hydrochloride
  • Step 1 Synthesis of N 2 ,N 6 -dibenzylbicyclo[3.3.1]nonane-2,6-diamine
  • Step 6 Synthesis of Tert-Butyl ((2R)-4-((6-(5-cyclopropylisoxazole-3-carboxamido) bicyclo[3.3.1]nonan-2-yl)amino)-4-oxobutan-2-yl)carbamate
  • Step 7 Synthesis of N-(6-((R)-3-aminobutanamido)bicyclo[3.3.]nonan-2-yl)-5-cyclopropylisoxazole-3-carboxamide
  • Step 2 Synthesis of Tert-Butyl 3-(4-(5-cyclopropylisoxazole-3-carboxamido) phenylamino)-3-oxopropylcarbamate
  • N-(4-aminophenyl)-5-cyclopropylisoxazole-3-carboxamide (170 mg, 0.70 mmol, 1.00 equiv), tetrahydrofuran (5 mL), dichloromethane (5 mL), EDCI (401 mg, 2.09 mmol, 2.99 equiv), DIEA (271 mg, 2.10 mmol, 3.00 equiv), HOBT (283 mg, 2.09 mmol, 3.00 equiv), and 3-[[(tert-butoxy)carbonyl]amino]propanoic acid (264 mg, 1.40 mmol, 2.00 equiv).
  • Step 3 Synthesis of N-(4-(3-aminopropanamido)phenyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Step 1 Synthesis of Tert-Butyl 3-(5-cyclopropylisoxazole-3-carboxamido)azetidine-1-carboxylate
  • Step 3 Synthesis of N-(1-((1-(4-chlorobenzyl)-1H-pyrazol-4-yl)methyl)azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide
  • SAM S-adenosylmethionine
  • SAH S-adenosylhomocysteine
  • Tris Tris
  • Tween20 dimethylsulfoxide (DMSO)
  • BSG bovine skin gelatin
  • TCEP Tris(2-carboxyethyl)phosphine hydrochloride solution
  • 3 H-SAM was purchase from American Radiolabeled Chemicals with a specific activity of 80 Ci/mmol.
  • 384-well opaque white OptiPlates and SPA beads (Perkin Elmer, catalog # RPNQ0013) were purchased from PerkinElmer.
  • MEKK2 N-terminally GST-tagged MEKK2 (MAP3K2) protein corresponding to reference sequence AAF63496.3 was purchased from Life Technologies (catalog # PV4010). This protein was expressed in High Five insect cells and purified to >85% purity. Protein identity was confirmed by MS/MS analysis after proteolytic digestion. The protein sequence used was:
  • Full-length human SMYD3 isoform 1 (BAB86333) was inserted into a modified pET21 b plasmid containing a His6 tag and TEV and SUMO cleavage sites. Because two common variants of SMYD3 exist in the population, site directed mutagenesis was subsequently performed to change amino acid 13 from an asparagine to a lysine, resulting in plasmid pEPZ533. A lysine at position 13 conforms to the more commonly occurring sequence (NP_001161212).
  • E. coli (BL21 codonplus RIL strain, Stratagene) were transformed with plasmid pEPZ553 by mixing competent cells and plasmid DNA and incubating on ice for 30 minutes followed by heat shock at 42° C. for 1 minute and cooling on ice for 2 minutes. Transformed cells were grown and selected on LB agar with 100 ⁇ g/mL ampicillin and 17 ⁇ g/mL chloramphenicol at 37° C. overnight. A single clone was used to inoculate 200 mL of LB medium with 100 g/mL ampicillin and 17 ⁇ g/mL chloramphenicol and incubated at 37° C. on an orbital shaker at 180 rpm.
  • the culture was diluted 1:100 into 2 L of LB medium and grown until OD 600 was about 0.3 after which the culture was incubated at 15° C. and 160 rpm. Once OD 600 reached about 0.4, IPTG was added to a final concentration of 0.1 mM and the cells were grown overnight at 15° C. and 160 rpm. Cells were harvested by centrifugation at 8000 rpm, for 4 minutes at 4° C. and stored at ⁇ 80° C. for purification.
  • Expressed full-length human His-tagged SMYD3 protein was purified from cell paste by Nickel affinity chromatography after equilibration of the resin with Buffer A (25 mM Tris, 200 mM NaCl, 5% glycerol, 5 mM ⁇ -mercaptoethanol, pH7.8).
  • Buffer A 25 mM Tris, 200 mM NaCl, 5% glycerol, 5 mM ⁇ -mercaptoethanol, pH7.8.
  • the column was washed with Buffer B (Buffer A plus 20 mM imidazole) and His-tagged SMYD3 was eluted with Buffer C (Buffer A plus 300 mM imidazole).
  • Buffer A Buffer A plus 20 mM imidazole
  • Buffer C Buffer A plus 300 mM imidazole.
  • the His tag, TEV and SUMO cleavage sites were removed generating native SMYD3 by addition of ULP1 protein at
  • Imidazole was removed by dialysis overnight in Buffer A.
  • the dialyzed solution was applied to a second Nickel column and the native SMYD3 protein was collected from the column flow-through.
  • the flow-through was dialyzed in Buffer D (25 mM Tris, 5% glycerol, 5 mM ⁇ -mercaptoethanol, 50 mM NaCl, pH7.8) and ULP1 was removed using a Q sepharose fast flow column.
  • SMYD3 was eluted in Buffer A and further purified using an S200 size-exclusion column equilibrated with Buffer A. SMYD3 was concentrated to 2 mg/mL with a final purity of 89%.
  • SMYD3 (Q9H7B4) (SEQ ID No. 2).
  • MEPLKVEKFATAKRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCD RCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPD
  • SVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMT FQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPS ISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERR KQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHW KWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFY GTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFD
  • the assays were all performed in a buffer consisting of 25 mM Tris-Cl pH 8.0, 1 mM TCEP, 0.005% BSG, and 0.005% Tween 20, prepared on the day of use.
  • Compounds in 100% DMSO (1 ul) were spotted into a 384-well white opaque OptiPlate using a Bravo automated liquid handling platform outfitted with a 384-channel head (Agilent Technologies).
  • DMSO (1 ul) was added to Columns 11, 12, 23, 24, rows A-H for the maximum signal control and 1 ul of SAH, a known product and inhibitor of SMYD3, was added to columns 11, 12, 23, 24, rows I-P for the minimum signal control.
  • the assays were stopped by the addition of non-radiolabeled SAM (10 ul) to a final concentration of 100 uM, which dilutes the 3 H-SAM to a level where its incorporation into MEKK2 is no longer detectable.
  • Radiolabeled MEKK2 was detected using a scintillation proximity assay (SPA). 10 uL of a 10 mg/mL solution of SPA beads in 0.5 M citric acid was added and the plates centrifuged at 600 rpm for 1 min to precipitate the radiolabeled MEKK2 onto the SPA beads. The plates were then read in a PerkinElmer TopCount plate reader to measure the quantity of 3 H-labeled MEKK2 as disintegrations per minute (dpm) or alternatively, referred to as counts per minute (cpm).
  • dpm disintegrations per minute
  • cpm counts per minute
  • % ⁇ ⁇ inh 100 - ( dpm cmpd - dpm m ⁇ ⁇ i ⁇ ⁇ n dpm ma ⁇ ⁇ x - dpm m ⁇ ⁇ i ⁇ ⁇ n ) ⁇ 100
  • top and bottom are the normally allowed to float, but may be fixed at 100 or 0 respectively in a 3-parameter fit.
  • the Hill Coefficient normally allowed to float but may also be fixed at 1 in a 3-parameter fit.
  • Y is the % inhibition and X is the compound concentration.
  • 293T/17 adherent cells were purchased from ATCC (American Type Culture Collection), Manassas, Va., USA.
  • MEM/Glutamax medium, Optimem Reduced Serum medium, penicillin-streptomycin, 0.05% trypsin and 1 ⁇ D-PBS were purchased from Life Technologies, Grand Island, N.Y., USA.
  • PBS-10X was purchased from Ambion, Life Technologies, Grand Island. N.Y., USA.
  • PBS with Tween 20 (PBST (10 ⁇ ) was purchased from KPL, Gaithersburg, Md., USA.
  • Tet System FBS— approved FBS US Source was purchased from Clontech. Mountain View, Calif., USA.
  • Tri-methyl-Lysine [A260]-MEKK2 antibody, MEKK2 and SMYD3 plasmids were made at Epizyne.
  • Anti-flag monoclonal mouse antibody was purchased from Sigma, St. Louis, Mo., USA.
  • Methanol was purchased from VWR. Franklin, Mass., USA.
  • 10% Tween 20 was purchased from KPL, Inc., Gaithersburg, Md. USA. Fugene was purchased from Promega, Madison, Wis., USA.
  • the Biotek ELx405 was purchased from BioTek, Winooski, Vt., USA.
  • the multidrop combi was purchased from Thermo Scientific, Waltham, Mass., USA.
  • 293T/17 adherent cells were maintained in growth medium (MEM/Glutamax medium supplemented with 10% v/v Tet System FBS and cultured at 37° C. under 5% CO 2 .
  • 293T/17 cells were seeded in assay medium at a concentration of 33,333 cells per cm 2 in 30 mL medium per T150 flask and incubated at 37° C. under 5% CO 2 . Plasmids were prepared for delivery to cells by first mixing 1350 ⁇ L Opti-MEM with Fugene (81 ⁇ L) in a sterile Eppendorf and incubated for five minutes at room temperature (RT).
  • MEKK2-flag (13.6 ug/T150)
  • SMYD3 p3XFlag-CMV-14 without C-3XFlag plasmids were aliquotted to a 1.7 mL sterile microfuge tube.
  • the gene ID for MEKK2 and SMYD3 is NM_006609.3 and Q9H7B4, respectively.
  • Entire volume of Opti-MEM/Fugene mixture was then added to a microfuge tube containing DNA plasmid, mixed and then incubated ⁇ 15 minutes at RT.
  • the medium on the 293T/17 cells was refreshed, and the DNA/Fugene complex is added aseptically to each flask, rocked gently, and incubated at 37 C for 5 hours. Medium was then removed, and cells were washed once with PBS in the flask. Trypsin 0.05% (3 mL) was added and cells incubated for three minutes. Room temperature MEM+10% Tet system FBS was added and cells were mixed gently, and counted using the Vi-cell. Cells were seeded at 100,000 cells/mL in 50 ⁇ L MEM/10% Tet FBS/Pen/Strep to a 384 well black/clear poly-D-lysine coated plate containing test agent diluted in DMSO.
  • test compound was 40 ⁇ M.
  • the total concentration of DMSO did not exceed 0.2% (v/v).
  • Plates were incubated ⁇ 30 minutes at RT in low-airflow area, followed by incubation at 37° C. under 5% CO 2 for 24 hours.
  • Medium was aspirated from all wells of assay plates prior to fixation and permeabilization with ice cold ( ⁇ 20° C.) methanol (90 ⁇ L/well) for ten minutes. Plates were rinsed with PBS three times on BioTek ELx405. PBS was removed with a final aspiration, and Odyssey blocking buffer (50 ⁇ L/well) was added to each well and incubated for one hour at RT.
  • Detection antibody solution (IRDye 800 CW goat anti-rabbit IgG diluted 1:400 in diluent (Odyssey Blocking buffer+0.1% Tween 20), plus IRDye 680CW goat anti-mouse IgG at 1:500 in diluent (Odyssey Blocking buffer+0.1% Tween 20) was added (20 ⁇ L/well) and incubated in dark for one hour at RT. Plates were then washed four times with PBS-T (1X) on ELx405. A final rinse with water was performed (115 ⁇ L/well ⁇ three washes on the ELx405).
  • Each plate included fourteen control wells of DMSO only treatment (Minimum Inhibition) as well as fourteen control wells for maximum inhibition (Background). The average of the ratio values for each control type was calculated and used to determine the percent inhibition for each test well in the plate. Reference compound was serially diluted two-fold in DMSO for a total of nine test concentrations, beginning at 40 ⁇ M. Percent inhibition was calculated (below).
  • Percent ⁇ ⁇ Inhibition 100 - ( ( ( individual ⁇ ⁇ Test ⁇ ⁇ Sample ⁇ ⁇ Ratio ) - ( Background ⁇ ⁇ Avg ⁇ ⁇ Ratio ) ( Minimum ⁇ ⁇ inhibition ⁇ ⁇ Ratio ) ⁇ ( Background ⁇ ⁇ Average ⁇ ⁇ Ratio ) ) * 100 )
  • Non-linear regression curves were generated to calculate the IC 50 and dose-response relationship using triplicate wells per concentration of compound.
  • SAM S-adenosylmethionine
  • SAH S-adenosylhomocysteine
  • bicine Tween20
  • dimethylsulfoxide DMSO
  • bovine skin gelatin BSG
  • Tris(2-carboxyethyl)phosphine hydrochloride TCEP
  • 3H-SAM was purchase from American Radiolabeled Chemicals with a specific activity of 80 Ci/mmol.
  • 384-well streptavidin Flashplates were purchased from PerkinElmer.
  • Peptide was synthesized with a N-terminal linker-affinity tag motif and a C-terminal amide cap by 21 st Century Biochemicals.
  • the peptide was high high-performance liquid chromatography (HPLC) purified to greater than 95% purity and confirmed by liquid chromatography mass spectrometry (LC-MS).
  • HPLC high-performance liquid chromatography
  • LC-MS liquid chromatography mass spectrometry
  • SMYD2 Full length SMYD2 (NP_064582.2) was cloned into a pFastbac-Htb-lic vector with an N-terminal His6 tag and FLAG tag, preceded by a TEV protease cleavage site.
  • the protein was expressed in Sf9 insect cells. Cells were resuspended in lysis buffer (25 mM HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol, and 5 mM ⁇ -ME) and lysed by sonication.
  • lysis buffer 25 mM HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol, and 5 mM ⁇ -ME
  • the protein was purified by Ni-NTA (Qiagen), followed by TEV cleavage to remove the His6 tag, subtractive Ni-NTA (Qiagen), and gel filtration chromatography using an S200 column (GE Healthcare). Purified protein was stored in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. and 1 mM TCEP.
  • Compounds in 100% DMSO (1 ul) were spotted into a polypropylene 384-well V-bottom plates (Greiner) using a Platemate Plus outfitted with a 384-channel head (Thermo Scientific).
  • DMSO (1 ul) was added to Columns 11, 12, 23, 24, rows A-H for the maximum signal control and 1 ul of SAH, a known product and inhibitor of SMYD2, was added to columns 11, 12, 23, 24, rows I-P for the minimum signal control.
  • the assays were stopped by the addition of non-radioactive SAM (10 ul) to a final concentration of 600 uM, which dilutes the 3 H-SAM to a level where its incorporation into the peptide substrate is no longer detectable.
  • 50 ul of the reaction in the 384-well polypropylene plate was then transferred to a 384-well Flashplate and the biotinylated peptides were allowed to bind to the streptavidin surface for at least 1 hour before being washed three times with 0.1% Tween20 in a Biotek ELx405 plate washer.
  • the plates were then read in a PerkinElmer TopCount plate reader to measure the quantity of 3 H-labeled peptide bound to the Flashplate surface, measured as disintegrations per minute (dpm) or alternatively, referred to as counts per minute (cpm).
  • top and bottom are the normally allowed to float, but may be fixed at 100 or 0 respectively in a 3-parameter fit.
  • the Hill Coefficient normally allowed to float but may also be fixed at 1 in a 3-parameter fit.
  • I is the compound concentration.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present disclosure provides substituted isoxazole carboxamide compounds having Formula (1) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, A, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2 Compounds of the present disclosure are especially useful for treating cancer.
Figure US20200148650A1-20200514-C00001

Description

    BACKGROUND OF THE INVENTION Field of the Invention
  • The present disclosure provides substituted isoxazole carboxamides as SMYD protein inhibitors, such as SMYD3 and SMYD2 inhibitors, and therapeutic methods of treating conditions and diseases wherein inhibition of SMYD proteins such as SMYD3 and SMYD2 provides a benefit.
    • Background
  • Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases. Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., SMYD proteins such as SMYD3 and SMYD2), many of which are associated with genetic alterations that can cause human disease, such as proliferative disorders. Thus, there is a need for the development of small molecules that are capable of inhibiting the activity of SMYD proteins such as SMYD3 and SMYD2.
    • BRIEF SUMMARY OF THE INVENTION
  • In one aspect, the present disclosure provides substituted isoxazole carboxamide compounds represented by Formulae I-XVII below, and the pharmaceutically acceptable salts and solvates thereof, collectively referred to herein as “Compounds of the Disclosure.”
  • In another aspect, the present disclosure provides a Compound of the Disclosure and one or more pharmaceutically acceptable carriers.
  • In another aspect, the present disclosure provides a method of inhibiting SMYD proteins, such as SMYD3 or SMYD2, or both, in a mammal, comprising administering to the mammal an effective amount of at least one Compound of the Disclosure.
  • In another aspect, the present disclosure provides methods for treating a disease, disorder, or condition, e.g., cancer, responsive to inhibition of SMYD proteins, such as SMYD3 or SMYD2, or both, comprising administering a therapeutically effective amount of a Compound of the Disclosure.
  • In another aspect, the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD3.
  • In another aspect, the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD2.
  • In another aspect, the present disclosure provides the use of Compounds of the Disclosure as inhibitors of SMYD proteins.
  • In another aspect, the present disclosure provides a pharmaceutical composition for treating a disease, disorder, or condition responsive to inhibition of SMYD proteins, such as SMYD3 or SMYD2, or both, wherein the pharmaceutical composition comprises a therapeutically effective amount of a Compound of the Disclosure in a mixture with one or more pharmaceutically acceptable carriers.
  • In another aspect, the present disclosure provides Compounds of the Disclosure for use in treating cancer in a mammal, e.g., breast, cervical, colon, kidney, liver, head and neck, skin, pancreatic, ovary, esophageal, lung, and prostate cancer.
  • In another aspect, the present disclosure provides a Compound of the Disclosure for use in the manufacture of a medicament for treating cancer in a mammal.
  • In another aspect, the present disclosure provides kit comprising a Compound of the Disclosure.
  • Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure. The embodiments and advantages of the disclosure will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
  • It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.
    • DETAILED DESCRIPTION OF TILE INVENTION
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD proteins. In view of this property, the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions, e.g., cancer, responsive to inhibition of SMYD proteins.
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD3. In view of this property, the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions. e.g., cancer, responsive to inhibition of SMYD3.
  • One aspect of the present disclosure is based on the use of Compounds of the Disclosure as inhibitors of SMYD2. In view of this property, the Compounds of the Disclosure are useful for treating diseases, disorders, or conditions, e.g., cancer, responsive to inhibition of SMYD2.
  • In one embodiment, Compounds of the Disclosure are compounds having Formula I:
  • Figure US20200148650A1-20200514-C00002
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof wherein:
  • R1 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-4 alkenyl, C1-4 haloalkyl, C3-6 cycloalkyl, and hydroxyalkyl;
  • R2 is selected from the group consisting of hydrogen, halo, and carboxamido;
  • A is selected from the group consisting of C1-10 alkylenyl, (cycloalkylenyl)alkyl, optionally substituted C3-12 cycloalkylenyl, optionally substituted C6-14 arylenyl, optionally substituted 5- to 14-membered heteroarylenyl, optionally substituted 4- to 14-membered heterocyclenyl, and —C(H)R3R4;
  • with the provisos:
  • a) when R1 is ethyl, n-propyl, isopropyl, isobutyl, or cyclopropyl; and R2 is hydrogen, then A is not optionally substituted, optionally bridged piperidinenyl;
  • b) when R1 is ethyl or cyclopropyl; R2 is hydrogen; and X is —N(R7)S(—O)2—, —N(R7)C(═O)—, or —N(R7)C(═O)C(R8)(H)—, then A is not optionally substituted 1,4-cyclohexylenyl;
  • c) when R1 is ethyl or cyclopropyl; R2 is hydrogen; X is absent; and Z is amino, alkylamino, dialkylamino, or heterocycloamino, then A is not optionally substituted 1,4-cyclohexylenyl; and
  • d) when R1 is hydrogen. C1-6 alkyl, or Cm cycloalkyl; and R2 is hydrogen, then A is not optionally substituted pyrrolidinenyl;
  • R3 is selected from the group consisting of hydrogen, C1-6 alkyl. (hydroxy)(aryl)alkyl, (amino)alkyl. (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, optionally substituted C3-12 cycloalkyl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted C6-14 aryl, aralkyl, alkoxycarbonyl, and —C(═O)N(R5)(R6);
  • R4 is selected from the group consisting of C1-6 alkyl, hydroxyalkyl, optionally substituted C3-12 cycloalkyl, optionally substituted C6-14 aryl, optionally substituted 5- to 14-membered heteroaryl, optionally substituted 4- to 14-membered heterocyclo, and (heteroaryl)alkyl;
  • R5 is selected from the from the group consisting of hydrogen and C1-4 alkyl;
  • R6 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, fluoroalkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(carboxamido)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl, (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
  • X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —N(R7)S(═O)2—, —S(═O)2C(R8)(H)—, —C(═O)—, —C(═O)N(R7)—, —N(R7)C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)C(R8)(H)N(R7)—, —N(R7)C(═O)C(R8)(H)—, —C(R8)(H)C(═O)N(R7)—, —C(R8)(H)N(R7)C(═O)—, and —C(═O)C(R8)(H)—; or X is absent, i.e., Z forms a bond with A;
  • Z is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, fluoroalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, heterocycloamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
  • wherein —X—Z is attached to any available carbon or nitrogen atom of A, R3, R4, or R6; e.g., when R4 is C1-6 alkyl. e.g., ethyl, a hydrogen atom of that ethyl group is replaced with —X—Z to give —CH2CH2—X—Z or
  • Figure US20200148650A1-20200514-C00003
  • or
  • when R4 is optionally substituted C3-12 cycloalkyl, e.g., cyclohexyl, a hydrogen atom of the cyclohexyl group is replaced with —X—Z to give:
  • Figure US20200148650A1-20200514-C00004
  • or
  • when R4 is optionally substituted 4- to 14-membered heterocyclo, e.g., piperidinyl, the hydrogen atom attached to the piperidinyl nitrogen atom is replaced with —X—Z to give:
  • Figure US20200148650A1-20200514-C00005
  • when R4 is optionally substituted C6-14 aryl, e.g., phenyl, a hydrogen atom on that phenyl group is replaced with —X—Z to give:
  • Figure US20200148650A1-20200514-C00006
  • R7 is selected from the group consisting of hydrogen and C1-4 alkyl; and
  • R8 is selected from the group consisting of hydrogen, C1-4 alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and hydroxyalkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is C1-10 alkylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula II:
  • Figure US20200148650A1-20200514-C00007
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R9a and R9b are independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • R9c and R9d are independently selected from the group consisting of hydrogen and C1-4alkyl; or
  • R9c and R9d taken together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
  • R9e is selected from the group consisting of hydrogen and C1-4 alkyl;
  • m is 0 or 1:
  • X is selected from the group consisting of —N(R7)C(═O)—, —N(R7)C(═O)C(R8)(H)—, and —N(R7)S(═O)2—;
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
  • Z is selected from the group consisting of C1-6 alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted 4- to 14-membered heterocyclo, and optionally substituted C1-4, cycloalkyl, and R1, R2, and R7 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted C6-14 arylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula III:
  • Figure US20200148650A1-20200514-C00008
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R10a is selected from the group consisting of hydrogen, halo, C1-6 alkyl, alkoxy, hydroxyalkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C(═O)N(R7)—, —N(R7)C(═O)—, —C(═O)C(R8)(H)N(R7)—, —C(R8)(H)C(═O)N(R7)— and —S(═O)2N(R7)—; or X is absent;
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
  • Z is selected from the group consisting of hydrogen, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, heteroalkyl, (amino)(hydroxy)alkyl, (heterocyclo)alkyl, optionally substituted C3-12 cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo, and R1, R2, and R7 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula IV:
  • Figure US20200148650A1-20200514-C00009
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R10a is selected from the group consisting of hydrogen, halo. C1-6 alkyl, alkoxy, hydroxyalkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C(═O)N(R7)—, —N(R7)C(═O)—, —C(═O)C(R8)(H)N(R7)—, —C(R8)(H)C(═O)N(R7)— and —S(═O)2N(R7)—; or X is absent;
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
  • Z is selected from the group consisting of hydrogen, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, heteroalkyl, (amino)hydroxy)alkyl, (heterocyclo)alkyl, optionally substituted C3-12 cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo, and R1, R2, and R7 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted C3-12 cycloalkylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula V:
  • Figure US20200148650A1-20200514-C00010
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R10a and R10b are independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —N(R7)C(═O)—, —C(═O)N(R7)—, —N(R7)S(═O)—, and —OC(═O)—; or X is absent;
  • Z is selected from the group consisting of amino, alkylamino, dialkylamino, heterocycloamino. (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and (hydroxyalkylamino)alkyl; n is 0 or 1; and p is 0 or 1, and R1, R2, and R7 are as defined above in connection with Formula I.
  • In another embodiment. Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is optionally substituted 4- to 14-membered heterocyclenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula VI:
  • Figure US20200148650A1-20200514-C00011
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R11a and R11b are each independently selected from the group consisting of hydrogen, C1-4 alkyl, and alkoxycarbonyl;
  • X is selected from the group consisting of —C(═O)—, —S(═O)2—, and —C(═O)C(R8)(H)—;
  • Z is selected from the group consisting of (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted C3-12 cycloalkyl, and aralkyl; and
  • r is 0 or 1, and R1, R2, and R8 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula XVI:
  • Figure US20200148650A1-20200514-C00012
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R11c and R11d are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • X is selected from the group consisting of —C(═O)— and —S(═O)2; or X is absent; and
  • Z, R1, and R2 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula XVI, and the pharmaceutically acceptable salts or solvates. e.g., hydrates, thereof, wherein R11c and R11d are hydrogen; X is absent; Z is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, fluoroalkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl. (dialkylamino)alkyl. (heterocyclo)alkyl, (cycloalkyl)alkyl, (hydroxy)(aryl)alkyl, alkoxyalkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl; R2 is hydrogen; and R1 is as defined above in connection with Formula I. In another embodiment, Z is selected from the group consisting of aralkyl, and (heteroaryl)alkyl. In another embodiment. Z is (heteroaryl)alkyl that is substituted with an aralkyl, e.g.,
  • Figure US20200148650A1-20200514-C00013
  • or (heteroaryl)alkyl, e.g.,
  • Figure US20200148650A1-20200514-C00014
  • In another embodiment, R1 is selected from the group consisting of C1-4 alkyl and C3-6 cycloalkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula XVII:
  • Figure US20200148650A1-20200514-C00015
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R″ is selected from the group consisting of aralkyl and (heteroaryl)alkyl; and
  • R1 is as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula XVII, wherein R1 is selected from the group consisting of C1-6 alkyl and C3-6 cycloalkyl. In another embodiment, R″ is aralkyl. In another embodiment, R″ is (heteroaryl)alkyl. In another embodiment, R″ is benzyl wherein the phenyl group is optionally substituted with one or two substituents, e.g., —CH2(4-Cl-Ph), —CH2(3-Cl-Ph), —CH2(3,4-di-Cl-Ph), and —CH2(4-CF3-Ph).
  • In another embodiment. Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein A is —C(H)R3R4. In another embodiment, R3 is selected from the group consisting of C1-6 alkyl and optionally substituted C3-12 cycloalkyl; and R4 is selected from the group consisting of optionally substituted C3-12 cycloalkyl and optionally substituted C6-14 aryl. In another embodiment, R4 is optionally substituted 4- to 14-membered heterocyclo. In another embodiment, R3 is C1-4 alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, optionally substituted C6-14 aryl, and aralkyl. In each of these embodiments. —X—Z replaces a hydrogen atom on the R4 substituent. In certain instances, —X—Z can be hydrogen, when X is absent and Z is hydrogen.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula VII, Formula VIII, or Formula IX:
  • Figure US20200148650A1-20200514-C00016
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • R3 is selected from the group consisting of hydrogen, C1-4 alkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted C6-14 aryl, aryloxyalkyl, and aralkyl;
  • X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —S(═O)2C(R8)(H)—, —C(═O)—, —C(═O)N(R7)—, —C(═O)O—, —OC(═O)—, and —C(═O)C(R8)(H)—; or X is absent;
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
  • Z is selected from the group consisting of C1-6 alkyl, (amino)alkyl. (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, hydroxyalkyl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl, and R1, R2, and R7 are as defined above in connection with Formula I. In another embodiment, R3 is selected from the group consisting of hydrogen and methyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula X, Formula XI, or Formula XII:
  • Figure US20200148650A1-20200514-C00017
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein R12 is selected from the group consisting of hydrogen, halo, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, (aralkyloxy)alkyl, alkoxyalkyl, heteroalkyl, (hydroxyalkylamino)alkyl, (heterocycloamino)alkyl, and carboxamido, and R1, R2, X, and Z are as defined above in connection with Formula I. In another embodiment, X is selected from the group consisting of —C(═O)N(R7)— and —S(═O)2N(R7)—; Z is optionally substituted C1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl. (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl; and R12 is hydrogen. In another embodiment, X is absent; Z is hydrogen; and R12 is selected from the group consisting of halo, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, (aralkyloxy)alkyl, alkoxyalkyl, heteroalkyl, (hydroxyalkylamino)alkyl, (hetcrocycloamino)alkyl, and carboxamido.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula XIII, Formula XIV, or Formula XV:
  • Figure US20200148650A1-20200514-C00018
  • and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein.
  • R6 is selected from the group consisting of optionally substituted C1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
  • X is selected from the group consisting of —C(═O)N(R7)—, —C(═O)C(R8)(H)—, and —S(═O)2N(R7)—; or X is absent;
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino:
  • Z is selected from the group consisting of C1-4 alkyl, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)heteroaryl)alkyl, and (amino)(hydroxy)alkyl, and R1, R2, and R7 are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein:
  • X is selected from the group consisting of:
  • Figure US20200148650A1-20200514-C00019
  • R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino, and R1, R2, A, and Z are as defined above in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds having any one of Formulae I-XVII, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, wherein R1 is selected from the group consisting of C10.4 alkyl and C3-6 cycloalkyl. In another embodiment, R1 is cyclopropyl. In another embodiment, R2 is hydrogen.
  • In another embodiment, a Compound of the Disclosure is not 5-cyclopropyl-N-(pyridin-3-yl)-1,2-oxazole-3-carboxamide.
  • In another embodiment, Compounds of the Disclosure are compounds of Table 1, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof. The chemical names of the compounds of Table 1 are provided in Table 1A.
  • In another embodiment, Compounds of the Disclosure are compounds of Table 1A, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof.
  • In another embodiment, Compounds of the Disclosure are compounds of Table 2, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • In another embodiment, Compounds of the Disclosure is the compound of Table 3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof.
  • In another embodiment, Compounds of the Disclosure are compounds of Tables 1 and 2, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • In another embodiment, Compounds of the Disclosure are compounds of Tables 1-3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof.
  • In another embodiment, Compounds of the Disclosure are compounds of Table 1, Table 1A, Table 2, and Table 3, and the pharmaceutically acceptable salts or solvates, e.g., hydrates, thereof, or different pharmaceutically acceptable salt thereof
  • It should be appreciated that the Compounds of the Disclosure in certain embodiments are the free base, various salts, and hydrate forms, and are not limited to the particular salt listed in Table 1, Table 2, and Table 3.
  • TABLE 1
    Cpd. Salt
    No. Structure Form
    2
    Figure US20200148650A1-20200514-C00020
         		None
    3
    Figure US20200148650A1-20200514-C00021
         		None
    4
    Figure US20200148650A1-20200514-C00022
         		HCl
    5
    Figure US20200148650A1-20200514-C00023
         		None
    6
    Figure US20200148650A1-20200514-C00024
         		TFA
    7
    Figure US20200148650A1-20200514-C00025
         		TFA
    8
    Figure US20200148650A1-20200514-C00026
         		HCl
    9
    Figure US20200148650A1-20200514-C00027
         		HCl
    10
    Figure US20200148650A1-20200514-C00028
         		HCl
    11
    Figure US20200148650A1-20200514-C00029
         		HCl
    12
    Figure US20200148650A1-20200514-C00030
         		None
    13
    Figure US20200148650A1-20200514-C00031
         		HCl
    14
    Figure US20200148650A1-20200514-C00032
         		HCl
    15
    Figure US20200148650A1-20200514-C00033
         		HCl
    16
    Figure US20200148650A1-20200514-C00034
         		HCl
    17
    Figure US20200148650A1-20200514-C00035
         		HCl
    18
    Figure US20200148650A1-20200514-C00036
         		None
    19
    Figure US20200148650A1-20200514-C00037
         		None
    20
    Figure US20200148650A1-20200514-C00038
         		None
    21
    Figure US20200148650A1-20200514-C00039
         		HCl
    22
    Figure US20200148650A1-20200514-C00040
         		HCl
    23
    Figure US20200148650A1-20200514-C00041
         		TFA
    24
    Figure US20200148650A1-20200514-C00042
         		HCl
    25
    Figure US20200148650A1-20200514-C00043
         		None
    26
    Figure US20200148650A1-20200514-C00044
         		None
    27
    Figure US20200148650A1-20200514-C00045
         		None
    28
    Figure US20200148650A1-20200514-C00046
         		None
    29
    Figure US20200148650A1-20200514-C00047
         		None
    30
    Figure US20200148650A1-20200514-C00048
         		None
    31
    Figure US20200148650A1-20200514-C00049
         		None
    32
    Figure US20200148650A1-20200514-C00050
         		None
    33
    Figure US20200148650A1-20200514-C00051
         		HCl
    34
    Figure US20200148650A1-20200514-C00052
         		HCl
    35
    Figure US20200148650A1-20200514-C00053
         		HCOOH
    36
    Figure US20200148650A1-20200514-C00054
         		None
    37
    Figure US20200148650A1-20200514-C00055
         		HCl
    38
    Figure US20200148650A1-20200514-C00056
         		HCl
    39
    Figure US20200148650A1-20200514-C00057
         		HCl
    40
    Figure US20200148650A1-20200514-C00058
         		HCl
    41
    Figure US20200148650A1-20200514-C00059
         		HCl
    42
    Figure US20200148650A1-20200514-C00060
         		None
    43
    Figure US20200148650A1-20200514-C00061
         		None
    44
    Figure US20200148650A1-20200514-C00062
         		HCl
    45
    Figure US20200148650A1-20200514-C00063
         		HCl
    46
    Figure US20200148650A1-20200514-C00064
         		None
    47
    Figure US20200148650A1-20200514-C00065
         		None
    48
    Figure US20200148650A1-20200514-C00066
         		None
    49
    Figure US20200148650A1-20200514-C00067
         		HCl
    50
    Figure US20200148650A1-20200514-C00068
         		None
    51
    Figure US20200148650A1-20200514-C00069
         		None
    52
    Figure US20200148650A1-20200514-C00070
         		None
    53
    Figure US20200148650A1-20200514-C00071
         		None
    54
    Figure US20200148650A1-20200514-C00072
         		None
    55
    Figure US20200148650A1-20200514-C00073
         		None
    56
    Figure US20200148650A1-20200514-C00074
         		HCl
    57
    Figure US20200148650A1-20200514-C00075
         		None
    58
    Figure US20200148650A1-20200514-C00076
         		None
    59
    Figure US20200148650A1-20200514-C00077
         		TFA
    60
    Figure US20200148650A1-20200514-C00078
         		TFA
    61
    Figure US20200148650A1-20200514-C00079
         		None
    62
    Figure US20200148650A1-20200514-C00080
         		HCl
    63
    Figure US20200148650A1-20200514-C00081
         		HCl
    64
    Figure US20200148650A1-20200514-C00082
         		None
    65
    Figure US20200148650A1-20200514-C00083
         		TFA
    66
    Figure US20200148650A1-20200514-C00084
         		HCl
    67
    Figure US20200148650A1-20200514-C00085
         		HCl
    68
    Figure US20200148650A1-20200514-C00086
         		HCl
    69
    Figure US20200148650A1-20200514-C00087
         		HCl
    70
    Figure US20200148650A1-20200514-C00088
         		HCl
    71
    Figure US20200148650A1-20200514-C00089
         		None
    72
    Figure US20200148650A1-20200514-C00090
         		HCl
    73
    Figure US20200148650A1-20200514-C00091
         		HCl
    74
    Figure US20200148650A1-20200514-C00092
         		HCl
    75
    Figure US20200148650A1-20200514-C00093
         		HCl
    76
    Figure US20200148650A1-20200514-C00094
         		HCl
    77
    Figure US20200148650A1-20200514-C00095
         		HCl
    78
    Figure US20200148650A1-20200514-C00096
         		HCl
    79
    Figure US20200148650A1-20200514-C00097
         		HCl
    80
    Figure US20200148650A1-20200514-C00098
         		HCl
    81
    Figure US20200148650A1-20200514-C00099
         		None
    82
    Figure US20200148650A1-20200514-C00100
         		HCl
    83
    Figure US20200148650A1-20200514-C00101
         		HCl
    84
    Figure US20200148650A1-20200514-C00102
         		HCl
    85
    Figure US20200148650A1-20200514-C00103
         		HCl
    86
    Figure US20200148650A1-20200514-C00104
         		HCl
    87
    Figure US20200148650A1-20200514-C00105
         		HCl
    88
    Figure US20200148650A1-20200514-C00106
         		HCl
    89
    Figure US20200148650A1-20200514-C00107
         		HCl
    90
    Figure US20200148650A1-20200514-C00108
         		HCl
    91
    Figure US20200148650A1-20200514-C00109
         		HCl
    92
    Figure US20200148650A1-20200514-C00110
         		HCl
    93
    Figure US20200148650A1-20200514-C00111
         		HCl
    94
    Figure US20200148650A1-20200514-C00112
         		HCl
    95
    Figure US20200148650A1-20200514-C00113
         		None
    96
    Figure US20200148650A1-20200514-C00114
         		HCl
    97
    Figure US20200148650A1-20200514-C00115
         		HCl
    98
    Figure US20200148650A1-20200514-C00116
         		HCl
    99
    Figure US20200148650A1-20200514-C00117
         		HCl
    100
    Figure US20200148650A1-20200514-C00118
         		HCl
    101
    Figure US20200148650A1-20200514-C00119
         		HCl
    102
    Figure US20200148650A1-20200514-C00120
         		HCl
    103
    Figure US20200148650A1-20200514-C00121
         		TFA
    104
    Figure US20200148650A1-20200514-C00122
         		TFA
    105
    Figure US20200148650A1-20200514-C00123
         		HCl
    106
    Figure US20200148650A1-20200514-C00124
         		HCl
    107
    Figure US20200148650A1-20200514-C00125
         		TFA
    108
    Figure US20200148650A1-20200514-C00126
         		TFA
    109
    Figure US20200148650A1-20200514-C00127
         		HCl
    110
    Figure US20200148650A1-20200514-C00128
         		HCl
    111
    Figure US20200148650A1-20200514-C00129
         		HCl
    112
    Figure US20200148650A1-20200514-C00130
         		HCl
    113
    Figure US20200148650A1-20200514-C00131
         		HCl
    114
    Figure US20200148650A1-20200514-C00132
         		HCl
    115
    Figure US20200148650A1-20200514-C00133
         		HCl
    116
    Figure US20200148650A1-20200514-C00134
         		HCl
    117
    Figure US20200148650A1-20200514-C00135
         		HCl
    118
    Figure US20200148650A1-20200514-C00136
         		HCl
    119
    Figure US20200148650A1-20200514-C00137
         		TFA
    120
    Figure US20200148650A1-20200514-C00138
         		HCl
    121
    Figure US20200148650A1-20200514-C00139
         		HCl
    122
    Figure US20200148650A1-20200514-C00140
         		None
    123
    Figure US20200148650A1-20200514-C00141
         		None
    124
    Figure US20200148650A1-20200514-C00142
         		None
    125
    Figure US20200148650A1-20200514-C00143
         		None
    126
    Figure US20200148650A1-20200514-C00144
         		None
    127
    Figure US20200148650A1-20200514-C00145
         		None
    128
    Figure US20200148650A1-20200514-C00146
         		None
    129
    Figure US20200148650A1-20200514-C00147
         		None
    130
    Figure US20200148650A1-20200514-C00148
         		TFA
    131
    Figure US20200148650A1-20200514-C00149
         		HCl
    132
    Figure US20200148650A1-20200514-C00150
         		HCl
    133
    Figure US20200148650A1-20200514-C00151
         		HCl
    134
    Figure US20200148650A1-20200514-C00152
         		None
    135
    Figure US20200148650A1-20200514-C00153
         		None
    136
    Figure US20200148650A1-20200514-C00154
         		None
    137
    Figure US20200148650A1-20200514-C00155
         		None
    138
    Figure US20200148650A1-20200514-C00156
         		None
    139
    Figure US20200148650A1-20200514-C00157
         		HCl
    140
    Figure US20200148650A1-20200514-C00158
         		TFA
    141
    Figure US20200148650A1-20200514-C00159
         		HCl
    142
    Figure US20200148650A1-20200514-C00160
         		TFA
    143
    Figure US20200148650A1-20200514-C00161
         		None
    144
    Figure US20200148650A1-20200514-C00162
         		None
    145
    Figure US20200148650A1-20200514-C00163
         		None
    146
    Figure US20200148650A1-20200514-C00164
         		None
    147
    Figure US20200148650A1-20200514-C00165
         		TFA
    148
    Figure US20200148650A1-20200514-C00166
         		None
    149
    Figure US20200148650A1-20200514-C00167
         		None
    150
    Figure US20200148650A1-20200514-C00168
         		None
    151
    Figure US20200148650A1-20200514-C00169
         		None
    152
    Figure US20200148650A1-20200514-C00170
         		HCl
    153
    Figure US20200148650A1-20200514-C00171
         		TFA
    154
    Figure US20200148650A1-20200514-C00172
         		None
    155
    Figure US20200148650A1-20200514-C00173
         		HCOOH
    156
    Figure US20200148650A1-20200514-C00174
         		None
    157
    Figure US20200148650A1-20200514-C00175
         		None
    158
    Figure US20200148650A1-20200514-C00176
         		TFA
    159
    Figure US20200148650A1-20200514-C00177
         		TFA
    160
    Figure US20200148650A1-20200514-C00178
         		HCl
    161
    Figure US20200148650A1-20200514-C00179
         		HCl
    162
    Figure US20200148650A1-20200514-C00180
         		HCl
    163
    Figure US20200148650A1-20200514-C00181
         		HCl
    164
    Figure US20200148650A1-20200514-C00182
         		HCl
    165
    Figure US20200148650A1-20200514-C00183
         		None
    166
    Figure US20200148650A1-20200514-C00184
         		None
    167
    Figure US20200148650A1-20200514-C00185
         		None
    168
    Figure US20200148650A1-20200514-C00186
         		None
    169
    Figure US20200148650A1-20200514-C00187
         		TFA
    170
    Figure US20200148650A1-20200514-C00188
         		HCl
    171
    Figure US20200148650A1-20200514-C00189
         		HCl
    172
    Figure US20200148650A1-20200514-C00190
         		HCl
    173
    Figure US20200148650A1-20200514-C00191
         		HCl
    174
    Figure US20200148650A1-20200514-C00192
         		HCl
    175
    Figure US20200148650A1-20200514-C00193
         		None
    176
    Figure US20200148650A1-20200514-C00194
         		HCl
    177
    Figure US20200148650A1-20200514-C00195
         		HCl
    178
    Figure US20200148650A1-20200514-C00196
         		HCl
    179
    Figure US20200148650A1-20200514-C00197
         		HCl
    180
    Figure US20200148650A1-20200514-C00198
         		HCl
    181
    Figure US20200148650A1-20200514-C00199
         		HCl
    182
    Figure US20200148650A1-20200514-C00200
         		HCl
    183
    Figure US20200148650A1-20200514-C00201
         		HCl
    184
    Figure US20200148650A1-20200514-C00202
         		HCl
    185
    Figure US20200148650A1-20200514-C00203
         		HCl
    186
    Figure US20200148650A1-20200514-C00204
         		HCl
    187
    Figure US20200148650A1-20200514-C00205
         		HCl
    188
    Figure US20200148650A1-20200514-C00206
         		HCl
    189
    Figure US20200148650A1-20200514-C00207
         		HCl
    190
    Figure US20200148650A1-20200514-C00208
         		HCl
    191
    Figure US20200148650A1-20200514-C00209
         		HCl
    192
    Figure US20200148650A1-20200514-C00210
         		HCl
    193
    Figure US20200148650A1-20200514-C00211
         		HCl
    194
    Figure US20200148650A1-20200514-C00212
         		HCl
    195
    Figure US20200148650A1-20200514-C00213
         		HCl
    196
    Figure US20200148650A1-20200514-C00214
         		HCl
    197
    Figure US20200148650A1-20200514-C00215
         		HCl
    198
    Figure US20200148650A1-20200514-C00216
         		TFA
    199
    Figure US20200148650A1-20200514-C00217
         		TFA
    200
    Figure US20200148650A1-20200514-C00218
         		HCl
    201
    Figure US20200148650A1-20200514-C00219
         		HCl
    202
    Figure US20200148650A1-20200514-C00220
         		HCl
    203
    Figure US20200148650A1-20200514-C00221
         		HCl
    204
    Figure US20200148650A1-20200514-C00222
         		HCl
    205
    Figure US20200148650A1-20200514-C00223
         		HCl
    206
    Figure US20200148650A1-20200514-C00224
         		HCl
    207
    Figure US20200148650A1-20200514-C00225
         		HCl
    208
    Figure US20200148650A1-20200514-C00226
         		HCl
    209
    Figure US20200148650A1-20200514-C00227
         		HCl
    210
    Figure US20200148650A1-20200514-C00228
         		HCl
    211
    Figure US20200148650A1-20200514-C00229
         		HCl
    212
    Figure US20200148650A1-20200514-C00230
         		None
    213
    Figure US20200148650A1-20200514-C00231
         		HCl
    214
    Figure US20200148650A1-20200514-C00232
         		HCl
    215
    Figure US20200148650A1-20200514-C00233
         		HCl
    216
    Figure US20200148650A1-20200514-C00234
         		HCl
    218
    Figure US20200148650A1-20200514-C00235
         		HCl
    219
    Figure US20200148650A1-20200514-C00236
         		HCl
    220
    Figure US20200148650A1-20200514-C00237
         		HCl
    221
    Figure US20200148650A1-20200514-C00238
         		HCl
    222
    Figure US20200148650A1-20200514-C00239
         		HCl
    223
    Figure US20200148650A1-20200514-C00240
         		HCl
    224
    Figure US20200148650A1-20200514-C00241
         		HCl
    225
    Figure US20200148650A1-20200514-C00242
         		HCl
    226
    Figure US20200148650A1-20200514-C00243
         		HCl
    227
    Figure US20200148650A1-20200514-C00244
         		HCl
    228
    Figure US20200148650A1-20200514-C00245
         		HCl
    229
    Figure US20200148650A1-20200514-C00246
         		HCl
    230
    Figure US20200148650A1-20200514-C00247
         		HCl
    231
    Figure US20200148650A1-20200514-C00248
         		HCl
    232
    Figure US20200148650A1-20200514-C00249
         		HCl
    233
    Figure US20200148650A1-20200514-C00250
         		TFA
    234
    Figure US20200148650A1-20200514-C00251
         		HCl
    235
    Figure US20200148650A1-20200514-C00252
         		TFA
    236
    Figure US20200148650A1-20200514-C00253
         		TFA
    237
    Figure US20200148650A1-20200514-C00254
         		HCl
    238
    Figure US20200148650A1-20200514-C00255
         		TFA
    239
    Figure US20200148650A1-20200514-C00256
         		TFA
    240
    Figure US20200148650A1-20200514-C00257
         		TFA
    241
    Figure US20200148650A1-20200514-C00258
         		HCl
    242
    Figure US20200148650A1-20200514-C00259
         		HCl
    243
    Figure US20200148650A1-20200514-C00260
         		HCl
    244
    Figure US20200148650A1-20200514-C00261
         		TFA
    245
    Figure US20200148650A1-20200514-C00262
         		TFA
    246
    Figure US20200148650A1-20200514-C00263
         		TFA
    247
    Figure US20200148650A1-20200514-C00264
         		HCl
    248
    Figure US20200148650A1-20200514-C00265
         		HCOOH
    249
    Figure US20200148650A1-20200514-C00266
         		HCl
    250
    Figure US20200148650A1-20200514-C00267
         		HCl
    251
    Figure US20200148650A1-20200514-C00268
         		HCl
    252
    Figure US20200148650A1-20200514-C00269
         		HCl
    253
    Figure US20200148650A1-20200514-C00270
         		TFA
    254
    Figure US20200148650A1-20200514-C00271
         		HCl
    255
    Figure US20200148650A1-20200514-C00272
         		HCl
    256
    Figure US20200148650A1-20200514-C00273
         		HCl
    257
    Figure US20200148650A1-20200514-C00274
         		TFA
    258
    Figure US20200148650A1-20200514-C00275
         		TFA
    259
    Figure US20200148650A1-20200514-C00276
         		TFA
    260
    Figure US20200148650A1-20200514-C00277
         		TFA
    261
    Figure US20200148650A1-20200514-C00278
         		HCl
    262
    Figure US20200148650A1-20200514-C00279
         		TFA
    263
    Figure US20200148650A1-20200514-C00280
         		TFA
    264
    Figure US20200148650A1-20200514-C00281
         		HCl
    265
    Figure US20200148650A1-20200514-C00282
         		TFA
    266
    Figure US20200148650A1-20200514-C00283
         		HCl
    267
    Figure US20200148650A1-20200514-C00284
         		TFA
    268
    Figure US20200148650A1-20200514-C00285
         		HCl
    269
    Figure US20200148650A1-20200514-C00286
         		TFA
    270
    Figure US20200148650A1-20200514-C00287
         		HCl
    271
    Figure US20200148650A1-20200514-C00288
         		TFA
    272
    Figure US20200148650A1-20200514-C00289
         		TFA
    273
    Figure US20200148650A1-20200514-C00290
         		TFA
    274
    Figure US20200148650A1-20200514-C00291
         		TFA
    275
    Figure US20200148650A1-20200514-C00292
         		TFA
    276
    Figure US20200148650A1-20200514-C00293
         		TFA
    277
    Figure US20200148650A1-20200514-C00294
         		TFA
    278
    Figure US20200148650A1-20200514-C00295
         		TFA
    279
    Figure US20200148650A1-20200514-C00296
         		TFA
    280
    Figure US20200148650A1-20200514-C00297
         		HCl
    281
    Figure US20200148650A1-20200514-C00298
         		HCl
    282
    Figure US20200148650A1-20200514-C00299
         		TFA
    283
    Figure US20200148650A1-20200514-C00300
         		TFA
    284
    Figure US20200148650A1-20200514-C00301
         		TFA
    285
    Figure US20200148650A1-20200514-C00302
         		TFA
    286
    Figure US20200148650A1-20200514-C00303
         		TFA
    287
    Figure US20200148650A1-20200514-C00304
         		TFA
    288
    Figure US20200148650A1-20200514-C00305
         		TFA
    290
    Figure US20200148650A1-20200514-C00306
         		TFA
    291
    Figure US20200148650A1-20200514-C00307
         		HCl
    292
    Figure US20200148650A1-20200514-C00308
         		None
    293
    Figure US20200148650A1-20200514-C00309
         		TFA
    294
    Figure US20200148650A1-20200514-C00310
         		TFA
    295
    Figure US20200148650A1-20200514-C00311
         		TFA
    296
    Figure US20200148650A1-20200514-C00312
         		TFA
    297
    Figure US20200148650A1-20200514-C00313
         		None
    298
    Figure US20200148650A1-20200514-C00314
         		None
    299
    Figure US20200148650A1-20200514-C00315
         		None
    300
    Figure US20200148650A1-20200514-C00316
         		HCl
    301
    Figure US20200148650A1-20200514-C00317
         		HCl
    302
    Figure US20200148650A1-20200514-C00318
         		HCl
    303
    Figure US20200148650A1-20200514-C00319
         		None
    304
    Figure US20200148650A1-20200514-C00320
         		None
    305
    Figure US20200148650A1-20200514-C00321
         		HCl
    306
    Figure US20200148650A1-20200514-C00322
         		HCl
    307
    Figure US20200148650A1-20200514-C00323
         		HCl
    308
    Figure US20200148650A1-20200514-C00324
         		HCl
    309
    Figure US20200148650A1-20200514-C00325
         		HCl
    310
    Figure US20200148650A1-20200514-C00326
         		HCl
    311
    Figure US20200148650A1-20200514-C00327
         		None
    312
    Figure US20200148650A1-20200514-C00328
         		HCl
    313
    Figure US20200148650A1-20200514-C00329
         		HCl
    314
    Figure US20200148650A1-20200514-C00330
         		HCl
    315
    Figure US20200148650A1-20200514-C00331
         		HCl
    316
    Figure US20200148650A1-20200514-C00332
         		None
    317
    Figure US20200148650A1-20200514-C00333
         		HCl
    318
    Figure US20200148650A1-20200514-C00334
         		HCl
    319
    Figure US20200148650A1-20200514-C00335
         		HCl
    320
    Figure US20200148650A1-20200514-C00336
         		HCl
    321
    Figure US20200148650A1-20200514-C00337
         		HCl
    322
    Figure US20200148650A1-20200514-C00338
         		HCl
    323
    Figure US20200148650A1-20200514-C00339
         		None
    324
    Figure US20200148650A1-20200514-C00340
         		HCl
    325
    Figure US20200148650A1-20200514-C00341
         		None
    326
    Figure US20200148650A1-20200514-C00342
         		HCl
    327
    Figure US20200148650A1-20200514-C00343
         		HCl
    328
    Figure US20200148650A1-20200514-C00344
         		HCl
    329
    Figure US20200148650A1-20200514-C00345
         		HCl
    330
    Figure US20200148650A1-20200514-C00346
         		HCl
    331
    Figure US20200148650A1-20200514-C00347
         		HCl
    332
    Figure US20200148650A1-20200514-C00348
         		None
    333
    Figure US20200148650A1-20200514-C00349
         		None
    334
    Figure US20200148650A1-20200514-C00350
         		HCl
    335
    Figure US20200148650A1-20200514-C00351
         		HCl
    336
    Figure US20200148650A1-20200514-C00352
         		HCl
    337
    Figure US20200148650A1-20200514-C00353
         		HCl
    338
    Figure US20200148650A1-20200514-C00354
         		HCl
    339
    Figure US20200148650A1-20200514-C00355
         		HCl
    340
    Figure US20200148650A1-20200514-C00356
         		HCl
    341
    Figure US20200148650A1-20200514-C00357
         		HCl
    342
    Figure US20200148650A1-20200514-C00358
         		HCl
    343
    Figure US20200148650A1-20200514-C00359
         		None
    344
    Figure US20200148650A1-20200514-C00360
         		HCl
    345
    Figure US20200148650A1-20200514-C00361
         		HCl
    346
    Figure US20200148650A1-20200514-C00362
         		HCl
    347
    Figure US20200148650A1-20200514-C00363
         		HCl
    348
    Figure US20200148650A1-20200514-C00364
         		HCl
    349
    Figure US20200148650A1-20200514-C00365
         		HCl
    350
    Figure US20200148650A1-20200514-C00366
         		None
    351
    Figure US20200148650A1-20200514-C00367
         		HCl
    352
    Figure US20200148650A1-20200514-C00368
         		HCl
    353
    Figure US20200148650A1-20200514-C00369
         		TFA
    354
    Figure US20200148650A1-20200514-C00370
         		HCl
    355
    Figure US20200148650A1-20200514-C00371
         		TFA
    356
    Figure US20200148650A1-20200514-C00372
         		HCl
    357
    Figure US20200148650A1-20200514-C00373
         		None
    358
    Figure US20200148650A1-20200514-C00374
         		TFA
    359
    Figure US20200148650A1-20200514-C00375
         		TFA
    360
    Figure US20200148650A1-20200514-C00376
         		HCl
    361
    Figure US20200148650A1-20200514-C00377
         		HCl
    362
    Figure US20200148650A1-20200514-C00378
         		None
    363
    Figure US20200148650A1-20200514-C00379
         		HCl
    364
    Figure US20200148650A1-20200514-C00380
         		HCl
    365
    Figure US20200148650A1-20200514-C00381
         		TFA
    366
    Figure US20200148650A1-20200514-C00382
         		HCl
    367
    Figure US20200148650A1-20200514-C00383
         		HCl
    368
    Figure US20200148650A1-20200514-C00384
         		None
    369
    Figure US20200148650A1-20200514-C00385
         		HCl
    370
    Figure US20200148650A1-20200514-C00386
         		HCl
    371
    Figure US20200148650A1-20200514-C00387
         		None
    372
    Figure US20200148650A1-20200514-C00388
         		TFA
    373
    Figure US20200148650A1-20200514-C00389
         		TFA
    374
    Figure US20200148650A1-20200514-C00390
         		None
    375
    Figure US20200148650A1-20200514-C00391
         		None
    376
    Figure US20200148650A1-20200514-C00392
         		HCl
    377
    Figure US20200148650A1-20200514-C00393
         		None
    378
    Figure US20200148650A1-20200514-C00394
         		None
    379
    Figure US20200148650A1-20200514-C00395
         		HCl
    380
    Figure US20200148650A1-20200514-C00396
         		HCl
    381
    Figure US20200148650A1-20200514-C00397
         		HCl
    382
    Figure US20200148650A1-20200514-C00398
         		None
    383
    Figure US20200148650A1-20200514-C00399
         		None
    384
    Figure US20200148650A1-20200514-C00400
         		HCl
    385
    Figure US20200148650A1-20200514-C00401
         		HCl
    386
    Figure US20200148650A1-20200514-C00402
         		HCl
    387
    Figure US20200148650A1-20200514-C00403
         		HCl
    388
    Figure US20200148650A1-20200514-C00404
         		None
    389
    Figure US20200148650A1-20200514-C00405
         		None
    390
    Figure US20200148650A1-20200514-C00406
         		None
    391
    Figure US20200148650A1-20200514-C00407
         		None
    392
    Figure US20200148650A1-20200514-C00408
         		HCl
    393
    Figure US20200148650A1-20200514-C00409
         		None
    394
    Figure US20200148650A1-20200514-C00410
         		None
    395
    Figure US20200148650A1-20200514-C00411
         		None
    396
    Figure US20200148650A1-20200514-C00412
         		HCl
    397
    Figure US20200148650A1-20200514-C00413
         		None
    398
    Figure US20200148650A1-20200514-C00414
         		HCl
    399
    Figure US20200148650A1-20200514-C00415
         		None
  • TABLE 2
    SMYD2
    Biochem
    Cpd. Salt LCMS IC50
    No. Structure Form Chemical Name M + H (μM)*
    400
    Figure US20200148650A1-20200514-C00416
         		None N-(1-acetylazetidin-3-yl)-5- cyclopropyl-1,2-oxazole-3- carboxamide 250.1 >50.0
    401
    Figure US20200148650A1-20200514-C00417
         		None 5-cyclopropyl-N-[1-(2- methylpropyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 264.2 1.55823
    402
    Figure US20200148650A1-20200514-C00418
         		None 5-cyclopropyl-N-[1-(2- fluoroethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 254.1 7.78955
    403
    Figure US20200148650A1-20200514-C00419
         		None 5-cyclopropyl-N-(1- methanesulfonylazetidin-3-yl)-1,2- oxazole-3-carboxamide 286.1 >50.0
    404
    Figure US20200148650A1-20200514-C00420
         		None 5-cyclopropyl-N-[1-(2- hydroxyethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 252.2 4.67695
    405
    Figure US20200148650A1-20200514-C00421
         		None 5-cyclopropyl-N-[1-(oxetan-3- yl)azetidin-3-yl]-1,2-oxazole-3- carboxamide 264.2 >50.0
    406
    Figure US20200148650A1-20200514-C00422
         		None 5-cyclopropyl-N-[1-(2,2- difluoroethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 272.2 >50.0
    407
    Figure US20200148650A1-20200514-C00423
         		None 5-cyclopropyl-N-[1-(2- methoxyethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 266.2 2.68352
    408
    Figure US20200148650A1-20200514-C00424
         		None 5-cyclopropyl-N-[1-(2,2,2- trifluoroethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 290.2 >50.0
    409
    Figure US20200148650A1-20200514-C00425
         		None 5-cyclopropyl-N-(1,3- dimethylazetidin-3-yl)-1,2- oxazole-3-carboxamide 236.2 >50.0
    410
    Figure US20200148650A1-20200514-C00426
         		None 5-cyclopropyl-N-[1-(propan-2- yl)azetidin-3-yl]-1,2-oxazole-3- carboxamide 250.1 1.04736
    411
    Figure US20200148650A1-20200514-C00427
         		None 5-cyclopropyl-N-(1- methylazetidin-3-yl)-1,2- oxazole-3-carboxamide 222.1 5.33712
    412
    Figure US20200148650A1-20200514-C00428
         		None 5-cyclopropyl-N-(1- ethylazetidin-3-yl)-1,2- oxazole-3-carboxamide 236.2 1.50829
    413
    Figure US20200148650A1-20200514-C00429
         		None 5-cyclopropyl-N-(1- cyclopropylazetidin-3-yl)-1,2- oxazole-3-carboxamide 248.1 1.46882
    414
    Figure US20200148650A1-20200514-C00430
         		None 5-cyclopropyl-N-(1- propylazetidin-3-yl)-1,2- oxazole-3-carboxamide 250.2 1.70142
    415
    Figure US20200148650A1-20200514-C00431
         		None N-(1-benzylazetidin-3-yl)-5- cyclopropyl-1,2- oxazole-3-carboxamide 298.1 2.47021
    416
    Figure US20200148650A1-20200514-C00432
         		None 5-cyclopropyl-N-[1-(1- phenylpropyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 326.1 0.61999
    417
    Figure US20200148650A1-20200514-C00433
         		None 5-cyclopropyl-N-[1-(2-hydroxy-1- phenylethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 328.2 2.22554
    418
    Figure US20200148650A1-20200514-C00434
         		None 5-cyclopropyl-N-[1-(1- phenylethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 312.1 0.58861
    419
    Figure US20200148650A1-20200514-C00435
         		None 5-cyclopropyl-N-[1-(2- phenylethyl)azetidin-3-yl]-1,2- oxazole-3-carboxamide 312.1 2.18872
    420
    Figure US20200148650A1-20200514-C00436
         		HCl N-(azetidin-3-yl)-5-cyclopropyl- 1,2-oxazole-3-carboxamide 208.1
    421
    Figure US20200148650A1-20200514-C00437
         		None 5-cyclopropyl-N-(pyridin-3-yl)- 1,2-oxazole-3-carboxamide 230.2 >50.0
    422
    Figure US20200148650A1-20200514-C00438
         		None 5-cyclopropyl-N-(pyridin-4-yl)- 1,2-oxazole-3-carboxamide 230.2 >50.0
    423
    Figure US20200148650A1-20200514-C00439
         		None 5-cyclopropyl-N-{[1-(propan-2- yl)azetidin-3-yl]methyl}-1,2- oxazole-3-carboxamide 264.1 >50.0
    424
    Figure US20200148650A1-20200514-C00440
         		None 5-cyclopropyl-N-{[1- (cyclopropylmethyl)azetidin-3- yl]methyl}-1,2- oxazole-3-carboxamide 276.1 >50.0
    425
    Figure US20200148650A1-20200514-C00441
         		None 5-cyclopropyl-N-[(1- propylazetidin-3-yl)methyl]- 1,2-oxazole-3-carboxamide 264.1 >50.0
    426
    Figure US20200148650A1-20200514-C00442
         		None N-(azetidin-3-ylmethyl)-5- cyclopropyl-1,2-oxazole-3- carboxamide 222.1 33.04122
    427
    Figure US20200148650A1-20200514-C00443
         		None (±)-cis-5-cyclopropyl-N-[5- methyl-1-(propan-2-yl)azepan- 4-yl]-1,2-oxazole-3-carboxamide 306.2 >50.0
    *IC50 values are an average of n = 1 to n = 50
  • TABLE 3
    SMYD2
    Biochem
    Cpd. Salt LCMS IC50
    No. Structure Form Chemical Name M + H (μM)*
    428
    Figure US20200148650A1-20200514-C00444
         		none N-(1-((1-(4-chlorobenzyl)-1H- pyrazol-4-yl)methyl)azetidin-3- yl)-5-cyclopropylisoxazole-3- carboxamide 412.2 0.0095
    *IC50 values are an average of n = 1 to n = 50
  • TABLE 1A
    SMYD3
    Biochem SMYD3
    LCMA IC50 cell IC50
    Cpd. No. Chemical Name M + H (μM)* (μM)*
    2 N-(1-((4- 447.15 48.11
    acetamidophenyl)sulfonyl)piperidin-4-
    yl)-5-cyclobutylisoxazole-3-carboxamide
    3 N-(4-((4- 431.91 23.37
    acetamidophenyl)sulfonyl)cyclohexyl)-5-
    cyclopropylisoxazole-3-carboxamide
    4 5-cyclopropyl-N-(piperidin-4- 250.05 31.8
    ylmethyl)isoxazole-3-carboxamide
    5 5-cyclopropyl-N-((1-methylpiperidin-4- 264.10 39.33
    yl)methyl)isoxazole-3-carboxamide
    6 N-((1s,3s)-3-((4- 419.25 32.91
    acetamidophenyl)sulfonamido)cyclobutyl)
    5-cyclopropylisoxazole-3-carboxamide
    7 N-((1r,3r)-3-((4- 419.3 46.75
    acetamidophenyl)sulfonamido)cyclobutyl)
    5-cyclopropylisoxazole-3-carboxamide
    8 N-((1r,4r)-4-aminocyclohexyl)-5- 375.83 20.73
    cyclopropyl-4-iodoisoxazole-3-
    carboxamide
    9 N-((1r,4r)-4-aminocyclohexyl)-5-(2- 254 33.25
    hydroxyethyl)isoxazole-3-carboxamide
    10 N3-((1r,4r)-4-ammocyclohexyl)-5- 349.10 38.97
    cyclopropyl-N4-isobutylisoxazole-3,4-
    dicarboxamide
    11 N-((1r,4r)-4-aminocyclohexyl)-5- 236.1 27.42
    vinylisoxazole-3-carboxamide
    12 5-cyclopropyl-N-(2,2-dimethyl-1- 299.05 12.75
    phenylpropyl)isoxazole-3-carboxamide
    13 N3-((1r,4r)-4-aminocyclohexyl)-5- 293.15 22.42
    cyclopropylisoxazole-3,4-dicarboxamide
    14 N-(4-(aminomethyl)phenyl)-5- 259.1 10.54
    cyclopropylisoxazole-3-carboxamide
    15 N-(1-(4-aminophenyl)ethyl)-5- 271.8 40.11
    cyclopropylisoxazole-3-carboxamide
    16 N-(4-(1-aminoethyl)phenyl)-5- 272.85 6.52
    cyclopropylisoxazole-3-carboxamide
    17 N-((1r,3r)-3-aminocyclobutyl)-5- 222.05 24.5
    cyclopropylisoxazole-3-carboxamide
    18 5-cyclopropyl-N-(1-(4-fluorophenyl)- 289.1 41.22
    propyl)isoxazole-3-carboxamide
    19 5-cyclopropyl-N-(1-(4-fluorophenyl)-2- 303.05 16.38
    methylpropyl)isoxazole-3-carboxamide
    20 5-cyclopropyl-N-(1-(4-methoxyphenyl)- 329.1 5.85
    2,2-dimethylpropyl)isoxazole-3-
    carboxamide
    21 N-((1r,4r)-4-aminocyclohexyl)-5-(3- 268.1 40.64
    hydroxypropyl)isoxazole-3-carboxamide
    22 N-(azepan-4-yl)-5-cyclopropylisoxazole- 250.15 14.88
    3-carboxamide
    23 N-(3-(azetidin-3-ylamino)cyclobutyl)-5- 277.1 32.28
    cyclopropylisoxazole-3-carboxamide
    24 N-((1r,4r)-4-aminocyclohexyl)-5- 234.79 24.63
    isopropylisoxazole-3-carboxamide (-NH2)
    25 5-cyclopropyl-N-(cyclopropyl(4- 301.05 16.21
    fluorophenyl)methyl)isoxazole-3-
    carboxamide
    26 5-cyclopropyl-N-(3,3-dimethylbutan-2- 237.05 45.92
    yl)isoxazole-3-carboxamide
    27 N-(1-(4-aminophenyl)-2,2- 336.25 8.54
    dimethylpropyl)-5-cyclopropylisoxazole- (+Na)
    3-carboxamide
    28 5-cyclopropyl-N-(2,2-dimethyl-1- 300.15 38.32
    (pyridin-2-yl)propyl)isoxazole-3-
    carboxamide
    29 5-cyclopropyl-N-(1-(4- 275 43.79
    fluorophenyl)ethyl)isoxazole-
    3-carboxamide
    30 5-cyclopropyl-N-(2,2-dimethylpentan-3- 251.15 27.12
    yl)isoxazole-3-carboxamide
    31 N-(1-(4-acetamidophenyl)-2,2- 356.25 12.82
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    32 N-(1-(4-chlorophenyl)-2,2- 333.15 9.03
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    33 N-(4-(aminomethyl)-2-methylphenyl)-5- 272.90 7.79
    cyclopropylisoxazole-3-carboxamide
    34 N-(4-(aminomethyl)-2-chlorophenyl)-5- 293.05 6.45
    cyclopropylisoxazole-3-carboxamide (295.00)
    35 N-((5-amino-1,3,3-trimethylcyclohexyl)- 306.30 12.99
    methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    36 5-cyclopropyl-N-(2,2-dimethyl-1-(p- 312.90 27.61
    tolyl)propyl)isoxazole-3-carboxamide
    37 N-(4-(2-aminoethyl)phenyl)-5- 272.15 7.25
    cyclopropylisoxazole-3-carboxamide
    38 N-(4-(1-aminopropyl)phenyl)-5- 286.96 4.43
    cyclopropylisoxazole-3-carboxamide
    39 N-(4-(1-amino-2,2- 297 2.52
    dimethylpropyl)phenyl)-5- (-NH3)
    cyclopropylisoxazole-3-carboxamide
    40 N-(4-(ammomethyl)-2-iodophenyl)-5- 366.9 7.21
    cyclopropylisoxazole-3-carboxamide (-NH3)
    41 N-(5-(aminomethyl)pyridin-2-yl)-5- 259.15 22.53
    cyclopropylisoxazole-3-carboxamide
    42 5-ethyl-N-(1-(3-methoxyphenyl)-2,2- 317.20 24.62
    dimethylpropyl)isoxazole-3-carboxamide
    43 5-cyclopropyl-N-(1-(3-methoxyphenyl)- 329.25 18.91
    2.2-dimethylpropyl)isoxazole-3-
    carboxamide
    44 N-(4-(1-amino-2-methylpropyl)phenyl)- 300.04 2.5
    5-cyclopropylisoxazole-3-carboxamide
    45 N-(5-(aminomethyl)-6-methylpyridin-2- 273.15 29.74
    yl)-5-cyclopropylisoxazole-3-
    carboxamide
    46 5-cyclopropyl-N-(2,2-dimethyl-1-(m- 313.25 22.2
    tolyl)propyl)isoxazole-3-carboxamide
    47 5-ethyl-N-(1-(3-fluorophenyl)-2,2- 305.15 7.26
    dimethylpropyl)isoxazole-3-carboxamide
    48 5-cyclopropyl-N-(1-(3-fluorophenyl)- 317.25 7.92
    2.2-dimethylpropyl)isoxazole-3-
    carboxamide
    49 5-cyclopropyl-N-(phenyl(piperidin-4- 326.25 8.09
    yl)methyl)isoxazole-3-carboxamide
    50 5-cyclopropyl-N-(2,2-dimethyl-1- 300.15 9.99
    (pyridin-3-yl)propyl)isoxazole-3-
    carboxamide
    51 5-cyclopropyl-N-(2,2-dimethyl-1- 300.20 4.08
    (pyridin-4-yl)propyl)isoxazole-3-
    carboxamide
    52 N-(1-cyclobutyl-2,2-dimethylpropyl)-5- 277.2 7.4
    cyclopropylisoxazole-3-carboxamide
    53 N-(1-cyclopentyl-2,2-dimethylpropyl)-5- 291.25 10.58
    cyclopropylisoxazole-3-carboxamide
    54 N-(1-cyclohexyl-2,2-dimethylpropyl)-5- 305.01 15.14
    cyclopropylisoxazole-3-carboxamide
    55 N-(cyclobutyl(phenyl)methyl)-5- 297.2 38.47
    cyclopropylisoxazole-3-carboxamide
    56 N-(4-(aminomethyl)-3-chlorophenyl)-5- 291.95 16.4
    cyclopropylisoxazole-3-carboxamide
    57 N-(1-(3-chlorophenyl)-2,2- 321.2 6.06
    dimethylpropyl)-5-ethylisoxazole-3-
    carboxamide
    58 N-(1-(3-chlorophenyl)-2,2- 333.2 9.97
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    59 N-(2-(4-amino-4- 306 10.23
    methylcyclohexyl)propan-
    2-yl)-5-cyclopropylisoxazole-3-
    carboxamide
    60 N-(4-(2-aminopropan-2-yl)-1- 306 2.98
    methylcyclohexyl)-
    5-cyclopropylisoxazole-3-carboxamide
    61 5-cyclopropyl-N-(2,2-dimethyl-1- 306.15 6.29
    (thiazol-4-yl)propyl)isoxazole-3-
    carboxamide
    62 5-cyclopropyl-N-(2,2-dimethyl-1- 306.25 4.35
    (piperidin-4-yl)propyl)isoxazole-3-
    carboxamide
    63 N-(((1r,4r)-4-aminocyclohexyl)(phenyl)- 340.25 6.99
    methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    64 5-ethyl-N-(phenyl(tetrahydro-2H-pyran- 337.25 37.06
    4-yl)methyl)isoxazole-3-carboxamide (+Na)
    65 N-(3-(aminomethyl)-3,5,5- 306.15 14.07
    trimethylcyclohexyl)-
    5-cyclopropylisoxazole-3-carboxamide
    66 5-cyclopropyl-N-((S)-phenyl((S)- 312.2 34.2
    pyrrolidin-2-yl)methyl)isoxazole-3-
    carboxamide
    67 N-(((1s,4s)-4- 340.25 13
    aminocyclohexyl)(phenyl)methyl)-
    5-cyclopropylisoxazole-3-carboxamide
    68 5-cyclopropyl-N-(2,2-dimethyl-1- 306.25 4.38
    (piperidin-3-yl)propyl)isoxazole-3-
    carboxamide
    69 5-cyclopropyl-N-(phenyl(piperidin-3- 326.25 12.68
    yl)methyl)isoxazole-3-carboxamide
    70 N-(4-(aminomethyl)-3-methylphenyl)-5- 272.97 8.22
    cyclopropylisoxazole-3-carboxamide
    71 5-ethyl-N-((1-methylpiperidin-4- 328.25 20.51
    yl)(phenyl)methyl)isoxazole-3-
    carboxamide
    72 N-((3-chlorophenyl)(piperidin-4- 348.2 1.4
    yl)methyl)-5-ethylisoxazole-3-
    carboxamide
    73 N-((3-chlorophenyl)(piperidin-4- 360.25 2.59
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    74 5-ethyl-N-(phenyl(piperidin-4-yl)- 314.2 7.44
    methyl)-isoxazole-3-carboxamide
    75 N-((3-((4-chlorobenzyl)carbamoyl) 493.3 13.58
    phenyl)(piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    76 N-((3- 465.35 34.82
    ((cyclohexylmethyl)carbamoyl)phenyl)-
    (piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    77 N-((3-(cyclohexylcarbamoyl)phenyl)- 451.4 49.05
    (piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    78 N-(4-(ammomethyl)-3-methoxyphenyl)- 270.92 32.1
    5-cyclopropylisoxazole-3-carboxamide (-NH2)
    79 5-cyclopropyl-N-((S)-1-(((S)-1,6- 368.25 15.03
    diamino-1-oxohexan-2-yl)amino)-
    3-hydroxy-1-oxopropan-2-yl)isoxazole-
    3-carboxamide
    80 N-((2-chlorophenyl)(piperidin-4- 348.15 15.86
    yl)methyl)-5-ethylisoxazole-3-
    carboxamide
    81 5-cyclopropyl-N-((1-methylpiperidin-4- 340.2 22.81
    yl)(phenyl)methyl)isoxazole-3-
    carboxamide
    82 N-((2-chlorophenyl)(piperidin-4- 360.20 9.05
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    83 5-cyclopropyl-N-(piperidin-4-yl(3- 460.3 30.8
    ((pyridin-3-ylmethyl)carbamoyl)-
    phenyl)methyl)isoxazole-
    3-carboxamide
    84 5-cyclopropyl-N-(piperidin-4-yl(3-((3- 480.4 10.57
    (pyrrolidin-1-yl)propyl)carbamoyl)
    phenyl)methyl)isoxazole-
    3-carboxamide
    85 5-cyclopropyl-N-((3-((2-(piperidin-1- 480.4 12.59
    yl)ethyl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    86 5-cyclopropyl-N-((3-((2- 475.35 20.84
    (methylsulfonyl)ethyl)carbamoyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    87 5-cyclopropyl-N-((3-((3- 454.35 24.56
    (dimethylamino)propyl)carbamoyl)-
    phenyl)(piperidin-4-yl)methyl)-
    isoxazole-3-carboxamide
    88 5-cyclopropyl-N-(piperidin-4-yl(3- 460.35 37.32
    ((pyridin-4-ylmethyl)carbamoyl)-
    phenyl)methyl)isoxazole-
    3-carboxamide
    89 N-((3-(((1r,4r)-4-aminocyclohexyl)- 466.35 39.36
    carbamoyl)phenyl)(piperidin-
    4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    90 5-cyclopropyl-N-((3-((pent-4-yn-1- 11.77
    yloxy)methyl)phenyl)(piperidine-4-
    yl)methyl)isoxazole-
    3-carboxamide
    91 N-(4-(aminomethyl)-2-isopropylphenyl)- 283.02 6.08
    5-cyclopropylisoxazole-3-carboxamide (−NH2)
    92 N-((1r,4r)-4-aminocyclohexyl)-5- 266.1 38.15
    isobutylisoxazole-3-carboxamide
    93 N-((1r,4r)-4-ammocycloliexyl)-5- 252.1 9.93
    propylisoxazole-3-carboxamide
    94 N-(4-(aminomethyl)-3-iodophenyl)-5- 383.98 19.48
    cyclopropylisoxazole-3-carboxamide
    95 N-(1-(2H-indazol-4-yl)-2,2- 339.01 6.82
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    96 5-cyclopropyl-N-((3-((1- 494.45 48.53
    isopropylpiperidin-4-
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-
    3-carboxamide
    97 5-cyclopropyl-N-((3-((3- 475.40 25.88
    hydroxybenzyl)carbamoyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    98 5-cyclopropyl-N-((3- 409.3 46.85
    (cyclopropylcarbamoyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-3-carboxamide
    99 5-cyclopropyl-N-(piperidin-4-yl(3- 394.24 11.9
    ((prop-2-yn-1-
    yloxy)methyl)phenyl)methyl)isoxazole-
    3-carboxamide
    100 5-cyclopropyl-N-((3- 411.3 17.98
    ((diethylamino)methyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-3-carboxamide
    101 N-(4-(aminomethyl)-2-ethylphenyl)-5- 268.99 3
    cyclopropylisoxazole-3-carboxamide (−NH2)
    102 N-((1r,4r)-4-aminocyclohexyl)-5- 266.10 32.62
    butylisoxazole-3-carboxamide
    103 5-cyclopropyl-N-((3-((2-hydroxy-3- 496.4 14.1
    (pyrrolidin-1-yl)propyl)carbamoyl)-
    phenyl)(piperidin-4-yl)methyl)-
    isoxazole-3-carboxamide
    104 5-cyclopropyl-N-((3-((3- 441.3 11.17
    hydroxypropyl)(methyl)carbamoyl)-
    phenyl)(piperidin-4-yl)methyl)-
    isoxazole-3-carboxamide
    105 5-cyclopropyl-N-(piperidin-4-yl(3- 460.35 45.5
    ((pyridin-2-ylmethyl)carbamoyl)-
    phenyl)methyl)isoxazole-
    3-carboxamide
    106 5-cyclopropyl-N-(piperidin-4-yl(3- 446.3 4.76
    (pyridin-3-ylcarbamoyl)phenyl)methyl)-
    isoxazole-3-carboxamide
    107 5-cyclopropyl-N-((3-(((3- 464.35 16.78
    fluorobenzyl)oxy)methyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    108 N-((3-((but-2-yn-1-yloxy)methyl)phenyl)- 408.3 6.36
    (piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    109 5-cyclopropyl-N-((3-(((3-hydroxypropyl)- 427.35 34.01
    (methyl)amino)methyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-
    3-carboxamide
    110 5-cyclopropyl-N-((3-(((2-iodobenzyl)- 572.3 4.98
    oxy)methyl)phenyl)(piperidin-4-yl)-
    methyl)isoxazole-3-carboxamide
    111 5-cyclopropyl-N-((3-((2- 490.4 11.35
    methoxyphenethoxy)methyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    112 5-cyclopropyl-N-((3-((2- 474.4 11.25
    methylplienethoxy)methyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    113 5-cyclopropyl-N-((3- 356.25 3.67
    (hydroxymethyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    114 N-(4-(aminomethyl)-3-ethylphenyl)-5- 268.99 13.86
    cyclopropylisoxazole-3-carboxamide (−NH2)
    115 5-cyclopropyl-N-((3-((3- 427.3 17.42
    hydroxypropyl)carbamoyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    116 5-cyclopropyl-N-((3-((2- 475.35 18.31
    hydroxybenzyl)carbamoyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    117 5-cyclopropyl-N-(piperidin-4-yl(3- 446.40 9.3
    (pyridin-2-ylcarbamoyl)phenyl)methyl)-
    isoxazole-3-carboxamide
    118 5-cyclopropyl-N-((3-((2- 427.35 19.37
    (ethylamino)ethoxy)methyl)phenyl)-
    (piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    119 N-((3-((2-aminoethoxy)methyl)phenyl)- 399.30 13.19
    (piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    120 5-cyclopropyl-N-(piperidin-4-yl(3- 398.35 20.62
    (propoxymethyl)phenyl)methyl)isoxazole-
    3-carboxamide
    121 N-(4-(1-amino-4-hydroxybutyl)phenyl)- 316.10 4.36
    5-cyclopropylisoxazole-3-carboxamide
    122 5-cyclopropyl-N-(1- 305.10 11.83
    oxaspiro[5.5]undecan-4-yl)isoxazole-3-
    carboxamide
    123 5-cyclopropyl-N-(3- 319.3 4.79
    ethoxyspiro[3.5[nonan-1-yl)isoxazole-3-
    carboxamide
    124 5-cyclopropyl-N-(3- 305.10 26.51
    oxaspiro[5.5]undecan-9-yl)isoxazole-3-
    carboxamide
    125 N-(1-benzyl-6-methylpiperidin-3-yl)-5- 340.10 21.2
    cyclopropylisoxazole-3-carboxamide
    126 5-cyclopropyl-N-(3-phenylcyclopentyl)- 297.1 29.97
    isoxazole-3-carboxamide
    127 5-cyclopropyl-N-(2-(3,4- 335.1 49.59
    difluorophenyl)tetrahydrofuran-3-yl)-
    isoxazole-3-carboxamide
    128 5-cyclopropyl-N-(2,2- 265.4 44.55
    dimethyltetrahydro-2H-pyran-
    4-yl)isoxazole-3-carboxamide
    129 5-cyclopropyl-N-(6-oxaspiro[4.5]decan- 291.1 18.41
    9-yl)isoxazole-3-carboxamide
    130 N-((3-((((1r,4r)-4- 1.38
    aminocyclohexyl)oxy)methyl)phenyl)-
    (piperidin-4-yl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    131 5-cyclopropyl-N-((3- 16.6
    ((isopropyl(tetrahydro-2H-pyran-
    4-yl)amino)methyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-3-
    carboxamide
    132 methyl 5-(aminomethyl)-2- 299.83 48.66
    (5-cyclopropylisoxazole-3- (M − NH2)
    carboxamido)benzoate
    133 5-cyclopropyl-N-(piperidin-4-yl(3- 466.12 6.48
    (pyridin-4-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    134 N-(3-butoxy-2,2-dimethylcyclobutyl)-5- 307.3 18.73
    cyclopropylisoxazole-3-carboxamide
    135 5-cyclopropyl-N-(6-hydroxy-1,2,3,4- 299.10 23.68
    tetiahydronaphthalen-2-yl)isoxazole-3-
    carboxamide
    136 5-cyclopropyl-N-(3-isobutoxy-2,2- 307.2 9.54
    dimethylcyclobutyl)isoxazole-3-
    carboxamide
    137 5-cyclopropyl-N-(2-(4- 331.3 2.56
    fluorophenyl)tetrahydro-2H-pyran-4-
    yl)isoxazole-3-carboxamide
    138 N-(1-(1-benzylpyrrolidin-3-yl)ethyl)-5- 340.3 24.96
    cyclopropylisoxazole-3-carboxamide
    139 5-cyclopropyl-N-((3-(((2- 413.25 41.77
    hydroxyethyl)(methyl)amino)methyl)-
    phenyl)(piperidin-4-yl)methyl)
    isoxazole-3-carboxamide
    140 5-cyclopropyl-N-((3-((4-methyl-1H- 462.17 28.35
    pyrrole-2-
    carboxamido)methyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-3-carboxamide
    141 5-cyclopropyl-N-((3-((3-(4-methyl-1H- 491.35 25.42
    pyrazol-1-
    yl)propanamido)methyl)phenyl)(piperidin-
    4-yl)methyl)isoxazole-3-carboxamide
    142 N-((3-carbamoylphenyl)(piperidin-4- 369.15 3.6
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    143 N-((1r,4r)-4-aminocyclohexyl)-5- 260.1 18.56
    (difluoromethyl)isoxazole-3-
    carboxamide
    144 5-cyclopropyl-N-(2-isobutyltetrahydro- 293.2 7.16
    2H-pyran-4-yl)isoxazole-3-carboxamide
    145 N-(1-(1-cyclobutylpiperidin-3-yl)ethyl)- 318.4 18.08
    5-cyclopropylisoxazole-3-carboxamide
    146 5-cyclopropyl-N-(2-isopropyl-4,5,6,7- 315.1 27.28
    tetrahydro-2H-indazo1-6-yl)isoxazole-3-
    carboxamide
    147 N-(4-(aminomethyl)-2- 310.15 4.07
    (hydroxymethyl)phenyl)-5- (+Na)
    cyclopropylisoxazole-3-carboxamide
    148 N-(4-(1-amino-3-(pyridin-2- 363.3 0.97
    yl)propyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    149 N-(4-(1-amino-3-(pyridin-3- 363.3 0.62
    yl)propyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    150 N-(4-(1-amino-3-(pyridin-4- 363.3 1.39
    yl)propyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    151 N-(4-(1-amino-3-phenylpropyl)phenyl)- 345.12 2.34
    5-cyclopropylisoxazole-3-carboxamide (M − NH2)
    152 5-cyclopropyl-N-((1-glycylpiperidin-4- 383.4 4.47
    yl)(phenyl)methyl)isoxazole-3-
    carboxamide
    153 N-((1-(D-alanyl)piperidin-4- 397.35 1.27
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    154 N-((1-(L-alanyl)piperidin-4- 397.35 1.53
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    155 5-cyclopropyl-N-((3- 445.4 4.15
    (phenylcarbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    156 (±)-cis-5-cyclopropyl-N-(3- 275.4 31.11
    cyclopropylcyclohexyl)isoxazole-3-
    carboxamide
    157 (±)-trans-5-cyclopropyl-N-(3- 275.3 39.9
    cyclopropylcyclohexyl)isoxazole-3-
    carboxamide
    158 (±)-cis-5-cyclopropyl-N-(3-(1-methyl- 315.1 10.07
    1H-imidazol-2-yl)cyclohexyl)isoxazole-
    3-carboxamide
    159 (±)-trans-5-cyclopropyl-N-((1S,3S)-3-(1 315.1 14.94
    methyl-1H-imidazol-2-
    yl)cyclohexyl)isoxazole-3-carboxamide
    160 N-(4-(aminomethyl)-3-isopropylphenyl) 322.2 17.14
    5-cyclopropylisoxazole-3-carboxamide (+Na)
    161 N-(4-(aminomethyl)-3- 310.2 12.36
    (hydroxymethyl)phenyl)-5- (+Na)
    cyclopropylisoxazole-3-carboxamide
    162 (R)-5-cyclopropyl-N-(piperidin-4-yl(3- 446.3 49
    (pyridin-3-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    163 (S)-5-cyclopropyl-N-(piperidin-4-yl(3- 446.3 0.85
    (pyridin-3-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    164 N-(4-((2- 337.1 17.78
    aminoacetamido)methyl)phenyl)-5- (+Na)
    cyclopropylisoxazole-3-carboxamide
    165 N-((1-benzyl-5-methylpyrrolidin-3- 340.2 43.84
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    166 N-((4-chlorophenyl)(4-methylmorpholin- 376.2 31.49
    2-yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    167 5-cyclopropyl-N-(1,2-dimethylpiperidin- 263.1 28.85
    3-yl)isoxazole-3-carboxamide
    168 N-(1-benzylpiperidin-3-yl)-5- 326.1 26.38
    cyclopropylisoxazole-3-carboxamide
    169 5-cyclopropyl-N-((3-(oxetan-3- 425.3 35.06
    ylcarbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    170 N-(4-(2-aminopropan-2-yl)phenyl)-5- 286.88 3.54
    cyclopropylisoxazole-3-carboxamide
    171 N-(4-(1-amino-2-((1-methylpiperidin-4- 398.25 24.39
    yl)amino)-2-oxoethyl)phenyl)-5-
    cyclopropylisoxazole-3-caxboxamide
    172 5-cyclopropyl-N-((3-((6-methylpyridin- 460.3 5.9
    3-yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    173 5-cyclopropyl-N-((3-(piperidin-3- 452.3 38.93
    ylcarbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    174 N-((3-((5-carbamoylpyridin-3- 489.3 10.82
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    175 5-cyclopropyl-N-(1-phenyl-3-(1H-1,2,4- 338.15 41.58
    triazol-1-yl)propyl)isoxazole-3-
    carboxamide
    176 5-cyclopropyl-N-((3-((6- 475.35 3.45
    (methylamino)pyridin-3-
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    177 5-cyclopropyl-N-((3-((6- 476.35 4.59
    methoxypyridin-3-
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    178 N-(1-(1-(L-alanyl)piperidin-4-yl)ethyl)- 335.25 0.47
    5-cyclopropylisoxazole-3-carboxamide
    179 N-((1-(L-alanyl)piperidin-4-yl)methyl)- 321.25 0.75
    5-cyclopropylisoxazole-3-carboxamide
    180 N-((1-(D-alanyl)piperidin-4-yl)methyl)- 321.2 9.05
    5-cyclopropylisoxazole-3-carboxamide
    181 5-cyclopropyl-N-(piperidin-4-yl(3- 447.35 7.34
    (pyridazin-4-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    182 5-cyclopropyl-N-(2-((2- 399.30 14.19
    hydroxybenzyl)amino)-2-oxo-1-
    (pipendin-4-yl)ethyl)isoxazole-3-
    carboxamide
    183 5-cyclopropyl-N-(piperidin-4-yl(3-((6- 514.35 8.28
    (trifluoromethyl)pyridin-3-
    yl)carbamoyl)phenyl)methyl)isoxazole-
    3-carboxamide
    184 5-cyclopropyl-N-(piperidin-4-yl(3- 447.85 2.16
    (pyrimidin-5-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    185 5-cyclopropyl-N-(piperidin-4-yl(3- 447.4 1.7
    (pyridazin-3-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    186 5-cyclopropyl-N-((3-((2-hydroxypyridin- 462.35 29.68
    3-yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    187 5-cyclopropyl-N-((3-((5-methylpyridin- 460.35 2.88
    3-yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxarnide
    188 N-(1-(1-(D-alanyl)piperidin-4-yl)ethyl)- 335.25 3.69
    5-cyclopropylisoxazole-3-carboxamide
    189 N-(1-(1-(L-tryptophyl)piperidin-4- 450.4 0.52
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    190 N-(1-(1-(D-tryptophyl)piperidin-4- 450.4 10.09
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    191 N-((1-(L-tryptophyl)piperidin-4- 436.35 0.56
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    192 N-((1-(D-tryptophyl)piperidin-4- 435.35 6.5
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    193 N-((1-(L-seryl)piperidin-4- 413.35 3.51
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    194 N-((1-(L-tyrosyl)piperidin-4- 489.5 2.69
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-caxboxamide
    195 N-((1-(L-tryptophyl)piperidin-4- 512.29 1.42
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    196 N-((1-(L-seryl)piperidin-4-yl)methyl)-5- 337.25 3.28
    cyclopropylisoxazole-3-carboxamide
    197 N-((1-(L-tyrosyl)piperidin-4-yl)methyl)- 413.35 0.43
    5-cyclopropylisoxazole-3-carboxamide
    198 (±)-trans-5-cyclopropyl-N-(4-(4- 319.2 17.68
    fluorophenyl)-4-hydroxybutan-2-
    yl)isoxazole-3-carboxamide
    199 ethyl 1-(L-tyrosyl)-5-(5- 471.4 43.3
    cyclopropylisoxazole-3-
    carboxamido)piperidine-3-carboxylate
    200 N-((3-((6-acetamidopyridin-3- 503.45 4.57
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    201 5-cyclopropyl-N-(piperidin-4-yl(3- 447.3 18.97
    (pyrazin-2-
    ylcarbamoyl)phenyl)methyl)isoxazole-3-
    carboxamide
    202 5-cyclopropyl-N-((3-((6-hydroxypyridin- 462.35 49.68
    3-yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    203 methyl 2-(1-(L-alanyl)piperidin-4-yl)-2- 379.3 0.74
    (5-cyclopropylisoxazole-3-
    carboxamido)acetate
    204 methyl 2-(1-(D-alanyl)piperidin-4-yl)-2- 379.3 7.54
    (5-cyclopropylisoxazole-3-
    carboxamido)acetate
    205 N-((1-(L-alanyl)piperidin-4-yl)(3- 517.35 0.29
    (pyridin-3-ylcarbamoyl)phenyl)methyl)-
    5-cyclopropylisoxazole-3-carboxamide
    206 N-((1-(D-alanyl)piperidin-4-yl)(3- 517.45 0.59
    (pyridin-3-ylcarbamoyl)phenyl)methyl)-
    5-cyclopropylisoxazole-3-carboxamide
    207 N-((1-(D-tryptophyl)piperidin-4- 534.5 23.23
    yl)(phenyl)methyl)-5- (+Na)
    cyclopropylisoxazole-3-carboxamide
    208 N-(1-(1-(L-valyl)piperidin-4-yl)ethyl)-5- 363.35 0.36
    cyclopropylisoxazole-3-carboxamide
    209 N-(1-(1-(D-valyl)piperidin-4-yl)ethyl)-5- 363.35 2.42
    cyclopropylisoxazole-3-caxboxamide
    210 N-(1-(1-(L-seryl)piperidin-4-yl)ethyl)-5- 373.3 1.2
    cyclopropylisoxazole-3-carboxamide (+Na)
    211 N-(1-(1-(L-tyrosyl)piperidin-4-yl)ethyl)- 427.35 0.2
    5-cyclopropylisoxazole-3-carboxamide
    212 tert-butyl4-(1-(5-cyclopropylisoxazole- 386.25 28.43
    3-carboxamido)ethyl)piperidine-1- (+Na)
    carboxylate
    213 5-cyclopropyl-N-(1-(piperidin-4- 264.2 7.12
    yl)ethyl)isoxazole-3-carboxamide
    214 5-cyclopropyl-N-(piperidin-4-yl(pyridin- 327.25 3.15
    4-yl)methyl)isoxazole-3-carboxamide
    215 N-((S)-(1-(L-alanyl)piperidin-4- 397.35 0.21
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    216 N-((R)-(1-(L-alanyl)piperidin-4- 397.35 4.48
    yl)(phenyl)methyl)-5-
    cyclopropylisoxazole-3-carboxamide
    218 5-cyclopropyl-N-(2-oxo-1-(piperidin-4- 370.3 26.87
    yl)-2-(pyridin-3-
    ylamino)ethyl)isoxazole-3-carboxamide
    219 5-cyclopropyl-N-(2-oxo-1-(piperidin-4- 384.3 34.17
    yl)-2-((pyridin-3-
    ylmethyl)amino)ethyl)isoxazole-3-
    carboxamide
    220 5-cyclopropyl-N-(piperidin-4-yl(3- 432.35 2.22
    ((pyridin-3-
    ylamino)methyl)phenyl)methyl)isoxazole-
    3-carboxamide
    221 N-((3-((6-aminopyridin-3- 461.4 7.49
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    222 5-cyclopropyl-N-((3-(methyl(pyridin-3- 460.4 31.99
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    223 methyl 2-(1-(L-tryptophyl)piperidin-4- 494.18 3.15
    yl)-2-(5-cyclopropylisoxazole-3-
    carboxamido)acetate
    224 methyl 2-(1-(D-tiyptophyl)piperidin-4- 494.23 29.42
    yl)-2-(5-cyclopropylisoxazole-3-
    carboxamido)acetate
    225 N-(1-(1-(D-seryl)piperidin-4-yl)ethyl)-5- 351.3 5.82
    cyclopropylisoxazole-3-carboxamide
    226 N-((1-(L-valyl)piperidin-4-yl)methyl)-5- 349.3 0.57
    cyclopropylisoxazole-3-carboxamide
    227 N-((1-(D-valyl)piperidin-4-yl)methyl)-5- 349.25 4.01
    cyclopropylisoxazole-3-carboxamide
    228 N-((1-(D-seryl)piperidin-4-yl)methyl)-5- 337.25 13.18
    cyclopropylisoxazole-3-carboxamide
    229 5-cyclopropyl-N-((3-((1-methyl-1H- 449.4 5.5
    pyrazol-4-
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    230 N-(1-(1-(D-alanyl)piperidin-4- 349.3 1.93
    yl)propyl)-5-cyclopropylisoxazole-3-
    carboxamide
    231 N-(1-(1-(L-alanyl)piperidin-4-yl)propyl)- 349.25 0.9
    5-cyclopropylisoxazole-3-carboxamide
    232 5-cyclopropyl-N-(2-oxo-1-(piperidin-4- 370.2 6.36
    yl)-2-(pyridin-2-
    ylamino)ethyl)isoxazole-3-carboxamide
    233 N-((3-((4-aminopyridin-2- 461.3 5.1
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    234 N-((3-((6-cyanopyridin-3- 471.4 5.42
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    235 N-(1-(1-(D-tyrosyl)piperidin-4-yl)ethyl)- 427.3 6.5
    5-cyclopropylisoxazole-3-carboxamide
    236 N-((1-(D-tyrosyl)piperidin-4-yl)methyl)- 413.25 14.3
    5-cyclopropylisoxazole-3-carboxamide
    237 5-cyclopropyl-N-(1-(1-((S)-2- 336.2 25.65
    hydroxypropanoyl)piperidin-4-
    yl)ethyl)isoxazole-3-carboxamide
    238 (R)-N-(3-(3-aminobutanamido)-2,2- 323.1 4.43
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    239 (S)-N-(3-(3-aminobutanamido)-2,2- 323.1 6.35
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    240 N-(3-(3-aminopropanamido)-2,2- 309.1 12.72
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    241 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 455.3 15.58
    2-((pyridin-3-ylmethyl)amino)ethyl)-5-
    cyciopropylisoxazole-3-carboxamide
    242 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 455.25 22.31
    2-((pyridin-4-ylmethyl)amino)ethyl)-5-
    cyclopropylisoxazole-3-caxboxamide
    243 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-((2- 470.35 2.72
    hydroxybenzyl)amino)-2-oxoethyl)-5-
    cyclopropylisoxazole-3-caxboxamide
    244 ethyl 2-(5-cyclopropylisoxazole-3- 322.2 20.57
    carboxamido)-2-(piperidin-4-yl)acetate
    245 N-((3-((2-aminopyridin-4- 461.3 4.13
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)-5-cyclopropylisoxazoIe-3-
    carboxamide
    246 5-cyclopropyl-N-((3-((6- 489.4 5.95
    (dimethylamino)pyridin-3-
    yl)carbamoyl)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    247 N-(1-(1-((R)-3-aminobutanoyl)piperidin- 349.25 0.62
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    248 N-(1-(1-((S)-3-aminobutanoyl)piperidin- 349.25 1.47
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    249 (S)-N-(4-(2-aminopropanamido)butyl)-5- 295.15 14.62
    cyclopropylisoxazole-3-caxboxamide
    250 (R)-N-(4-(2-aminopropanamido)butyl)- 295.15 36.02
    5-cyclopropylisoxazole-3-carboxamide
    251 N-(((S)-1-(D-alanyl)pyrrolidin-3- 307.15 30.73
    yl)methyl)-5-cyclopropylisoxazole-3-
    caxboxamide
    252 N-(((S)-1-(L-alanyl)pyrrolidin-3- 307.05 21.36
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    253 N-(((R)-1-(D-alanyl)pyrrolidin-3- 307.15 32.34
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    254 N-(4-aminobutyl)-5- 224.1 41.44
    cyclopropylisoxazole-3-carboxamide
    255 (R)-5-cyclopropyl-N-(pyrrolidin-3- 236.1 39.25
    ylmethyl)isoxazole-3-carboxamide
    256 (S)-5-cyclopropyl-N-(pyrrolidin-3- 236.1 37.48
    ylmethyl)isoxazole-3-carboxamide
    257 5-cyclopropyl-N-((3- 446.35 7.37
    (nicotmamido)phenyl)(piperidin-4-
    yl)methyl)isoxazole-3-carboxamide
    258 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 441.3 11.47
    2-(pyridin-3-ylamino)ethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    259 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 455.3 11.04
    2-((pyridin-2-ylmethyl)amino)ethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    260 N-(((R)-1-(L-alanyl)pyrrolidin-3- 307.15 15.5
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    261 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 441.3 0.39
    2-(pyridin-2-ylamino)ethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    262 N-(1-(1-(L-alanyl)piperidin-4-yl)-2-oxo- 441.35 8.5
    2-(pyridin-4-ylamino)ethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    263 5-cyclopropyl-N-((4-hydroxypiperidin-4- 266.15 14.89
    yl)methyl)isoxazole-3-carboxamide
    264 ethyl 4-((5-cyclopropylisoxazole-3- 322.1 43.56
    carboxamido)methyl)piperidine-4-
    carboxylate
    265 5-cyclopropyl-N-((4-methylpiperidin-4- 264.15 41.74
    yl)methyl)isoxazole-3-carboxamide
    266 5-cyclopropyl-N-((-fluoropiperidin-4- 268.05 18.82
    yl)methyl)isoxazole-3-carboxamide
    267 N-((1-(L-alanyl)-4-hydroxypiperidin-4- 337.35 5.47
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    268 ethyl 1-(L-alanyl)-4-((5- 393.15 3.22
    cyclopropylisoxazole-3-
    carboxamido)methyl)piperidine-4-
    carboxylate
    269 N-((1-(L-alanyl)-4-methylpiperidin-4- 335.15 1.67
    yl)methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    270 N-((1-(L-alanyl)-4-fluoropiperidin-4- 339.15 4.15
    yl)methyl)-5-cyclopropylisoxazoIe-3-
    carboxamide
    271 N-(1-(1-(L-alanyl)piperidin-4-yl)-2- 351.3 2.23
    hydroxyethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    272 ethyl 2-(1-(L-tyrosyl)piperidin-4-yl)-2- 485.3 7.39
    (5-cyclopropylisoxazole-3-
    carboxamido)acetate
    273 N-(1-(1-(L-tyrosyl)piperidin-4-yl)-2- 465.25 2.37
    hydroxyethyl)-5-cyclopropylisoxazole-3- (+Na)
    carboxamide
    274 5-cyclopropyl-N-(2-hydroxy-1- 280.1 5.93
    (piperidin-4-yl)ethyl)isoxazole-3-
    carboxamide
    275 N-(6-(3- 333.2 1.8
    aminopropanamido)spiro[3.3]heptan-2-
    yl)-5-cyclopropylisoxazole-3-
    carboxamide[transisomer
    276 5-cyclopropyl-N-(2-methoxy-1- 294.1 11.92
    (piperidin-4-yl)ethyl)isoxazole-3-
    carboxamide
    277 5-cyclopropyl-N-(2-phenoxy-1- 356.1 10.51
    (piperidin-4-yl)ethyl)isoxazole-3-
    carboxamide
    278 5-cyclopropyl-N-(2-isopropoxy-1- 322.2 15.25
    (piperidin-4-yl)ethyl)isoxazole-3-
    carboxamide
    279 N-(6-((R)-3- 347.5 1.25
    aminobutanamido)spiro[3.3]heptan-2-
    yl)-5-cyclopropylisoxazole-3-
    carboxamide[transisomer
    280 N-((1r,4r)-4-aminocyclohexyl)-5- 224.2 18.75
    methylisoxazole-3-caxboxamide
    281 N-(6-((R)-3- 347.1 5.6
    aminobutanamido)spiro[3.3]heptan-2-
    yl)-5-cyclopropylisoxazole-3-
    carboxamide[cisisomer
    282 N-(1-(1-(L-alanyl)piperidin-4-yl)-2- 387 2.08
    methoxyethyl)-5-cyclopropylisoxazole- (+Na)
    3-carboxamide
    283 N-(1-(1-(L-alanyl)piperidin-4-yl)-2- 427.35 2.67
    phenoxyethyl)-5-cyclopropylisoxazole-3
    carboxamide
    284 N-(1-(1-(L-alajiyl)piperidin-4-yl)-2- 393.35 1.19
    isopropoxyethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    285 N-(1-(1-(L-tyrosyl)piperidin-4-yl)-2- 457.25 1.07
    methoxyethyl)-5-cyclopropylisoxazole-
    3-carboxamide
    286 N-(1-(1-(L-tyrosyl)piperidin-4-yl)-2- 519.3 4.35
    phenoxyethyl)-5-cyclopropylisoxazole-3
    carboxamide
    287 N-(1-(1-(L-tyrosyl)piperidin-4-yl)-2- 485.3 5.2
    isopropoxyethyl)-5-
    cyclopropylisoxazole-3-carboxamide
    288 N-(6-((S)-3- 347.58 3.94
    aminobutanamido)spiro[3,3]heptan-2-
    yl)-5-cyclopropylisoxazole-3-
    carboxamide[transisomer
    290 N-(6-((S)-3- 347.6 1.82
    aminobutanamido)spiro[3.3]heptan-2-
    yl)-5-cyclopropylisoxazole-3-
    carboxamide[cisisomer
    291 N-(1-(3-aminopropanoyl)piperidin-3-yl)- 307 25.86
    5-cyclopropylisoxazole-3-carboxamide
    292 5-cyclopropyl-N-((1r,4r)-4-((2-((2- 365.1 4.88
    hydroxyethyl)amino)ethyl)carbamoyl)-
    cyclohexyl)isoxazole-3-carboxamide
    293 N-(6-((R)-3- 375.4 0.56
    aminobutanamido)bicyclo[3.3.1]nonan-
    2-yl)-5-cyclopropylisoxazole-3-
    carboxamide
    294 N-(6-((S)-3- 375.3 0.66
    aminobutanamido)bicyclo[3.3.1]nonan-
    2-yl)-5-cyclopropylisoxazole-3-
    carboxamide
    295 N-(6-(3- 361.4 1.2
    aminopropanamido)bicyclo[3.3.1Jnonan-
    2-yl)-5-cyclopropylisoxazole-3-
    carboxamide
    296 5-cyclopropyl-N-((1-oxo-2-(pyridin-3- 472.63 36.37
    yl)-1,2,3,4-tetrahydroisoquinolin-5-
    yl)(piperidin-4-yl)methyl)isoxazole-3-
    carboxamide
    297 N-(1-(4-aminobutanoyl)piperidin-3-yl)- 321.05 18.59
    5-cyclopropylisoxazole-3-carboxamide
    298 N-(1-(1-(3-aminopropanoyl)piperidin-3- 335.1 37.71
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    299 5-cyclopropyl-N-(1-(1-glycylpiperidin-3- 321.1 21.81
    yl)ethyl)isoxazole-3-carboxamide
    300 5-cyclopropyl-N-(1-(piperidin-4- 292.1 8.7
    yl)butyl)isoxazole-3-carboxamide
    301 5-cyclopropyl-N-(2-phenyl-1-(piperidin- 340.1 36.88
    4-yl)ethyl)isoxazole-3-carboxamide
    302 N-(1-(((1r,4r)-4-(2- 378.1 27.66
    aminoacetamido)cyclohexyl)amino)-1-
    oxopropan-2-yl)-5-cyclopropylisoxazole-
    3-carboxamide
    303 5-cyclopropyl-N-(1-glycylpiperidin-3- 293.1 32.81
    yl)isoxazole-3-carboxamide
    304 N-(1-(1-(4-aminobutanoyl)piperidin-3- 349.1 21.81
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    305 5-cyclopropyl-N-(3-methyl-1-(piperidin- 306.15 9.24
    4-yl)butyl)isoxazole-3-carboxamide
    306 N-(3-(3-aminopropanamido)-2- 295.1 41.9
    methylpropyl)-5-cyclopropylisoxazole-3-
    carboxamide
    307 N-(1-(3-aminopropanamido)pentan-3- 309.1 21.73
    yl)-5-cyclopropylisoxazole-3-
    carboxamide
    308 N-(4-(3-aminopropanamido)-2- 309.1 22.05
    methylbutan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    309 (1r,4r)-4-(5-cyclopropylisoxazole-3- 322.1 0.71
    carboxamido)cyclohexyl3-
    aminopropanoate
    310 N-(3-(4-aminobutanamido)cyclohexyl)- 335.1 27.03
    5-cyclopropylisoxazole-3-carboxamide
    311 (R)-N-((1-((3- 335.05 10.15
    aminobutanamido)methyl)cyclobutyl)
    methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    312 N-((1r,4r)-4-((3- 335.1 2.75
    aminopropyl)carbamoyl)cyclohexyl)-5-
    cyclopropylisoxazole-3-carboxamide
    313 N-(4-((R)-3-aminobutanamido)-3,3- 337.1 0.8
    dimethylbutan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    314 N-(4-(3-aminopropanamido)butan-2-yl)- 295.05 27.98
    5-cyclopropylisoxazole-3-carboxamide
    315 N-(3-(3-aminopropanamido)cyclohexyl)- 321.1 20.78
    5-cyclopropylisoxazole-3-carboxamide
    316 N-((1r,4r)-4-(3- 295.1 8.58
    aminopropanamido)cyclohexyl)-5-
    methylisoxazole-3-caxboxamide
    317 N-((1r,4r)-4-((2- 321.1 3.67
    aminoethyl)carbamoyl)cyclohexyl)-5-
    cyclopropylisoxazole-3-carboxamide
    318 N-(4-((S)-3-aminobutanamido)-3,3- 337.1 2.03
    dimethylbutan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    319 N-(1-((1r,4r)-4-aminocyclohexane-1- 335.1 1.83
    carboxamido)propan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    320 N-(1-(4-aminobutanamido)propan-2-yl)- 295.1 12.94
    5-cyclopropylisoxazole-3-carboxamide
    321 5 -cyclopropyl-N-(1-(piperidin-3 - 264 26.78
    yl)ethyl)isoxazole-3-carboxamide
    322 N-(1-(4-aminobutanamido)butan-2-yl)-5- 309.1 17.38
    cyclopropylisoxazole-3-carboxamide
    323 N-(1-((1r,4r)-4-aminocyclohexane-1- 349.1 1.3
    carboxamido)butan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    324 N-(1-(3-aminopropanamido)butan-2-yl)- 295.1 19.68
    5-cyclopropylisoxazole-3-carboxamide
    325 N-(4-(3-aminopropanamido)phenyl)-5- 315 1.06
    cyclopropylisoxazole-3-carboxamide
    326 N-(4-(2-aminoacetamido)phenyl)-5- 301.3 4.24
    cyclopropylisoxazole-3-carboxamide
    327 N-(4-(4-aminobutanamido)phenyl)-5- 329.05 1.19
    cyclopropylisoxazole-3-carboxamide
    328 N-(4-((3-aminopropyl)amino)phenyl)-5- 301.05 3.74
    cyclopropylisoxazole-3-carboxamide
    329 N-(4-((2-aminoethyl)amino)phenyl)-5- 287.05 4.63
    cyclopropylisoxazole-3-carboxamide
    330 N-((1-((3- 307.1 37.55
    aminopropanamido)methyl)cyclopropyl)
    methyl)-5-cyclopropylisoxazole-3-
    carboxamide
    331 N-(4-(3-aminopropanamido)-1- 311.1 13.31
    hydroxybutan-2-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    332 5-cyclopropyl-N-(4-(piperidin-4- 355.1 1.37
    ylcarbamoyl)phenyl)isoxazole-3-
    carboxamide
    333 N-(4-(((1s,4s)-4- 369.1 8.34
    aminocyclohexyl)carbamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    334 N-(4-(((1r,4r)-4- 369.10 3.83
    aminocyclohexyl)carbamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    335 N-(3-(N-(2- 351 10
    aminoethyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    336 N-(4-(N-(3- 365.10 5.89
    aminopropyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    337 N-(3-((2-aminoethyl)carbamoyl)phenyl)- 315 >10
    5-cyclopropylisoxazole-3-carboxamide
    338 N-(3-(N-(3- 365.1 >10
    aminopropyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    339 N-(4-(N-(2- 351.1 7.68
    aminoethyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    340 (R)-N-(1-(1-(4-aminobutanoyl)piperidin- 349.15 1.29
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    341 (S)-N-(1-(1-(4-aminobutanoyl)piperidin- 349.15 3.54
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    342 N-(1-((R)-3-aminobutanamido)-2,2- 351.2 1.31
    dimethylpentan-3-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    343 N-(1-((3-aminopropyl)sulfonyl)azetidin- 329 >10 >40
    3-yl)-5-cyclopropylisoxazole-3-
    carboxamide
    344 (R)-N-(1-(1-((3- 385 5.03 23.42
    aminopropyl)sulfonyl)piperidin-4-
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    345 (S)-N-(1-(1-((3- 385 >10 >40
    aminopropyl)sulfonyl)piperidin-4-
    yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    346 (S)-5-cyclopropyl-N-(1-(1-(2-(piperidin- 389.1 >10
    4-yl)acetyl)piperidin-4-
    yl)ethyl)isoxazole-3-carboxamide
    347 (R)-5-cyclopropyl-N-(1-(1-(2-(piperidin- 389.2 2.6
    4-yl)acetyl)piperidin-4-
    yl)ethyl)isoxazole-3-carboxamide
    348 N-((R)-1-(1-((1r,4R)-4- 389.2 0.46 5.16
    aminocyclohexane-1-carbonyl)piperidin-
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    349 N-((S)-1-(1-((1r,4S)-4- 389.2 2.79 >40
    aminocyclohexane-1-carbonyl)piperidin-
    4-yl)ethyl)-5-cyclopropylisoxazole-3-
    carboxamide
    350 N-(1-((1r,4r)-4-aminocyclohexane-1- 333 >10 >40
    carbonyl)azetidin-3-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    351 N-(3-((3- 329.10 >10 >40
    aminopropyl)carbamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    352 N-(1-(4-aminobutanoyl)azetidin-3-yl)-5- 293.05 >10 >40
    cyclopropylisoxazole-3-carboxamide
    353 N-(3-bromo-4-(piperidin-4- 433.1/ 1.44
    ylcarbamoyl)phenyl)-5- (433)
    cyclopropylisoxazole-3-carboxamide
    354 5-cyclopropyl-N-(2-methyl-4-(piperidin- 369.2 2.17
    4-ylcarbamoyl)phenyl)isoxazole-3-
    carboxamide
    355 N-(4-((3-aminopropyl)carbamoyl)-3- 407.05/ 1.77
    bromophenyl)-5-cyclopropylisoxazole-3- (409)
    carboxamide
    356 N-(4-((3-aminopropyl)carbamoyl)-2- 343.10 3.52
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide 447.1/ 7.25
    357 N-(3-bromo-4-((piperidin-4- (449)
    ylmethyl)carbamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    358 N-(4-((3-aminocyclobutyl)carbamoyl)-3- 419/ 1.4
    bromophenyl)-5-cyclopropylisoxazole-3- (421.05)
    carboxamide
    359 5-cyclopropyl-N-(4-(N-(piperidin-4- 405 5.81 >40
    ylmethyl)sulfamoyl)phenyl)isoxazole-3-
    carboxamide
    360 5-cyclopropyl-N-(3-methyl-4-(piperidin- 369.15 1.41
    4-ylcarbamoyl)phenyl)isoxazole-3-
    carboxamide
    361 N-(2-bromo-4-(piperidin-4- 433 1.77 >40
    ylcarbamoyl)phenyl)-5- (435)
    cyclopropylisoxazole-3-carboxamide
    362 N-(4-((4-aminocyclohcxyl)carbamoyl)-3- 383.4 3.74
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    363 N-(4-((4-aminocyclohcxyl)carbamoyl)-2- 447/ 5.59 >40
    bromophenyl)-5-cyclopropylisoxazole-3- (449.0)
    carboxamide
    364 N-(4-((2-aminoethyl)carbamoyl)-3- 329.1 6
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    365 N-(4-((2-aminoethyl)carbamoyl)-3- 393.05/ 4.5 >40
    bromophenyl)-5-cyclopropylisoxazole-3- (395)
    carboxamide
    366 N-(4-((2-aminoethyl)carbamoyl)-2- 393/ 3.7 38.81
    bromophenyl)-5-cyclopropylisoxazole-3- (395.1)
    carboxamide
    367 N-(4-((3-aminopropyl)carbamoyl)-3- 343.1 5.23
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    368 N-(3-bromo-4-(pyrrolidin-3- 419.1/ 3.06 >40
    ylcarbamoyl)phenyl)-5- (421)
    cyclopropylisoxazole-3-carboxamide
    369 5-cyclopropyl-N-(2-methyl-4- 383.1 8.43
    ((piperidin-4-
    ylmethyl)carbamoyl)phenyl)isoxazole-3-
    carboxamide
    370 N-(4-((3-aminocyclobutyl)carbamoyl)-2- 419.1/ 2.74 >40
    bromophenyl)-5-cyclopropylisoxazole-3- (421)
    carboxamide
    371 N-(4-((3-aminocyclohexyl)carbamoyl)-3- 447/
    bromophenyl)-5-cyclopropylisoxazole-3- (449.15) 9.11
    carboxamide
    372 N-(4-(N-(4- 405 2.57 21.71
    aminocyclohexyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    373 5-cyclopropyl-N-(4-(N-(piperidin-4- 391 6.04 39.07
    yl)sulfamoyl)phenyl)isoxazole-3-
    carboxamide
    374 5-cyclopropyl-N-(4-(N-(pyrrolidin-3- 377.2 4.03 >40
    yl)sulfamoyl)phenyl)isoxazole-3-
    carboxamide
    375 N-(4-(N-(3- 377 4.72 >40
    aminocyclobutyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    376 N-(1-((S)-3-aminobutanamido)-2,2- 351.1 1.17
    dimethylpentan-3-yl)-5-
    cyclopropylisoxazole-3-carboxamide
    377 N-(4-((4-aminocyclohexyl)carbamoyl)-3- 447.3/ 2.81
    bromophenyl)-5-cyclopropylisoxazole-3- (449)
    carboxamide
    378 N-(4-((4-aminocyclohexyl)carbamoyl)-2- 383.3 6.36
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    379 N-(4-((2-aminoethyl)carbamoyl)-2- 329 2.76
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    380 N-(4-((3-aminopropyl)carbamoyl)-2- 406.9 1.74
    bromophenyl)-5-cyclopropylisoxazole-3- (409)
    carboxamide
    381 5-cyclopropyl-N-(2-methyl-4- 355 2
    (pyrrolidin-3-
    ylcarbamoyl)phenyl)isoxazole-3-
    carboxamide
    382 N-(2-bromo-4-(pyrrolidin-3- 419/ 2.95
    ylcarbamoyl)phenyl)-5- (420.9)
    cyclopropylisoxazole-3-carboxamide
    383 N-(4-((3-aminocyclopentyl)carbamoyl)- 433.1/ 3.23
    3-bromophenyl)-5-cyclopropylisoxazole- (435)
    3-carboxamide
    384 N-(4-((3-aminocyclopentyl)carbamoyl)- 369.15 5.54
    2-methylphenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    385 N-(4-((3-aminocyclopentyl)carbamoyl)- 433.15/ 3.29
    2-bromophenyl)-5-cyclopropylisoxazole- (435)
    3-carboxamide
    386 N-(4-((3-aminocyclohexyl)carbamoyl)-2- 383.1 8.02
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    387 N-(4-((3-aminocyclohexyl)carbamoyl)-2- 447/ 5.37
    bromophenyl)-5-cyclopropylisoxazole-3- (449.0)
    carboxamide
    388 N-(4-(N-(3- 391 5.11 >40
    aminocyclopentyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    389 N-(4-(N-(3- 405.15 3.79 38.09
    aminocyclohexyl)sulfamoyl)phenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    390 5-cyclopropyl-N-(3-methyl-4- 355.1 4.45
    (pyrrolidin-3-
    ylcarbamoyl)phenyl)isoxazole-3-
    carboxamide
    391 5-cyclopropyl-N-(3-methyl-4- 383.1 >10
    ((piperidin-4-
    ylmethyl)carbamoyl)phenyl)isoxazole-3-
    carboxamide
    392 N-(2-bromo-4-((piperidin-4- 447/ 4.78
    ylmethyl)carbamoyl)phenyl)-5- (449.0)
    cyclopropylisoxazole-3-carboxamide
    393 N-(4-((3-aminocyclohexyl)carbamoyl)-3- 383.1 >10
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    394 N-((1s,4s)-4-(N-(2- 357 2.12
    aminocthyl)sulfamoyl)cyclohexyl)-5-
    cyclopropylisoxazole-3-carboxamide
    395 N-(4-((3-aminocyclopentyl)carbamoyl)- 369 4.61
    3-methylphenyl)-5-
    cyclopropylisoxazole-3-carboxamide
    396 N-(4-((3-aminocyclobutyl)carbamoyl)-2- 355.2 3.29
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    397 N-(3-((3-aminopropyl)sulfonamido)-2,2- 359.1 2.16
    dimethylpropyl)-5-cyclopropylisoxazole-
    3-carboxamide
    398 5-cyclopropyl-N-(2,2-dimethyl-3- 385.15 1.74
    (piperidine-4-
    sulfonamido)propyl)isoxazole-3-
    carboxamide
    399 N-(4-((3-aminocyclobutyl)carbamoyl)-3- 355 4.56
    methylphenyl)-5-cyclopropylisoxazole-
    3-carboxamide
    *IC50 values are an averagoe of n = 1 to n = 50
    • Definitions
  • For the purpose of the present disclosure, the term “alkyl” as used by itself or as part of another group refers to a straight- or branched-chain aliphatic hydrocarbon containing one to twelve carbon atoms (i.e., C1-12 alkyl) or the number of carbon atoms designated (i.e., a C1 alkyl such as methyl, a C2 alkyl such as ethyl, a C3 alkyl such as propyl or isopropyl, etc.). In one embodiment, the alkyl group is chosen from a straight chain C1-10 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C3-10 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain C1-6 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C3-6 alkyl group. In another embodiment, the alkyl group is chosen from a straight chain C1-4 alkyl group. In another embodiment, the alkyl group is chosen from a branched chain C3-4 alkyl group. In another embodiment, the alkyl group is chosen from a straight or branched chain C3-4 alkyl group. In another embodiment, the alkyl group is partially or completely deuterated, i.e., one or more hydrogen atoms of the alkyl group are replaced with deuterium atoms. Non-limiting exemplary C1-10 alkyl groups include methyl (including —CD3), ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. Non-limiting exemplary C1-4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and iso-butyl. Non-limiting exemplary C1-4 groups include methyl, ethyl, propyl, isopropyl, and tert-butyl.
  • For the purpose of the present disclosure, the term “optionally substituted alkyl” as used by itself or as part of another group means that the alkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, alkoxycarbonyl, and carboxyalkyl. In one embodiment, the alkyl is a C1-6 alkyl. In another embodiment, the alkyl is a C1-4 alkyl. In one embodiment, the optionally substituted alkyl is substituted with two substituents. In another embodiment, the optionally substituted alkyl is substituted with one substituent. Non-limiting exemplary optionally substituted alkyl groups include —CH2CH2NO2, —CH2CH2CO2H, —CH2CH2SO2CH3, —CH2CH2COPh, and —CH2C6H11.
  • For the purpose of the present disclosure, the term “alkylenyl” as used herein by itself or part of another group refers to a divalent form of an alkyl group as defined above. In one embodiment, the alkylenyl is a divalent form of a C1-6 alkyl. In one embodiment, the alkylenyl is a divalent form of a C1-4 alkyl. Non-limiting exemplary alkylenyl groups include —CH2CH2—, —CH2CH2CH2—, —CH2CH(CH3)CH2—, and —CH2C(CH3)2CH2—.
  • For the purpose of the present disclosure, the term “cycloalkyl” as used by itself or as part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C3-12 cycloalkyl) or the number of carbons designated. In one embodiment, the cycloalkyl group has two rings. In one embodiment, the cycloalkyl group has one ring. In another embodiment, the cycloalkyl group is chosen from a C3-8 cycloalkyl group. In another embodiment, the cycloalkyl group is chosen from a C3-6 cycloalkyl group. Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, spiro[3.3]heptane, and bicyclo[3.3.1]nonane.
  • For the purpose of the present disclosure, the term “optionally substituted cycloalkyl” as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl. (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, or (heteroaryl)alkyl. In one embodiment, the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent. In one embodiment, the optionally substituted cycloalkyl is an (amino)cycloalkyl. For the purpose of the present disclosure, the term “(amino)cycloalkyl” as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is substituted with one amino or alkylamino group, and optionally one or two additional substituents. In one embodiment, the optionally substituted cycloalkyl is an (amino)cyclohexyl. For the purpose of the present disclosure, the term “(amino)cyclohexyl” as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is a cyclohexyl group substituted with one amino or alkylamino group, and optionally one or two additional substituents. Non-limiting exemplary optionally substituted cycloalkyl groups include:
  • Figure US20200148650A1-20200514-C00445
    Figure US20200148650A1-20200514-C00446
  • Non-limiting exemplary (amino)cycloalkyl groups include:
  • Figure US20200148650A1-20200514-C00447
  • Non-limiting exemplary (amino)cyclohexyl groups include:
  • Figure US20200148650A1-20200514-C00448
  • For the purpose of the present disclosure, the term “optionally substituted cyclohexyl” as used by itself or as part of another group means that the optionally substituted cycloalkyl as defined above is an optionally substituted cyclohexyl group.
  • For the purpose of the present disclosure, the term “cycloalkylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted cycloalkyl group as defined above. In one embodiment, the cycloalkylenyl is a “cyclohexylenyl.” The term “cyclohexylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted cyclohexyl group. Non-limiting exemplary cycloalkylenyl groups include:
  • Figure US20200148650A1-20200514-C00449
  • For the purpose of the present disclosure, the term “1,4-cyclohexylenyl” as used herein by itself or part of another group refers to a cyclohexylenyl as defined above wherein the radicals are in the 1 and 4 positions of the cyclohexyl ring. Non-limiting exemplary 1,4-cyclohexylenyl groups include:
  • Figure US20200148650A1-20200514-C00450
  • For the purpose of the present disclosure, the term “(cycloalkylenyl)alkyl” as used herein by itself or part of another group refers to an alkyl group substituted with a divalent form of an optionally substituted cycloalkyl group. In one embodiment, the cycloalkylenyl is a divalent form of optionally substituted cyclohexyl. In one embodiment, the alkyl is C1-4 alkyl. Non-limiting exemplary (cycloalkylenyl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00451
  • For the purpose of the present disclosure, the term “cycloalkenyl” as used by itself or part of another group refers to a partially unsaturated cycloalkyl group as defined above. In one embodiment, the cycloalkenyl has one carbon-to-carbon double bond. In another embodiment, the cycloalkenyl group is chosen from a C4-8 cycloalkenyl group. Exemplary cycloalkenyl groups include cyclopentenyl and cyclohexenyl.
  • For the purpose of the present disclosure, the term “optionally substituted cycloalkenyl” as used by itself or as part of another group means that the cycloalkenyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, monohydroxyalkyl, dihydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, and (heteroaryl)alkyl. In one embodiment, the optionally substituted cycloalkenyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkenyl is substituted with one substituent. In another embodiment, the cycloalkenyl is unsubstituted.
  • For the purpose of the present disclosure, the term “alkenyl” as used by itself or as part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the alkenyl group is chosen from a C2-6 alkenyl group. In another embodiment, the alkenyl group is chosen from a C2-4 alkenyl group. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.
  • For the purpose of the present disclosure, the term “optionally substituted alkenyl” as used herein by itself or as part of another group means the alkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclo.
  • For the purpose of the present disclosure, the term “alkynyl” as used by itself or as part of another group refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. In one embodiment, the alkynyl group is chosen from a C2-6 alkynyl group. In another embodiment, the alkynyl group is chosen from a C2-4 alkynyl group. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
  • For the purpose of the present disclosure, the term “optionally substituted alkynyl” as used herein by itself or as part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
  • For the purpose of the present disclosure, the term “haloalkyl” as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine, chlorine, bromine and/or iodine atoms. In one embodiment, the alkyl group is substituted by one, two, or three fluorine and/or chlorine atoms. In another embodiment, the haloalkyl group is chosen from a C1-4 haloalkyl group. Non-limiting exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.
  • For the purpose of the present disclosure, the term “fluoroalkyl” as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine atoms. In one embodiment, the alkyl group is substituted by one, two, or three fluorine atoms. In another embodiment, the fluoroalkyl group is chosen from a C1-4 fluoroalkyl group. Non-limiting exemplary fluoroalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, and 4,4,4-trifluorobutyl.
  • For the purpose of the present disclosure, the term “hydroxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with one or more, e.g., one, two, or three, hydroxy groups. In one embodiment, the hydroxyalkyl group is a monohydroxyalkyl group, i.e., substituted with one hydroxy group. In another embodiment, the hydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with two hydroxy groups. In another embodiment, the hydroxyalkyl group is chosen from a C1-4 hydroxyalkyl group. Non-limiting exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as I-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl.
  • For the purpose of the present disclosure, the term “alkoxy” as used by itself or as part of another group refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom. In one embodiment, the alkoxy group is chosen from a C1-4 alkoxy group. In another embodiment, the alkoxy group is chosen from a C1-4 alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, tert-butoxy, —OCH2C≡CH, —OCH2C≡CCH3, and —OCH2CH2CH2C≡CH.
  • For the purpose of the present disclosure, the term “alkylthio” as used by itself or as part of another group refers to a sulfur atom substituted by an optionally substituted alkyl group. In one embodiment, the alkylthio group is chosen from a C1-4 alkylthio group. Non-limiting exemplary alkylthio groups include —SCH3, and —SCH2CH3.
  • For the purpose of the present disclosure, the term “alkoxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with an alkoxy group. Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sc-butoxymethyl, pentyloxymethyl, —CH2OCH2C≡CH and —CH2OCH2CH2CH2C≡CH.
  • For the purpose of the present disclosure, the term “haloalkoxy” as used by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen atom. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.
  • For the purpose of the present disclosure, the term “heteroalkyl” as used by itself or part of another group refers to a stable straight or branched chain hydrocarbon radical containing 1 to 10 carbon atoms and at least two heteroatoms, which can be the same or different, selected from O, N, or S, wherein: 1) the nitrogen atom(s) and sulfur atom(s) can optionally be oxidized; and/or 2) the nitrogen atom(s) can optionally be quaternized. The heteroatoms can be placed at any interior position of the heteroalkyl group or at a position at which the heteroalkyl group is attached to the remainder of the molecule. In one embodiment, the heteroalkyl group contains two oxygen atoms. In one embodiment, the heteroalkyl contains one oxygen and one nitrogen atom, e.g., a (hydroxyalkylamino)alkyl group, e.g., —CH2N(CH3)CH2CH2CH2OH. In one embodiment, the heteroalkyl contains two nitrogen atoms. Non-limiting exemplary heteroalkyl groups include —CH2OCH2CH2OCH3, —OCH2CH2OCH2CH2OCH3, —CH—2NHCH2CH2OCH2, —OCH2CH2NH2, —NHCH2CH2N(H)CH7, —NHCH2CH2OCH3, —CH2OCH2CH2NH2, —CH2OCH2CH2N(H)CH2CH3, and —OCH2CH2OCH3.
  • For the purpose of the present disclosure, the term “aryl” as used by itself or as part of another group refers to a monocyclic or bicyclic aromatic ring system having from six to fourteen carbon atoms (i.e., C6-14 aryl). Non-limiting exemplary aryl groups include phenyl (abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one embodiment, the aryl group is chosen from phenyl or naphthyl. In one embodiment, the aryl group is phenyl.
  • For the purpose of the present disclosure, the term “optionally substituted aryl” as used herein by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently selected from the group consisting of halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, aralkyl aralkyloxy, (aralkyloxy)alkyl, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, heteroalkyl optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, (C1-4 haloalkoxy)alkyl, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (cycloalkylamino)alkyl, (hydroxyalkylamino)alkyl, (amino)(heteroaryl)alkyl, (heterocycloamino)alkyl (amino)(hydroxy)alkyl, (heteroaryl)alkyl, —N(R43)(R44), —CH2N(H)C(═O)—R45, and —N(H)C(═O)—R45, wherein R43 is hydrogen, C1-4 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R44 is alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, (alkylamino)alkyl, or (dialkylamino)alkyl; and R45 is alkyl, alkoxyalkyl, (heterocyclo)alkyl. (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted aryl, optionally substituted heteroaryl, aralkyl, or (heteroaryl)alkyl In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. In another embodiment, the optionally substituted phenyl has at least one amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl. (amino)(heteroaryl)alkyl, or (amino)(hydroxy)alkyl substituent. Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, 3-chloro-4-fluorophenyl, and 2-phenylpropan-2-amine. The term optionally substituted aryl is meant to include aryl groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include:
  • Figure US20200148650A1-20200514-C00452
  • For the purpose of the present disclosure, the term “arylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted aryl group as defined above. In one embodiment, the arylenyl is a divalent form of an optionally substituted phenyl. In one embodiment, the arylenyl is a divalent form of phenyl. Non-limiting exemplary alkylenyl groups include:
  • Figure US20200148650A1-20200514-C00453
  • For the purpose of the present disclosure, the term “aryloxy” as used by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom. A non-limiting exemplary aryloxy group is PhO—.
  • For the purpose of the present disclosure, the term “heteroaryloxy” as used by itself or as part of another group refers to an optionally substituted heteroaryl attached to a terminal oxygen atom.
  • For the purpose of the present disclosure, the term “aralkyloxy” or “arylalkyloxy” as used by itself or as part of another group refers to an aralkyl group attached to a terminal oxygen atom. A non-limiting exemplary aralkyloxy group is PhCH2O—.
  • For the purpose of the present disclosure, the term “(aralkyloxy)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an aralkyloxy group. In one embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary “(aralkyloxy)alkyl” groups include —CH4OCH1(3-F-Ph) and —CH2OCH2CH2CH2(2-OMe-Ph).
  • For the purpose of the present disclosure, the term “heteroaryl” or “heteroaromatic” refers to monocyclic and bicyclic aromatic ring systems having 5 to 14 ring members (i.e., a 5- to 14-membered heteroaryl) and 1, 2, 3, or 4 heteroatoms independently chosen from oxygen, nitrogen or sulfur. In one embodiment, the heteroaryl has three heteroatoms. In another embodiment, the heteroaryl has two heteroatoms. In another embodiment, the heteroaryl has one heteroatom. In one embodiment, the heteroaryl has 5 ring atoms, e.g., thienyl. In another embodiment, the heteroaryl has 6 ring atoms, e.g., pyridyl. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. In one embodiment, the heteroaryl is chosen from thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl) and isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl). The term “heteroaryl” is also meant to include possible N-oxides. Exemplary N-oxides include pyridyl N-oxide.
  • For the purpose of the present disclosure, the term “optionally substituted heteroaryl” as used by itself or as part of another group means that the heteroaryl as defined above is either unsubstituted or substituted with one to four substituents, e.g., one or two substituents, independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aralkyl, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl. (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, (heteroaryl)alkyl, —N(R43)(R44), or —N(H)C(═O)—R45, wherein R43 is hydrogen or C1-4 alkyl; R44 is alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, (alkylamino)alkyl, or (dialkylamino)alkyl; and R45 is alkyl, optionally substituted aryl, or optionally substituted heteroaryl. In one embodiment, the optionally substituted heteroaryl has one substituent. In one embodiment, the substituent is amino, alkylamino, dialkylamino, (amino)alkyl, hydroxyalkylamino, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, —N(R43)(R44), or —N(H)C(═O)—R45. In one embodiment, the substituent is aralkyl or (heteroaryl)alkyl. Examples include:
  • Figure US20200148650A1-20200514-C00454
  • In one embodiment, the optionally substituted heteroaryl is an optionally substituted pyridyl, i.e., 2-, 3-, or 4-pyridyl. Any available carbon or nitrogen atom can be substituted. The term optionally substituted heteroaryl is meant to include heteroaryl groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Examples include:
  • Figure US20200148650A1-20200514-C00455
  • For the purpose of the present disclosure, the term “heteroarylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted heteroaryl group as defined above. In one embodiment, the heteroarylenyl is a divalent form of an optionally substituted pyridyl. Non-limiting exemplary heteroarylenyl groups include:
  • Figure US20200148650A1-20200514-C00456
  • For the purpose of the present disclosure, the term “heterocycle” or “heterocyclo” as used by itself or as part of another group refers to saturated and partially unsaturated (e.g., containing one or two double bonds) cyclic groups containing one, two, or three rings having from three to fourteen ring members (i.e., a 3- to 14-membered heterocyclo) and at least one heteroatom. Each heteroatom is independently selected from the group consisting of oxygen, sulfur, including sulfoxide and sulfone, and/or nitrogen atoms, which can be quaternized. The term “heterocyclo” is meant to include cyclic ureido groups such as imidazolidinyl-2-one, cyclic amide groups such as β-lactam, γ-lactam, δ-lactam and ε-lactam, and cyclic carbamate groups such as oxazolidinyl-2-one. The term “heterocyclo” is also meant to include groups having fused optionally substituted aryl groups, e.g., indolinyl, indolinyl-2-one, benzo[d]oxazolyl-2(3H)one. In one embodiment, the heterocyclo group is chosen from a 4-, 5-, 6-, 7- or 8-membered cyclic group containing one ring and one or two oxygen and/or nitrogen atoms. In one embodiment, the heterocyclo group is chosen from a 5- or 6-membered cyclic group containing one ring and one or two nitrogen atoms. In one embodiment, the heterocyclo group is chosen from a 8-, 9-, 10-, 11-, or 12-membered cyclic group containing two rings and one or two nitrogen atoms. The heterocyclo can be optionally linked to the rest of the molecule through a carbon or nitrogen atom. Non-limiting exemplary heterocyclo groups include 2-oxopyrrolidin-3-yl, 2-imidazolidinone, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, 8-azabicyclo[3.2.1]octane (nortropane), 6-azaspiro[2.5]octane, 6-azaspiro[3.4]octane, indolinyl, indolinyl-2-one, 1,3-dihydro-2H-benzo[d]imidazol-2-one
  • For the purpose of the present disclosure, the term “optionally substituted heterocyclo” as used herein by itself or part of another group means the heterocyclo as defined above is either unsubstituted or substituted with one to four substituents independently selected from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyl aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, ureido, guanidino, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, alkoxyalkyl, (amino)alkyl, hydroxyalkylamino. (alkylamino)alkyl, (dialkylamino)alkyl, (cyano)alkyl, (carboxamido)alkyl, mercaptoalkyl, (heterocyclo)alkyl, and (heteroaryl)alkyl. Substitution may occur on any available carbon or nitrogen atom, and may form a spirocycle. In one embodiment, the optionally substituted heterocyclo is substituted with at least one amino, alkylamino, or dialkylamino group. Non-limiting exemplary optionally substituted heterocyclo groups include:
  • Figure US20200148650A1-20200514-C00457
  • For the purpose of the present disclosure, the term “heterocyclenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted heterocyclo group as defined above. In one embodiment, the heterocyclenyl is a divalent form of an optionally substituted azetidine. In one embodiment, the heterocyclenyl is a divalent form of an optionally substituted piperidinyl. Non-limiting exemplary heterocyclenyl groups include:
  • Figure US20200148650A1-20200514-C00458
  • For the purpose of the present disclosure, the term “optionally substituted pyrrolidinyl” as used by itself or as part of another group means that the optionally substituted heterocyclo as defined above is an optionally substituted pyrrolidinyl group.
  • For the purpose of the present disclosure, the term “optionally substituted pyrrolidinonyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted pyrrolidinyl group as defined above. Non-limiting exemplary optionally substituted pyrrolidinenyl groups include:
  • Figure US20200148650A1-20200514-C00459
  • For the purpose of the present disclosure, the term “optionally substituted, optionally bridged piperidinenyl” as used by itself or as part of another group refers to a divalent form having the following structure:
  • Figure US20200148650A1-20200514-C00460
  • wherein:
  • R2′a, R2′b, R3′a, R3′b, R4′a, R4′b, R5′a, and R5′b are each independently selected from the group consisting of hydrogen, halo, C1-6 alkyl, C3-12 cycloalkyl, haloalkyl, hydroxyalkyl, optionally substituted C6-14 aryl, aralkyl, and alkoxycarbonyl; or
  • R2′a and R2′b taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl; and R3′a, R3′b, R4′a, R4′bR5′a, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R3′a and R3′b taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl; and R2′a, R2′b, R4′a, R4′b, R5′a, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R4a and R4b taken together with the carbon atom to which they are attached form a Cu cycloalkyl; and R2′a, R2′b, R3′a, R3′b, R4′a, and R4′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R5′a and R5′b taken together with the carbon atom to which they are attached form a C3-6 cycloalkyl; and R2′a, R2′b, R3′a, R3′b, R4′a, and R4′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R2′a and R5′a taken together form a C1-4 bridge; and R2′b, R3′a, R3′b, R4′a, R4′b, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl, or
  • R3′a and R4′a taken together form a C1-4 bridge; and R2′a, R2′b, R3′b, R4′a, R5′a, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R2′a and R4′a taken together form a C1-4 bridge; and R2′b, R3′a, R3′b, R4′b, R5′a, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl; or
  • R3′a and R5′a taken form a C1-4 bridge; and R2′a, R2′b, R3′b, R4′a, R4′b, and R5′b are each independently selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R6′ is selected from the group consisting of hydrogen and C1-4 alkyl;
  • For the purpose of the present disclosure, the term “amino” as used by itself or as part of another group refers to —NH2.
  • For the purpose of the present disclosure, the term “alkylamino” as used by itself or as part of another group refers to —NHR22, wherein R22 is C1-6 alkyl. In one embodiment, R22 is C1-4 alkyl. Non-limiting exemplary alkylamino groups include —N(H)CH3 and —N(H)CH2CH3.
  • For the purpose of the present disclosure, the term “dialkylamino” as used by itself or as part of another group refers to —NR23aR23b, wherein R23a and R23b are each independently C1-6 alkyl. In one embodiment, R23a and R23b are each independently C1-4 alkyl. Non-limiting exemplary dialkylamino groups include —N(CH3)2 and —N(CH3)CH2CH(CH3)2.
  • For the purpose of the present disclosure, the term “hydroxyalkylamino” as used by itself or as part of another group refers to —NR24a R24b, wherein R24a is hydrogen or C1-4 alkyl, and R24b is hydroxyalkyl. Non-limiting exemplary hydroxyalkylamino groups include —N(H)CH2CH2OH, —N(H)CH2CH2CH2OH, —N(CH3)CH2CH2OH, and —N(CH3)CH2CH2CH2OH
  • For the purpose of the present disclosure, the term “(hydroxyalkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an hydroxyalkylamino group. In one embodiment, the alkyl is a C1-4 alkyl. A non-limiting exemplary (hydroxyalkylamino)alkyl group is —CH2N(CH3)CH2CH2CH2OH.
  • For the purpose of the present disclosure, the term “cycloalkylamino” as used by itself or as part of another group refers to —NR25aR25b, wherein R25a is optionally substituted cycloalkyl and R25b is hydrogen or C1-4 alkyl.
  • For the purpose of the present disclosure, the term “heterocycloamino” as used by itself or as part of another group refers to —NR25cR25d, wherein R25c is optionally substituted heterocyclo and R25d is hydrogen or C1-4 alkyl. Non-limiting exemplary heterocycloamino groups include:
  • Figure US20200148650A1-20200514-C00461
  • For the purpose of the present disclosure, the term “(heterocycloamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an heterocycloamino group. In one embodiment, the alkyl is a C1-4 alkyl.
  • For the purpose of the present disclosure, the term “aralkylamino” as used by itself or as part of another group refers to —NR26aR26b, wherein R26a is aralkyl and R26b is hydrogen or C1-4 alkyl. Non-limiting exemplary aralkylamino groups include —N(H)CH2Ph and —N(CH3)CH2Ph.
  • For the purpose of the present disclosure, the term “(amino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an amino group. In one embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary (amino)alkyl groups include —CH2NH2, —C(NH2)(H)CH3, —CH2CH2NH2, —CH2C(NH2)(H)CH3, —CH2CH2CH2NH2, —CH2CH2CH2CH2NH2, and —CH2C(CH3)2CH2NH2.
  • For the purpose of the present disclosure, the term “(alkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an alkylamino group. In one embodiment, the alkyl is a C1-4 alkyl. A non-limiting exemplary (alkylamino)alkyl group is —CH2CH2N(H)CH3.
  • For the purpose of the present disclosure, the term “(dialkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted by a dialkylamino group. In one embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary (dialkylamino)alkyl groups are —CH2CH2N(CH3)2.
  • For the purpose of the present disclosure, the term “(cycloalkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted by a cycloalkylamino group. In one embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary (cycloalkylamino)alkyl groups include —CH2N(H)cyclopropyl, —CH2N(H)cyclobutyl, and —CH2N(H)cyclohexyl.
  • For the purpose of the present disclosure, the term “(aralkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an aralkylamino group. In one embodiment, the alkyl is a C1-4 alkyl. A non-limiting exemplary (aralkylamino)alkyl group is —CH2CH2CH2N(H)CH2Ph.
  • For the purpose of the present disclosure, the term “(hydroxyalkylamino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an hydroxyalkylamino group. A non-limiting exemplary (hydroxyalkylamino)alkyl group is —CH2CH2NHCH2CH2OH
  • For the purpose of the present disclosure, the term “(cyano)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one or more cyano, e.g., —CN, groups. In one embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary (cyano)alkyl groups include —CH2CH2CN, —CH2CH2CH2CN, and —CH2C2CH2CH2CH2CN.
  • For the purpose of the present disclosure, the term “(amino)(hydroxy)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one amino, alkylamino, dialkylamino, or heterocyclo group and one hydroxy group. In one embodiment, the alkyl is a C1-6 alkyl. In another embodiment, the alkyl is a C1-4 alkyl. Non-limiting exemplary (amino)(hydroxy)alkyl groups include:
  • Figure US20200148650A1-20200514-C00462
  • For the purpose of the present disclosure, the term “(amino)(carboxamido)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino, and one carboxamido group. In one embodiment, the alkyl is a C1-6 alkyl. Non-limiting exemplary (amino)(carboxamido)alkyl groups include:
  • Figure US20200148650A1-20200514-C00463
  • For the purpose of the present disclosure, the term “(amino)(aryl)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino group and one optionally substituted aryl group. In one embodiment, the alkyl is a C1-6 alkyl. In one embodiment, the optionally substituted aryl group is an optionally substituted phenyl. Non-limiting exemplary (amino)(aryl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00464
  • For the purpose of the present disclosure, the term “(amino)(heteroaryl)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one amino, alkylamino, or dialkylamino group and one optionally substituted heteroaryl group. In one embodiment, the alkyl is a C1-6 alkyl. In one embodiment, the alkyl is a C1-4 alkyl. In one embodiment, the optionally substituted heteroaryl group is an optionally substituted pyridyl. Non-limiting exemplary (amino)(heteroaryl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00465
  • For the purpose of the present disclosure, the term “(cycloalkyl)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one optionally substituted cycloalkyl group. In one embodiment, the alkyl is a C1-4 alkyl. In one embodiment, the cycloalkyl is a C3-6 cycloalkyl. In one embodiment, the optionally substituted cycloalkyl group is substituted with an amino or (amino)alkyl group. Non-limiting exemplary (cycloalkyl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00466
  • For the purpose of the present disclosure, the term “(hydroxy)(aryl)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one hydroxy group and one optionally substituted aryl group. In one embodiment, the alkyl is a C1-6 alkyl. In one embodiment, the optionally substituted aryl group is an optionally substituted phenyl. Non-limiting exemplary (hydroxy)(aryl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00467
  • For the purpose of the present disclosure, the term “carboxamido” as used by itself or as part of another group refers to a radical of formula —C(═O)NR26aR26b, wherein R26a and R26b are each independently hydrogen, optionally substituted alkyl, optionally substituted aryl, aralkyl, (heteroaryl)alkyl, or optionally substituted heteroaryl, or R26a and R26b taken together with the nitrogen to which they are attached from a 3- to 8-membered heterocyclo group. In one embodiment, R26a and R26b are each independently hydrogen or optionally substituted alkyl. Non-limiting exemplary carboxamido groups include —CONH2, —CON(H)CH3, CON(CH3)2, and —CON(H)Ph.
  • For the purpose of the present disclosure, the term “(carboxamido)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with a carboxamido group. Non-limiting exemplary (carboxamido)alkyl groups include —CH2CONH2, —C(H)CH3—CONH2, and —CH2CON(H)CH3.
  • For the purpose of the present disclosure, the term “sulfonamido” as used by itself or as part of another group refers to a radical of the formula —SO2NR27aR27b, wherein R27a and R27b are each independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, or R27a and R27b taken together with the nitrogen to which they are attached from a 3- to 8-membered heterocyclo group. Non-limiting exemplary sulfonamido groups include —SO2NH2, —SO2N(H)CH3, and —SO2N(H)Ph.
  • For the purpose of the present disclosure, the term “alkylcarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an alkyl group. A non-limiting exemplary alkylcarbonyl group is —COCH3.
  • For the purpose of the present disclosure, the term “arylcarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an optionally substituted aryl group. A non-limiting exemplary arylcarbonyl group is —COPh.
  • For the purpose of the present disclosure, the term “alkylsulfonyl” as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO2—, substituted by any of the above-mentioned optionally substituted alkyl groups. A non-limiting exemplary alkylsulfobnyl group is —SO2CH3.
  • For the purpose of the present disclosure, the term “arylsulfonyl” as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO2—, substituted by any of the above-mentioned optionally substituted aryl groups. A non-limiting exemplary arylsulfonyl group is —SO2Ph.
  • For the purpose of the present disclosure, the term “mercaptoalkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted by a —SH group.
  • For the purpose of the present disclosure, the term “carboxy” as used by itself or as part of another group refers to a radical of the formula —COOH.
  • For the purpose of the present disclosure, the term “carboxyalkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with a —COOH. A non-limiting exemplary carboxyalkyl group is —CH2CO2H.
  • For the purpose of the present disclosure, the term “alkoxycarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an alkoxy group. Non-limiting exemplary alkoxycarbonyl groups are —CO2Me and —CO2Et.
  • For the purpose of the present disclosure, the term “aralkyl” or “arylalkyl” as used by itself or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted aryl groups. In one embodiment, the aralkyl group is a C1-4 alkyl substituted with one optionally substituted aryl group. Non-limiting exemplary aralkyl groups include benzyl, phenethyl, —CHPh2, —CH2(4-OH-Ph), and —CH(4-F-Ph)2.
  • For the purpose of the present disclosure, the term “ureido” as used by itself or as part of another group refers to a radical of the formula —NR30a—C(═O)—NR30bR30c, wherein R22a is hydrogen, alkyl, or optionally substituted aryl, and R30b and R30c are each independently hydrogen, alkyl, or optionally substituted aryl, or R30b and R30c taken together with the nitrogen to which they are attached form a 4- to 8-membered heterocyclo group. Non-limiting exemplary ureido groups include —NH—C(C═O)—NH2 and —NH—C(C═O)—NHCH3.
  • For the purpose of the present disclosure, the term “guanidino” as used by itself or as part of another group refers to a radical of the formula —NR28a—C(═NR29)—NR28bR28c, wherein R28a, R28b, and R28c are each independently hydrogen, alkyl, or optionally substituted aryl, and R29 is hydrogen, alkyl, cyano, alkylsulfonyl, alkylcarbonyl, carboxamido, or sulfonamido. Non-limiting exemplary guanidino groups include —NH—C(C═NH)—NH2, —NH—C(C═NCN)—NH2, and —NH—C(C═NH)—NHCH3.
  • For the purpose of the present disclosure, the term “(heterocyclo)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted heterocyclo groups. In one embodiment, the (heterocyclo)alkyl is a C1-4 alkyl substituted with one optionally substituted heterocyclo group. The heterocyclo can be linked to the alkyl group through a carbon or nitrogen atom. Non-limiting exemplary (heterocyclo)alkyl groups include:
  • Figure US20200148650A1-20200514-C00468
  • For the purpose of the present disclosure, the term “(heteroaryl)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted heteroaryl groups. In one embodiment, the (heteroaryl)alkyl group is a C1-4 alkyl substituted with one optionally substituted heteroaryl group. Non-limiting exemplary (heteroaryl)alkyl groups include:
  • Figure US20200148650A1-20200514-C00469
  • For the purpose of the present disclosure, the term “alkylcarbonylamino” as used by itself or as part of another group refers to an alkylcarbonyl group attached to an amino. A non-limiting exemplary alkylcarbonylamino group is —NHCOCH3.
  • For the purpose of the present disclosure, the term “C1-4 bridge” refers to a —CH2—, —(CH2)2—, —(CH2)3—, or —(CH2)4— group that joins two carbon atoms of a piperidine to form an azabicyclo group. For example, in Formula I, R3a and R4a of B can be taken together to form a 6-azabicyclo[3.1.1]heptane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, or 10-azabicyclo[4.3.1]decane group. Each methylene unit of the C1-4 bridge can be optionally substituted with one or two substituents independently selected from the group consisting of C1-4 alkyl and halo.
  • The present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled (i.e., radiolabeled) by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H (or deuterium (D)), 3H, 11C, 13C, 14C, 5N, 13O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively, e.g., 3H, 11C, and 14C. In one embodiment, provided is a composition wherein substantially all of the atoms at a position within the Compound of the Disclosure are replaced by an atom having a different atomic mass or mass number. In another embodiment, provided is a composition wherein a portion of the atoms at a position within the Compound of the disclosure are replaced, i.e., the Compound of the Disclosure is enriched at a position with an atom having a different atomic mass or mass number.” Isotopically-labelled Compounds of the Disclosure can be prepared by methods known in the art.
  • Compounds of the Disclosure may contain one or more asymmetric centers and may thus give rise to enantiomers, diasteromers, and other stereoisomeric forms. The present disclosure is meant to encompass the use of all such possible forms, as well as their racemic and resolved forms and mixtures thereof. The individual enantiomers can be separated according to methods known in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present disclosure as well.
  • As used herein, the term “stereoisomers” is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • The term “chiral center” or “asymmetric carbon atom” refers to a carbon atom to which four different groups are attached.
  • The terms “enantiomer” and “enantiomeric” refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
  • The term “racemic” refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.
  • The term “absolute configuration” refers to the spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description, e.g., R or S.
  • The stereochemical terms and conventions used in the specification are meant to be consistent with those described in Pure & Appl. Chem 68:2193 (1996), unless otherwise indicated.
  • The term “enantiomeric excess” or “ee” refers to a measure for how much of one enantiomer is present compared to the other. For a mixture of R and S enantiomers, the percent enantiomeric excess is defined as |R−S|*100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R+S=1. With knowledge of the optical rotation of a chiral substance, the percent enantiomeric excess is defined as ([α]obs/[α]max)*100, where [α]obs is the optical rotation of the mixture of enantiomers and [α]max is the optical rotation of the pure enantiomer. Determination of enantiomeric excess is possible using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography or optical polarimetry.
  • The terms “enantiomerically pure” or “enantiopure” refer to a sample of a chiral substance all of whose molecules (within the limits of detection) have the same chirality sense.
  • The terms “enantiomerically enriched” or “enantioenriched” refer to a sample of a chiral substance whose enantiomeric ratio is greater than 50:50. Enantiomerically enriched compounds may be enantiomerically pure.
  • The terms “a” and “an” refer to one or more.
  • The term “about,” as used herein, includes the recited number±10%. Thus, “about 10” means 9 to 11.
  • The present disclosure encompasses the preparation and use of salts of the Compounds of the Disclosure, including non-toxic pharmaceutically acceptable salts. Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts. The pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like; organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, asparaginate, glutamate and the like. The term “pharmaceutically acceptable salt” as used herein, refers to any salt, e.g., obtained by reaction with an acid or a base, of a Compound of the Disclosure that is physiologically tolerated in the target patient (e.g., a mammal, e.g., a human).
  • Acid addition salts can be formed by mixing a solution of the particular Compound of the Disclosure with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, or the like. Basic salts can be formed by mixing a solution of the compound of the present disclosure with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.
  • The present disclosure encompasses the preparation and use of solvates of Compounds of the Disclosure. Solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents. The term “solvate” as used herein is a combination, physical association and/or solvation of a compound of the present disclosure with a solvent molecule such as, e.g. a desolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, “solvate” encompasses both solution-phase and isolatable solvates. Compounds of the Disclosure can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure. One type of solvate is a hydrate. A “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E. C, van Tonder et al., AAPS Pharm. Sci. Tech., 5(l):Article 12 (2004), and A. L. Bingham et al., Chem. Commun. 603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20° C. to about 25° C., then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
  • Since Compounds of the Disclosure are inhibitors of SMYD proteins, such as SMYD3 and SMYD2, a number of diseases, conditions, or disorders mediated by SMYD proteins, such as SMYD3 and SMYD2, can be treated by employing these compounds. The present disclosure is thus directed generally to a method for treating a disease, condition, or disorder responsive to the inhibition of SMYD proteins, such as SMYD3 and SMYD2, in an animal suffering from, or at risk of suffering from, the disorder, the method comprising administering to the animal an effective amount of one or more Compounds of the Disclosure.
  • The present disclosure is further directed to a method of inhibiting SMYD proteins in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • The present disclosure is further directed to a method of inhibiting SMYD3 in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • The present disclosure is further directed to a method of inhibiting SMYD2 in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one Compound of the Disclosure.
  • As used herein, the terms “treat,” “treating,” “treatment,” and the like refer to eliminating, reducing, or ameliorating a disease or condition, and/or symptoms associated therewith. Although not precluded, treating a disease or condition does not require that the disease, condition, or symptoms associated therewith be completely eliminated. As used herein, the terms “treat.” “treating.” “treatment,” and the like may include “prophylactic treatment,” which refers to reducing the probability of redeveloping a disease or condition, or of a recurrence of a previously-controlled disease or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or condition or a recurrence of the disease or condition. The term “treat” and synonyms contemplate administering a therapeutically effective amount of a Compound of the Disclosure to an individual in need of such treatment.
  • Within the meaning of the disclosure, “treatment” also includes relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
  • The term “therapeutically effective amount” or “effective dose” as used herein refers to an amount of the active ingredient(s) that is(are) sufficient, when administered by a method of the disclosure, to efficaciously deliver the active ingredient(s) for the treatment of condition or disease of interest to an individual in need thereof. In the case of a cancer or other proliferation disorder, the therapeutically effective amount of the agent may reduce (i.e., retard to some extent and preferably stop) unwanted cellular proliferation; reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., retard to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., retard to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; modulate protein methylation in the target cells; and/or relieve, to some extent, one or more of the symptoms associated with the cancer. To the extent the administered compound or composition prevents growth and/or kills existing cancer cells, it may be cytostatic and/or cytotoxic.
  • The term “container” means any receptacle and closure therefore suitable for storing, shipping, dispensing, and/or handling a pharmaceutical product.
  • The term “insert” means information accompanying a pharmaceutical product that provides a description of how to administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and patient to make an informed decision regarding use of the product. The package insert generally is regarded as the “label” for a pharmaceutical product.
  • The term “disease” or “condition” or “disorder” denotes disturbances and/or anomalies that as a rule are regarded as being pathological conditions or functions, and that can manifest themselves in the form of particular signs, symptoms, and/or malfunctions. As demonstrated below, Compounds of the Disclosure inhibit SMYD proteins, such as SMYD3 and SMYD2 and can be used in treating diseases and conditions such as proliferative diseases, wherein inhibition of SMYD proteins, such as SMYD3 and SMYD2 provides a benefit.
  • In some embodiments, the Compounds of the Disclosure can be used to treat a “SMYD protein mediated disorder” (e.g., a SMYD3-mediated disorder or a SMYD2-mediated disorder). A SMYD protein mediated disorder is any pathological condition in which a SMYD protein is know to play a role. In some embodiments, a SMYD-mediated disorder is a proliferative disease.
  • In some embodiments inhibiting SMYD proteins, such as SMYD3 and SMYD2, is the inhibition of the activity of one or more activities of SMYD proteins such as SMYD3 and SMYD2. In some embodiments, the activity of the SMYD proteins such as SMYD3 and SMYD2 is the ability of the SMYD protein such as SMYD3 or SMYD2 to transfer a methyl group to a target protein (e.g., histone). It should be appreciated that the activity of the one or more SMYD proteins such as SMYD3 and SMYD2 may be inhibited in vitro or in vivo. Examplary levels of inhibition of the activity one or more SMYD proteins such as SMYD3 and SMYD2 include at least 10% inhibition, at least 20% inhibition, at least 30% inhibition, at least 40% inhibition, at least 50% inhibition, at least 60% inhibition, at least 70% inhibition, at least 80% inhibition, at least 90%/0 inhibition, and up to 100% inhibition.
  • The SMYD (SET and MYND domain) family of lysine methyltransferases (KMTs) plays pivotal roles in various cellular processes, including gene expression regulation and DNA damage response. The family of human SMYD proteins consists of SMYD1, SMYD2, SMYD3. SMYD4 and SMYD5. SMYD1, SMYD2, and SMYD3 share a high degree of sequence homology and, with the exception of SMYD5, human SMYD proteins harbor at least one C-terminal tetratrico peptide repeat (TPR) domain. (See e.g., Abu-Farha et al. J Mol Cell Biol (2011) 3 (5) 301-308). The SMYD proteins have been found to be linked to various cancers (See e.g., Hamamoto et al. Nat Cell. Biol. 2004, 6: 731-740), Hu et al. Cancer Research 2009, 4067-4072, and Komatsu et al. Carcinogenesis 2009, 301139-1146.)
  • SMYD3 is a protein methyltransferase found to be expressed at high levels in a number of different cancers (Hamamoto, R., et al., Nat. Cell Biol., 6(8):731-40 (2004)). SMYD3 likely plays a role in the regulation of gene transcription and signal transduction pathways critical for survival of breast, liver, prostate and lung cancer cell lines (Hamamoto, R., et al., Nat. Cell Biol., 6(8):731-40 (2004); Hamamoto, R., et al., Cancer Sci., 97(2):113-8 (2006); Van Aller, G. S., et al., Epigenetics, 7(4):340-3 (2012); Liu, C., et al., J. Natl. Cancer Inst., 105(22):1719-28 (2013): Mazur, P. K., et al., Nature, 510(7504):283-7 (2014)).
  • Genetic knockdown of SMYD3 leads to a decrease in proliferation of a variety of cancer cell lines (Hamamoto, R., et al., Nat. Cell Biol., 6(8):731-40 (2004); Hamamoto. R., et al., Cancer Sci., 97(2):113-8 (2006); Van Aller, U.S., et al., Epigenetics, 7(4):340-3 (2012); Liu. C., et al., J. Natl. Cancer Inst., 105(22):1719-28 (2013); Mazur. P. K., et al., Nature, 510(7504):283-7 (2014)). Several studies employing RNAi-based technologies have shown that ablation of SMYD3 in hepatocellular carcinoma cell lines greatly reduces cell viability and that its pro-survival role is dependent on its catalytic activity (Hamamoto. R., et al., Nat. Cell Biol., 6(8):731-40 (2004); Van Aller, G. S., et al., Epigenetics, 7(4):340-3 (2012)). Moreover, SMYD3 has also been shown to be a critical mediator of transformation resulting from gain of function mutations in the oncogene, KRAS for both pancreatic and lung adenocarcinoma in mouse models. The dependence of KRAS on SMYD3 was also shown to be dependent on its catalytic activity (Mazur, P. K., et al., Nature, 510(7504):283-7 (2014)). SMYD3 function has also been implicated in colerectal cancers and RNAi mediated knockdown of SMYD3 has been shown to impair colerectal cell proliferation. (Peserico et al., Cell Physiol. 2015 Feb. 28. doi: 10.1002/jcp.24975. [Epub ahead of print]).
  • Furthermore. SMYD3 function has also been shown to play a role in immunology and development. For instance, de Almeida reported that SMYD3 plays a role in generation of inducible regulatory T cells (iTreg) cells. In a mouse model of respiratory syncytial virus (RSV) infection, a model in which iTreg cells have a critical role in regulating lung pathogenesis, SMYD3−/− mice demonstrated exacerbation of RSV-induced disease related to enhanced proinflammatory responses and worsened pathogenesis within the lung (de Almeida et al. Mucosal Immunol. 2015 Feb. 11. doi: 10.1038/mi.2015.4. [Epub ahead of print]). In addition, as to development, Proserpio et al. have shown the importance of SMYD3 in the regulation of skeletal muscle atrophy (Proserpio et al. Genes Dev. 2013 Jun. 1; 27(11):1299-312), while Fujii et al. have elucidated the role of SMYD3 in cardiac and skeletal muscle development (Fujii et al. PLoS One. 2011; 6(8):e23491).
  • SMYD2 (SET and MYND domain-containing protein 2) was first characterized as protein that is a member of a sub-family of SET domain containing proteins which catalyze the site-specific transfer of methyl groups onto substrate proteins. SMYD2 was initially shown to have methyltransferase activity towards lysine 36 on histone H3 (H3K36) but has subsequently been shown to have both histone and non-histone methyltrasferase activity.
  • SMYD2 has been implicated in the pathogenesis of multiple cancers. It has been shown to be over-expressed, compared to matched normal samples, in tumors of the breast, cervix, colon, kidney, liver, head and neck, skin, pancreas, ovary, esophagus and prostate, as well as hematologic malignancies such as AML, B- and T-ALL, CLL and MCL, suggesting a role for SMYD2 in the biology of these cancers. More specifically, studies using genetic knock-down of SMYD2 have demonstrated anti-proliferative effects in esophageal squamous cell carcinoma (ESCC), bladder carcinoma and cervical carcinoma cell lines. (See e.g., Komatsu et al., Carcinogenesis 2009, 30, 1139, and Cho et al., Neoplasia, 2012 June; 14(6):476-86). Moreover, high expression of SMYD2 has been shown to be a poor prognostic factor in both ESCC and pediatric ALL. (See e.g., Komatsu et al. Br J Cancer. 2015 Jan. 20; 112(2):357-64, and Sakamoto et al., Leuk Res. 2014 April; 38(4):496-502). Recently, Nguyen et al., have shown that a small molecule inhibitor of SMYD2 (LLY-507) inhibited the proliferation of several esophageal, liver and breast cancer cell lines in a dose-dependent manner. (Nguyen et al. J Bio Chem. 2015 Mar. 30, pii: jbc.M114.626861. [Epub ahead of print]).
  • SMYD2 has also been implicated in immunology. For instance, Xu et al. have shown that SMYD2 is a negative regulator of macrophage activation by suppressing Interleukin-6 and TNF-alpha production. (Xu et al., J Biol Chem. 2015 Feb. 27; 290(9):5414-23).
  • In one aspect, the present disclosure provides a method of treating cancer in a patient comprising administering a therapeutically effective amount of a Compound of the Disclosure. While not being limited to a specific mechanism, in some embodiments, Compounds of the Disclosure can treat cancer by inhibiting SMYD proteins, such as SMYD3 and SMYD2. Examples of treatable cancers include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentigious melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogeous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma periotonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma. Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma. Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor.
  • In another embodiment, the cancer is breast, cervix, colon, kidney, liver, head and neck, skin, pancreas, ovary, esophagus, or prostate cancer.
  • In another embodiment, the cancer is a hematologic malignancy such as acute myeloid leukemia (AML), B- and T-acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or mantle cell lymphoma (MCL).
  • In another embodiment, the cancer is esophageal squamous cell carcinoma (ESCC), bladder carcinoma, or cervical carcinoma.
  • In another embodiment, the cancer is a leukemia, for example a leukemia selected from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia and mixed lineage leukemia (MLL). In another embodiment the cancer is NUT-midline carcinoma. In another embodiment the cancer is multiple myeloma. In another embodiment the cancer is a lung cancer such as small cell lung cancer (SCLC). In another embodiment the cancer is a neuroblastoma. In another embodiment the cancer is Burkitt's lymphoma. In another embodiment the cancer is cervical cancer. In another embodiment the cancer is esophageal cancer. In another embodiment the cancer is ovarian cancer. In another embodiment the cancer is colorectal cancer. In another embodiment, the cancer is prostate cancer. In another embodiment, the cancer is breast cancer.
  • In another embodiment, the present disclosure provides a therapeutic method of modulating protein methylation, gene expression, cell proliferation, cell differentiation and/or apoptosis in vivo in the cancers mentioned above by administering a therapeutically effective amount of a Compound of the Disclosure to a subject in need of such therapy.
  • Compounds of the Disclosure can be administered to a mammal in the form of a raw chemical without any other components present. Compounds of the Disclosure can also be administered to a mammal as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier. Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries. The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 19th ed. 1995.
  • Pharmaceutical compositions within the scope of the present disclosure include all compositions where a Compound of the Disclosure is combined with one or more pharmaceutically acceptable carriers. In one embodiment, the Compound of the Disclosure is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal ranges of effective amounts of each compound is within the skill of the art. Typically, a Compound of the Disclosure can be administered to a mammal, e.g., a human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof, per day to treat the particular disorder. A useful oral dose of a Compound of the Disclosure administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt or solvate thereof. For intramuscular injection, the dose is typically about one-half of the oral dose.
  • A unit oral dose may comprise from about 0.01 mg to about 1 g of the Compound of the Disclosure, e.g., about 0.01 mg to about 500 mg, about 0.01 mg to about 250 mg, about 0.01 mg to about 100 mg, 0.01 mg to about 50 mg, e.g., about 0.1 mg to about 10 mg, of the compound. The unit dose can be administered one or more times daily, e.g., as one or more tablets or capsules, each containing from about 0.01 mg to about 1 g of the compound, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof.
  • A pharmaceutical composition of the present disclosure can be administered to any patient that may experience the beneficial effects of a Compound of the Disclosure. Foremost among such patients are mammals, e.g., humans and companion animals, although the disclosure is not intended to be so limited. In one embodiment, the patient is a human.
  • A pharmaceutical composition of the present disclosure can be administered by any means that achieves its intended purpose. For example, administration can be by the oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, transmucosal, rectal, intravaginal or buccal route, or by inhalation. The dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, gender, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • In one embodiment, a pharmaceutical composition of the present disclosure can be administered orally. In another embodiment, a pharmaceutical composition of the present disclosure can be administered orally and is formulated into tablets, dragees, capsules, or an oral liquid preparation. In one embodiment, the oral formulation comprises extruded multiparticulates comprising the Compound of the Disclosure.
  • Alternatively, a pharmaceutical composition of the present disclosure can be administered rectally, and is formulated in suppositories.
  • Alternatively, a pharmaceutical composition of the present disclosure can be administered by injection.
  • Alternatively, a pharmaceutical composition of the present disclosure can be administered transdermally.
  • Alternatively, a pharmaceutical composition of the present disclosure can be administered by inhalation or by intranasal or transmucosal administration.
  • Alternatively, a pharmaceutical composition of the present disclosure can be administered by the intravaginal route.
  • A pharmaceutical composition of the present disclosure can contain from about 0.01 to 99 percent by weight, e.g., from about 0.25 to 75 percent by weight, of a Compound of the Disclosure, e.g., about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or about 75% by weight of a Compound of the Disclosure.
  • A pharmaceutical composition of the present disclosure is manufactured in a manner which itself will be known in view of the instant disclosure, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or lyophilizing processes. Thus, pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries are typically flow-regulating agents and lubricants such as, for example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol. Dragee cores are provided with suitable coatings that are resistant to gastric juices. For this purpose, concentrated saccharide solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate can be used. Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain a compound in the form of granules, which can be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers, or in the form of extruded multiparticulates. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin. In addition, stabilizers can be added.
  • Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base. Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution. Alternatively, a suspension of the active compound can be prepared as an oily suspension. Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil), synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400). An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. The suspension may optionally contain stabilizers.
  • In another embodiment, the present disclosure provides kits which comprise a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a manner that facilitates their use to practice methods of the present disclosure. In one embodiment, the kit includes a Compound of the Disclosure (or a composition comprising a Compound of the Disclosure) packaged in a container, such as a sealed bottle or vessel, with a label affixed to the container or included in the kit that describes use of the compound or composition to practice the method of the disclosure. In one embodiment, the compound or composition is packaged in a unit dosage form. The kit further can include a device suitable for administering the composition according to the intended route of administration.
    • General Synthesis of Compounds
  • Compounds of the Disclosure are prepared using methods known to those skilled in the art in view of this disclosure, or by the illustrative methods shown in the General Schemes below. In the General Schemes, R1, R2, R3, and Z of Formulae A-C are as defined in connection with Formula VII, unless otherwise indicated. In the General Schemes, suitable protecting can be employed in the synthesis, for example, when Z is (amino)alkyl or any other group that may require protection. (See, Wuts, P. G. M.; Greene, T. W., “Greene's Protective Groups in Organic Synthesis”, 4th Ed., J. Wiley & Sons, N Y, 2007).
  • Figure US20200148650A1-20200514-C00470
  • Compound A is converted to compound B (i.e, a compound having Formula VII, wherein X is —S(═O)2—) by coupling with a suitable sulfonyl chloride (Z—SO2Cl) in the presence of a suitable base such as TEA or DIPEA in a suitable solvent such as dichloromethane, acetonitrile, or DMF.
  • Figure US20200148650A1-20200514-C00471
  • Compound A was converted to compound C by coupling with a suitable carboxylic acid (ZCO2H) in the presence of a suitable coupling reagent such as HATU or HOBT in the presence of a suitable base such as TEA or DIPEA in a suitable solvent such as DMF. Compound A can also be converted to compound C by coupling with a suitable acid chloride (ZCOCl) in the presence of a suitable base such as TEA or DIPEA in the presence of a suitable solvent such as dichloromethane, acetonitrile or DMF.
    • EXAMPLES General Synthetic Methods
  • General methods and experimental procedures for preparing and characterizing compounds of Tables 1 and 2 are set forth in the general schemes above and the examples below. Wherever needed, reactions were heated using conventional hotplate apparatus or heating mantle or microwave irradiation equipment. Reactions were conducted with or without stirring, under atmospheric or elevated pressure in either open or closed vessels. Reaction progress was monitored using conventional techniques such as TLC, HPLC, UPLC, or LCMS using instrumentation and methods described below. Reactions were quenched and crude compounds isolated using conventional methods as described in the specific examples provided. Solvent removal was carried out with or without heating, under atmospheric or reduced pressure, using either a rotary or centrifugal evaporator.
  • Compound purification was carried out as needed using a variety of traditional methods including, but not limited to, preparative chromatography under acidic, neutral, or basic conditions using either normal phase or reverse phase HPLC or flash columns or Prep-TLC plates. Compound purity and mass confirmations were conducted using standard HPLC and/or UPLC and/or MS spectrometers and/or LCMS and/or GC equipment (i.e., including, but not limited to the following instrumentation: Waters Alliance 2695 with 2996 PDA detector connected with ZQ detector and ESI source: Shimadzu LDMS-2020; Waters Acquity H Class with PDA detector connected with SQ detector and ESI source; Agilent 1100 Series with PDA detector; Waters Alliance 2695 with 2998 PDA detector; AB SCIEX API 2000 with ESI source; Agilent 7890 GC).
  • Compound structure confirmations were carried out using standard 300 or 400 MHz NMR spectrometers with nOe's conducted whenever necessary.
  • The following abbreviations are used herein:
  • Abbreviation Meaning
    ACN acetonitrile
    atm. atmosphere
    DCM dichloromethane
    DHP dihydropyran
    DIBAL diisobutyl aluminum hydride
    DIEA diisopropyl ethylamine
    DMF dimethyl formamide
    DMF-DMA dimethyl formamide dimethyl
    acetal
    DMSO dimethyl sulfoxide
    Dppf 1,1′-
    bis(diphenylphosphino)ferrocene
    EA ethyl acetate
    ESI electrospray ionization
    EtOH Ethanol
    FA formic acid
    GC gas chromatography
    H hour
    Hex hexanes
    HMDS hexamethyl disilazide
    HPLC high performance liquid
    chromatography
    IPA Isopropanol
    LCMS liquid chromatography/mass
    spectrometry
    MeOH Methanol
    Min Minutes
    NBS N-bromo succinimide
    NCS N-chloro succinimide
    NIS N-iodo succinimide
    NMR nuclear magnetic resonance
    nOe nuclear Overhauser effect
    Prep. Preparative
    PTSA para-toluene sulfonic acid
    Rf retardation factor
    rt room temperature
    RT retention time
    sat. Saturated
    SGC silica gel chromatography
    TBAF tetrabutyl ammonium fluoride
    TEA Triethylamine
    TFA trifluoroacetic acid
    THF Tetrahydrofuran
    TLC thin layer chromatography
    UPLC ultra performance liquid
    chromatography
    • Example 1 Synthesis of 5-cyclopropylisoxazole-3-carboxylic Acid
  • Figure US20200148650A1-20200514-C00472
    • Step 1: Synthesis of Ethyl 4-cyclopropyl-2,4-dioxobutanoate
  • Figure US20200148650A1-20200514-C00473
  • Into a 10-L 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen Na (164 g, 1.20 equiv) was added in portions to ethanol (5 L). A solution of (CO2Et)2 (869 g, 1.00 equiv) and 1-cyclopropylethan-1-one (500 g, 5.94 mol, 1.00 equiv) was added dropwise with stirring at 0-20° C. The resulting solution was stirred for 1 h at 20-30° C. and then for an additional 1 h at 80° C. The resulting solution was diluted with 15 L of H2O. The pH was adjusted to 2 with hydrochloric acid (12N). The resulting mixture was extracted with ethyl acetate and the organic layers combined and washed with NaHCO3 (sat. aq.). The extract was concentrated under vacuum yielding 820 g (crude) of ethyl 4-cyclopropyl-2,4-dioxobutanoate as yellow oil. TLC (ethyl acetate/petroleum ether=1/5): Rf=0.5.
    • Step 2: Synthesis of Ethyl 5-cyclopropylisoxazole-3-carboxylate
  • Figure US20200148650A1-20200514-C00474
  • Into a 10 L round-bottom flask, was placed a solution of ethyl 4-cyclopropyl-2,4-dioxobutanoate (177 g) in ethanol (1.1 L) and NH2OH—HCl (200 g). The resulting solution was stirred for 1 h at 20-30° C. The resulting solution was allowed to react, with stirring, for an additional 1 h at 80° C. The resulting mixture was concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1/10). This resulted in 143 g (the two step yield was 66.3%) of ethyl 5-cyclopropylisoxazole-3-carboxylate as a yellow oil. TLC (ethyl acetate/petroleum ether=1/5): Rf=0.2.
    • Step 3: Synthesis of 5-cyclopropylisoxazole-3-carboxylic Acid
  • Figure US20200148650A1-20200514-C00475
  • Into a 10-L round-bottom flask was placed ethyl 5-cyclopropylisoxazole-3-carboxylate (280 g, 1.55 mol, 1.00 equiv) and a solution of sodium hydroxide (74.3 g, 1.20 equiv) in water (4 L). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was washed with ether. The pH value of the aqueous solution was adjusted to 2-3 with hydrochloric acid (12N). The resulting solution was extracted with ethyl acetate and the organic layers combined and concentrated under vacuum. This resulted in 220 g (93%) of 5-cyclopropylisoxazole-3-carboxylic acid as an off-white solid. 1H-NMR (300 MHz CDCl3): δ 8.42 (brs, 1H), 6.37 (s, 1H), 2.16-2.05 (m, 1H), 1.29-1.12 (m, 2H), 1.12-0.99 (m, 2H): LCMS m/z=153.9 [M+H]−.
    • Example 2 Synthesis of 5-cyclopropylisoxazole-3-carbonyl Chloride
  • Figure US20200148650A1-20200514-C00476
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.750 g, 4.90 mmol) in DCM (5 ml) was added oxalyl chloride (1.68 ml, 19.60 mmol) and 2 drops of DMF. The reaction was stirred at RT 2 hr. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain 5-cyclopropylisoxazole-3-carbonyl chloride as a residue (0.6 g, crude). The material was used without further purification.
    • Example 3 Synthesis of 5-cyclopropyl-N-(1-(piperidin-4-yl)ethyl)isoxazole-3-carboxamide hydrochloride (Cpd. No. 213
  • Figure US20200148650A1-20200514-C00477
    • Step 1: Synthesis of Tert-Butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00478
  • To a stirred solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (5.0 g, 21.7 mmol) in DMF (20 mL) was added HATU (12.39 g, 32.60 mmol) and diisopropylethylamine (18.94 ml, 108.6 mmol). The solution was stirred for 10 min at 0° C. After that N,O-dimethylhydroxylamine hydrochloride (2.12 g, 21.7 mmol) was added and stirred at RT for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (4.3 g, 71%). LCMS: m/z=173.05 (M-Boc)+.
    • Step 2: Synthesis of Tert-Butyl 4-acetylpiperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00479
  • To a stirred solution of tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (4.3 g, 15.8 mmol) in dry THF (20 mL) was added a solution of methyl magnesium bromide (20 mL, 23.71 mmol, 1.6 M in THF:toluene) at −78° C. and the reaction was stirred at −78° C. for 2 h and RT for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with saturated NH4Cl solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to a crude residue which was purified by column chromatography to afford tert-butyl 4-acetylpiperidine-1-carboxylate (2.8 g, 62%).
    • Step 3: Synthesis of Tert-Butyl 4-(1-aminoethyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00480
  • To a stirred solution of compound tert-butyl 4-acetylpiperidine-1- (2.8 g, 9.68 mmol) in dry MeOH (6 mL) was added ammonium acetate (8.9 g, 16.2 mmol) and the reaction was stirred at RT for 15 min, sodium cyanoborohydride (2.43 g, 38.7 mmol) was then added. The reaction mixture was heated to reflux for 16 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with 0.5 M NaOH solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a residue of tert-butyl 4-(1-aminoethyl)piperidine-1-carboxylate (2.1 g, crude). This was used in the next step without further purification. LCMS: m/z=191.25 (M-Boc)+.
    • Step 4: Synthesis of Tert-Butyl 4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00481
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (1.0 g, 6.5 mmol) in DMF (3 mL) was added HATU (3.72 g, 9.8 mmol) and diisopropylethylamine (3.5 ml, 19.6 mmol). The solution was stirred for 10 min at 0° C. tert-Butyl 4-(1-aminoethyl)piperidine-1-carboxylate (1.45 g, 6.5 mmol) was added and the reaction stirred at RT for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford compound tert-butyl 4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidine-1-carboxylate (2.1 g, 84%). 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J=8.9 Hz, 1H), 6.46 (s, 1H), 3.98-3.90 (m, 2H), 3.79 (p, J=7.3 Hz, 1H), 2.53-2.47 (m, 2H), 2.19-2.16 (m, 1H), 1.6-1.58 (m, 3H), 1.38 (s, 9H), 1.18-0.86 (m, 9H); LCMS: m/z=386.25 (M+H)+.
    • Step 5: Synthesis of 5-cyclopropyl-N-(1-(piperidin-4-yl)ethyl)isoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00482
  • To a stirred solution of tert-butyl 4-(l-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidine-1-carboxylate (2.1 g, 5.8 mmol) in dioxane (5 mL) was added 4 M dioxane:HCl (20 mL) at 0° C. and the reaction mixture was stirred at RT for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a crude residue which was purified by repeated washing with ether and pentane to obtain 5-cyclopropyl-N-(1-(piperidin-4-yl)ethyl)isoxazole-3-carboxamide hydrochloride (1.3 g, 86%). 1H NMR (400 MHz, DMSO-d6) δ 8.95-8.86 (m, 1H), 8.54 (t, J=11.8 Hz, 2H), 6.49 (s, 1H), 3.91-3.77 (m, 1H), 3.24 (d, 0.1=12.4 Hz, 2H), 2.88-2.66 (m, 2H), 2.18 (tt, J=8.4, 5.0 Hz, 1H), 1.86-1.60 (m, 3H), 1.44-1.27 (m, 2H), 1.15-1.03 (m, 5H), 0.95-0.84 (m, 2H); LCMS: m/z=264.20 (M+H)+.
    • Example 4 Synthesis of 5-cyclopropyl-N-(phenyl(piperidin-4-yl)methyl)isoxazole-3-carboxamide (Cpd. No. 49
  • Figure US20200148650A1-20200514-C00483
    • Step 1: Synthesis of Tert-Butyl 4-benzoylpiperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00484
  • To a stirred solution of tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (0.5 g, 1.83 mmol) in THF (1.5 mL) was added a 1M solution of phenyl magnesium bromide in THF (3.67 mL, 3.67 mmol) at 0° C. The reaction was stirred overnight at RT. The reaction completion was monitored by TLC and the reaction was quenched with ammonium chloride solution and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to a residue. The residue was purified by column chromatography to obtain ten-butyl 4-benzoylpiperidine-1-carboxylate (0.188 g, 35.5%) LCMS: m/z=190.1 (M+H)+.
    • Step 2: Synthesis of Tert-Butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00485
  • To a solution of tert-butyl 4-benzoylpiperidine-1-carboxylate (0.188 g, 0.65 mmol) in MeOH (5 mL) was added ammonium acetate (0.6 g, 7.8 mmol). The reaction was stirred for 10 minutes at 25° C., then sodium cyanoborohydride (0.163 g, 2.59 mmol) was added. The reaction heated to 60° C. for 16 hours. The reaction completion was monitored by TLC and the reaction was quenched with 0.5N NaOH solution and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to a residue which was purified by column chromatography to obtain tert-butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate (0.2 g, 40%). LCMS: m/z=190.3 (M+H)+.
    • Step 3: Synthesis of Tert-Butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00486
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.1 g, 0.34 mmol) in DCM (5 ml) was added oxalyl chloride (0.2 ml, 0.68 mmol) and 2 drops of DMF. The reaction was stirred at RT 2 hr. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a residue. The residue was dissolved in DCM and cooled to 0° C. tert-Butyl 4-(amino(phenyl)methyl)piperidine-1-carboxylate was added (0.070 g, 0.41 mmol) in DCM (5 mL) followed by triethylamine (0.23 mL, 0.17 mmol). The reaction was stirred at RT for 1 hr. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with sodium bicarbonate and, extracted with DCM. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to obtain tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidine-1-carboxylate (0.057 g, 50%) LCMS: m/z=326.23 (M+H)+.
    • Step 4: Synthesis of 5-cyclopropyl-N-(phenyl(piperidin-4-yl)methyl)isoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00487
  • To a stirred solution of tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidine-1-carboxylate (0.057 g, 0.13 mmol) in dioxane (1 mL) at 0° C. was added 4 M dioxane:HCl (2 mL). The reaction was stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure and the residue was purified by washing with ether and pentane to obtain 5-cyclopropyl-N-(phenyl(piperidin-4-yl)methyl)isoxazole-3-carboxamide hydrochloride (0.028 g, 65%). 1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J=9.0 Hz, 1H), 8.70 (d, J=11.2 Hz, 1H), 8.36 (d, J=11.7 Hz, 1H), 7.46-7.37 (m, 2H), 7.39-7.22 (m, 3H), 6.47 (s, 1H), 4.71 (t, J=9.5 Hz, 1H), 3.22-3.13 (m, 2H), 2.77 (q, J=11.0, 10.1 Hz, 2H), 2.23-2.03 (m, 3H), 1.47-1.19 (m, 3H), 1.14-1.02 (m, 2H), 0.94-0.83 (m, 2H); LCMS: m/z=326.25 (M+H).
    • Example 5 Synthesis of N-(1-(1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)piperidin-4-yl)ethyl)-5-cyclopropylisoxazole-3-carboxamide (Cpd. No. 211
  • Figure US20200148650A1-20200514-C00488
    • Step 1: Synthesis of Tert-Butyl ((2S)-1-(4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00489
  • To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl) propanoic acid (0.188 g, 0.68 mmol) in DMF (2 mL) was added EDCI (0.191 g, 1.10 mmol), HOBt (0.135 g, 1.10 mmol), and triethylamine (0.3 mL, 2.27 mmol). The solution was stirred for 30 min at 0° C. 5-Cyclopropyl-N-(1-(piperidin-4-yl)ethyl)isoxazole-3-carboxamide hydrochloride (0.2 g, 0.66 mmol) was then added and the reaction stirred at rt overnight. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl ((2S)-1-(4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate (0.09 g, 25%). LCMS: m/z=428.05 (M-Boc)+.
    • Step 2: Synthesis of N-1-(1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)piperidin-4-yl)ethyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00490
  • To a stirred solution of tert-butyl ((2S)-1-(4-(1-(5-cyclopropylisoxazole-3-carboxamido)ethyl)piperidin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate (0.09 g, 0.17 mmol) in dioxane (1 mL) was added 4 M dioxane:HCl (5 mL) at 0° C. and the reaction mixture stirred at rt for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a crude residue which was purified by repeated washing with ether and pentane to obtain N-(1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)piperidin-4-yl)ethyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.020 g, 28%). 1H NMR (400 MHz, DMSO-d6) δ 9.44-9.35 (m, 1H), 8.46 (q, J=7.3 Hz, 1H), 8.12 (s, 3H), 6.99 (dd, J=173, 7.9 Hz, 2H), 6.75-6.66 (m, 2H), 6.46 (d, J=3.5 Hz, 1H), 4.52 (p, J=6.8, 6.2 Hz, 1H), 4.37 (d, J=12.8 Hz, 1H), 3.83-3.59 (m, 2H), 2.96-2.73 (m, 2H), 2.47-2.33 (m, 2H), 2.27-2.12 (m, 1H), 1.76-1.62 (m, 1H), 1.62-1.35 (m, 2H), 1.14-0.81 (m, 9H); LCMS: m/z=427.35 (M+H)+.
    • Example 6 Synthesis N—((S)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 215) and N—((R)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 216
  • Figure US20200148650A1-20200514-C00491
    • Step 1: Synthesis of tert-butyl ((S)-1-(4-((S)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate and tert-butyl ((S)-1-(4-((R)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00492
  • To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)propanoic acid (0.044 g, 0.230 mmol) in DMF (1 mL) was added HATU (0.131 g, 0.34 mmol) and diisopropyl ethylamine (0.12 mL, 0.69 mmol). The solution was stirred for 10 min at 0° C. Next, 5-cyclopropyl-N-(phenyl(piperidin-4-yl)methyl)isoxazole-3-carboxamide ((0.1 g, 0.277 mmol) was added and the reaction stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by preparative chiral HPLC to afford tert-butyl ((S)-1-(4-((S)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.13 g, 18%) and tert-butyl ((S)-1-(4-((R)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.12 g, 17.4%).
    • Step 2: Synthesis of N—((S)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00493
  • To a stirred solution of tert-butyl ((S)-1-(4-(5)-5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.05 g, 0.126 mmol) in dioxane (1 mL) at 0° C. was added 4 M dioxane:HCl (3 mL). The reaction mixture was stirred at RT for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue. The material was purified by repeated washing with ether and pentane to obtain N—((S)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.035 g, 50%). 1H NMR (400 MHz, DMSO-d6): δ 9.19 (dd. J=9.0, 6.3 Hz, 1H), 8.09 (s, 3H), 7.44-7.21 (m, 5H), 6.46 (s, 1H), 4.69 (q, J=10.0 Hz, 1H), 4.29 (s, 2H), 3.76 (d, J=13.7 Hz, 1H), 2.98-2.96 (m, 1H), 2.66-2.50 (m, 1H), 2.23-2.06 (m, 2H), 2.02-1.91 (m, 1H), 1.30 (d, J=6.8 Hz, 1H), 1.21 (dd, J=24.0, 9.9 Hz, 4H), 1.14-0.83 (m, 5H); LCMS: m/z=397.35 (M+H)+.
    • Step 2: Synthesis of N—((R)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00494
  • To a stirred solution of tert-butyl ((S)-1-(4-((R)-(5-cyclopropylisoxazole-3-carboxamido)(phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.06 g, 0.12 mmol) in dioxane (1 mL) at 0° C. was added 4 M dioxane:HCl (3 mL). The reaction mixture was stirred at RT for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue. The material was purified by repeated washing with ether and pentane to obtain N—(R)-(1-((S)-2-aminopropanoyl)piperidin-4-yl)(phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide (0.02 g, 30%). 1H NMR (400 MHz, DMSO-d6): δ 9.20 (t, J=8.8 Hz, 1H), 8.08 (s, 3H), 7.46-7.21 (m, 5H), 6.46 (d, J 1.5 Hz, 1H), 4.7-4.68 (m, 1H), 4.35-4.32 (m, 2H), 3.90 (d, J=13.7 Hz, 1H), 3.07-2.87 (m, 1H), 2.66-2.51 (m, 1H), 2.23-2.06 (m, 2H), 1.95 (d, J=11.4 Hz, 1H), 1.36-1.00 (m, 8H), 1.01-0.82 (m, 2H); LCMS: m/z=397.22 (M+H)+.
    • Example 7 Synthesis of N-((1-((S)-2-aminopropanoyl)piperidin-4-yl)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 205
  • Figure US20200148650A1-20200514-C00495
    • Step 1: Synthesis of Tert-Butyl 4-(hydroxy(3-(methoxycarbonyl)phenyl)methyl) piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00496
  • To a stirred solution of methyl 3-iodobenzoate (3.0 g, 11.45 mmol) in anhydrous THF (100 mL) was added isopropyl magnesium chloride (6.27 mL, 12.59 mmol, 2M solution in THF) at −40° C., tert-Butyl 4-formylpiperidine-1-carboxylate (2.68 g, 12.59 mmol) was added. The reaction was stirred at rt overnight. The reaction was quenched with saturated NH4Cl solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl 4-(hydroxy(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate (2.91 g, 73%). LCMS: m/z=350.15 (M+H)+.
    • Step 2: Synthesis of tert-butyl 4-(3-(methoxycarbonyl)benzoyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00497
  • To a stirred solution of 4-(hydroxy(3-(methoxycarbonyl)phenyl) methyl)piperidine-1-carboxylate (1.9 g, 5.44 mmol) in DCM (30 mL) was added Dess Martin periodane (3.0 g, 7.07 mmol) at 0° C. The reaction mixture was stirred at rt for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched by the addition of a mixture of saturated solution of Na2S2O3 (10 mL) and NaHCO3 (10 mL). The organic layer was extracted, dried over anhydrous Na2SO4, concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl 4-(3-(methoxycarbonyl)benzoyl)piperidine-1-carboxylate (1.78 g, 94%). LCMS: m/z=348.15 (M+H)+.
    • Step 3: Synthesis of Tert-Butyl 4-(amino(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00498
  • To a stirred solution of tert-butyl 4-(3-(methoxycarbonyl)benzoyl)piperidine-1-carboxylate (1.5 g, 4.32 mmol) in methanol (30 mL) at 0° C. was added ammonium acetate (4.0 g, 51.8 mmol) followed by portionwise addition of sodium cyanoborohydride (1.0 g, 17.2 mmol). The reaction mixture was heated to reflux at 80° C. for 12 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with dilute HCl solution and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl 4-(amino(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate (1.05 g, 70%).
    • Step 4: Synthesis of tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00499
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.65 g, 1.86 mmol) in DMF (10 mL) was added HATU (1.0 g, 2.8 mmol) and diisopropylethylamine (1.2 ml, 7.44 mmol). The reaction mixture was stirred for 10 min at 0° C. and then tert-butyl 4-(amino(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate (0.284 g, 1.86 mmol) was added. The reaction mixture was stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(methoxycarbonyl) phenyl)methyl)piperidine-1-carboxylate (0.789 g, 95%).
    • Step 5: Synthesis of 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(5-cyclopropylisoxazole-3-carboxamido)methyl)benzoic Acid
  • Figure US20200148650A1-20200514-C00500
  • To a stirred solution of tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(methoxycarbonyl)phenyl)methyl)piperidine-1-carboxylate (0.77 g, 1.59 mmol) in THF:MeOH:H2O (1:1:1, 15 mL) was added lithium hydroxide (0.133 g, 3.18 mmol). The reaction mixture was then stirred at rt for 12 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue. The residue was taken up in MeOH and acidified with dilute HCl to pH=2. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain 3-((l-(ten-butoxycarbonyl)piperidin-4-yl)(5-cyclopropylisoxazole-3-carboxamido)methyl)benzoic acid (0.580 g, crude).
    • Step 6: Synthesis of Tert-Butyl 4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00501
  • To a stirred solution of 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(5-cyclopropylisoxazole-3-carboxamido)methyl)benzoic acid (0.5 g, 1.06 mmol) in DMF (3 mL) was added HATU (0.607 g, 1.59 mmol) and diisopropylethylamine (0.63 mL, 3.73 mmol). The solution was stirred for 10 min at 0° C. Then pyridin-3-amine (0.14 g, 1.49 mmol) was added and stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl-4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidine-1-carboxylate (0.445 g, 76%). LCMS: m/z=446.4 (M-Boc)−.
    • Step 7: Synthesis of 5-cyclopropyl-N-(piperidin-4-yl(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)isoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00502
  • To a stirred solution of tert-butyl-4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidine-1-carboxylate (0.445 g, 0.81 mmol) in dioxane (4 mL) at 0° C. was added 4 M dioxane:HCl (8 mL) and the reaction mixture stirred at rt for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue which was purified by repeated washing with ether and pentane to obtain 5-cyclopropyl-N-(piperidin-4-yl(3-(pyridin-3-ylcarbamoyl)phenyl)methyl) isoxazole-3-carboxamide hydrochloride (0.380 g, 96%). LCMS: m/z=446.25 (M+H)+.
    • Step 8: Synthesis of Tert-butyl ((2S)-1-(4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00503
  • To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)propanoic acid (0.089 g, 0.474 mmol) in DMF (3 mL) was added HATU (0.225 g, 0.592 mmol) and diisopropylethylamine (0.23 mL, 1.38 mmol). The solution was stirred for 10 min at 0° C. Next 5-cyclopropyl-N-(piperidin-4-yl(3-(pyridin-3-ylcarbamoyl)phenyl)methyl) isoxazole-3-carboxamide hydrochloride (0.19 g, 0.395 mmol) was added and the reaction stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl ((2S)-1-(4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.170 g, 83%). LCMS: m/z=517.4 (M-Boc)+.
    • Step 9: Synthesis of N-((1-((S)-2-aminopropanoyl)piperidin-4-yl)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00504
  • To a stirred solution of tert-butyl ((2S)-1-(4-((5-cyclopropylisoxazole-3-carboxamido)(3-(pyridin-3-ylcarbamoyl)phenyl methyl)piperidin-1-yl)-1-oxopropan-2-yl)carbamate (0.170 g, 0.275 mmol) in dioxane (3 mL) at 0° C. was added 4 M dioxane:HCl (2 mL) and the reaction mixture stirred at rt for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue which was purified by repeated washing with ether and pentane to obtain N-((1-((S)-2-aminopropanoyl)piperidin-4-yl)(3-(pyridin-3-ylcarbamoyl)phenyl)methyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.135 g, 83%). 1H NMR (400 MHz. DMSO-d6)(mixture of diastereomers): δ 11.09 (d, J=14.5 Hz, 1H), 9.38-9.24 (m, 2H), 8.64 (d, 0.1=8.0 Hz, 1H), 8.55 (dd, J=5.4, 1.4 Hz, 1H), 8.17-8.09 (m, 4H), 8.03-7.94 (m, 1H), 7.84 (dd, J=8.4, 5.2 Hz, 1H), 7.71 (dd, J=7.7, 5.0 Hz, 1H), 7.56 (td, J=7.7, 4.2 Hz, 1H), 6.51 (d, J=3.7 Hz, 1H), 4.90-4.74 (m, 1H), 4.48-4.32 (m, 1H), 4.35-4.23 (m, 2H), 3.92 (d, J=13.6 Hz, 1H), 3.79 (dd, J=13.8, 9.2 Hz, 1H), 3.69-3.53 (m, 1H), 3.18-2.91 (m, 211), 2.67-2.51 (m, 211), 2.19-2.17 (m, 311), 1.97 (d, J=12.6 Hz, 111), 1.35-0.97 (m, 2H), 0.95-0.82 (m, 2H); LCMS: m/z=517.35 (M+H)+.
    • Example 8 Synthesis of 5-cyclopropyl-N-(piperidin-4-ylmethyl)isoxazole-3-carboxamide Hydrochloride (Cpd. No. 4)
  • Figure US20200148650A1-20200514-C00505
    • Step 1: Synthesis of Tert-Butyl 4-((5-cyclopropylisoxazole-3-carboxamido)methyl) piperidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00506
  • To a stirred solution of tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (0.514 g, 2.43 mmol) in DCM (10 mL) was added triethylamine (0.68 mL, 4.87 mmol) and the solution was stirred at 0° C. for 10 min. 5-Cyclopropylisoxazole-3-carbonyl chloride (0.6 g, 3.166 mmol) in DCM (5 mL) was added dropwise and the reaction mixture stirred at rt overnight. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was diluted with excess of DCM and washed with water and, the organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to afford tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidine-1-carboxylate (0.750 g, 89%). 1H NMR (DMSO-d6, 400 MHz) δ 8.69-8.66 (t, J=5.8 Hz, 1H) 6.46 (s, 1H), 3.90 (d, J=12.4 Hz, 2-), 3.11-3.08 (m, J=6.4 Hz, 2H), 2.67 (brs, 2H), 2.19-2.15 (m, 1H), 1.70-1.68 (m, 1H), 1.6 (brs, 1H), 1.58 (brs, 1H), 1.38 (s, 9H), 1.11-1.06 (m, 2H), 0.90-0.89 (m, 4H).
    • Step 2: Synthesis of 5-cyclopropyl-N-(piperidin-4-ylmethyl)isoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00507
  • To a stirred solution of tert-butyl 4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidine-1-carboxylate (0.750 g, 2.148 mmol) in MeOH (4 mL) at 0° C. was added 4 M methanolic HCl (6 mL). The reaction was stirred at rt for 16 hours. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure and the residue was washed with DCM and hexanes to obtain 5-cyclopropyl-N-(piperidin-4-ylmethyl)isoxazole-3-carboxamide hydrochloride (0.590 g, 96%). 1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.78 (t, J=6.1 Hz, 1H), 8.59 (m, 1H), 6.49 (s, 1H), 3.27-3.09 (m, 4H), 2.80 (q, J=11.8 Hz, 2H), 2.18 (m, 1H), 1.79 (m, 3H), 1.41-1.26 (m, 2H), 1.09 (m, 2H), 1.00-0.87 (m, 2H); LCMS: m/z=250.05 (M+H).
    • Example 9 Synthesis of (S)—N-((1-(2-amino-3-methylbutanoyl)piperidin-4-yl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 226)
  • Figure US20200148650A1-20200514-C00508
    • Step 1: Synthesis of (S)-tert-butyl (1-(4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidin-1l-yl)-3-methyl-1-oxobutan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00509
  • To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoic acid (0.156 g, 0.72 mmol) in DMF (2 mL) was added EDCI (0.172 g, 0.9 mmol), HOBt (0.121 g, 0.9 mmol), and triethylamine (0.3 mL, 1.8 mmol). The solution was stirred for 30 min at 0° C. 5-Cyclopropyl-N-(piperidin-4-ylmethyl)isoxazole-3-carboxamide (0.15 g, 0.6 mmol) was added and the reaction stirred at rt overnight. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford (S)-tert-butyl (1-(4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate (0.185 g, 68%). LCMS m/z=349.1 (M-Boc)+.
    • Step 2: Synthesis of (S)—N-((1-(2-amino-3-methylbutanoyl)piperidin-4-yl)methyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00510
  • To a stirred solution of (S)-tert-butyl (1-(4-((5-cyclopropylisoxazole-3-carboxamido)methyl)piperidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate (0.185 g, 0.33 mmol) in dioxane (1 mL) at 0° C. was added 4M dioxane:HCl (3 mL). The reaction mixture was stirred at rt for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material the solvent was removed under reduced pressure to obtain a crude residue. The material was purified by repeated washing with ether and pentane to obtain (S)—N—((-(2-amino-3-methylbutanoyl)piperidin-4-yl)methyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.1 g, 69%). 1H NMR (400 MHz. DMSO-d6): δ 8.75 (dt, J=7.1, 3.4 Hz, 1H), 8.03 (s, 3H), 6.48 (s, 1H), 4.43-4.31 (m, 1H), 4.27 (s, 1H), 3.93 (d, J=13.6 Hz, 1H), 3.21-2.97 (m, 3H), 2.66-2.53 (m, 1H), 2.18 (tt, J=8.4, 5.0 Hz, 1H), 2.01 (h, J=6.9 Hz, 1H), 1.89-1.78 (m, 1H), 1.70 (t, J=12.7 Hz, 1H), 1.26 (dd, J=10.3, 4.4 Hz, 1H), 1.16-0.82 (m, 12H); LCMS: m/z=349.3 (M+H)+.
    • Example 10 Synthesis of N-(4-(1-amino-3-(pyridin-3-yl)propyl)phenyl)-5-cyclopropylisoxazole-3-carboxamide (Cpd. No. 149)
  • Figure US20200148650A1-20200514-C00511
    • Step 1: Synthesis of (E)-1-(4-aminophenyl)-3-(pyridin-3-yl)prop-2-en-1-one
  • Figure US20200148650A1-20200514-C00512
  • To a stirred solution of 1-(4-aminophenyl)ethanone (2.0 g, 14.81 mmol) in MeOH:Water (1:1, 30 mL) was added nicotinaldehyde (1.58 g, 14.81 mmol) and potassium hydroxide (1.24 g, 22.22 mmol). The reaction mixture was stirred at rt for 12 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with dilute HCl and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford (E)-1-(4-aminophenyl)-3-(pyridin-3-yl)prop-2-en-1-one (2.0 g, 60%). LCMS: m/z=225.3 (M+H)+.
    • Step 2. Synthesis of 1-(4-aminophenyl)-3-(pyridin-3-yl)propan-1-one
  • Figure US20200148650A1-20200514-C00513
  • To a stirred solution of (E)-1-(4-aminophenyl)-3-(pyridin-3-yl)prop-2-en-1-one (2.0 g, 8.9 mmol) in methanol (20 mL), 10% palladium-carbon (0.2 g) was added and the reaction mixture stirred under hydrogen atmosphere at 1 atm pressure at rt for 3 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure to obtain a crude residue of 1-(4-aminophenyl)-3-(pyridin-3-yl)propan-1-one (1.5 g) which was used in the next step without purification. LCMS: m/z=227.05 (M+H)+.
    • Step 3: Synthesis of 5-cyclopropyl-N-(4-(3-(pyridin-3-yl)propanoyl)phenyl)isoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00514
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.2 g, 1.3 mmol) and 2 drops of DMF in DCM (10 mL) was added oxalyl chloride (1 mL). The reaction mixture was stirred at rt for 2 h. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a crude residue. The residue was redissolved in DCM (5 mL). Triethylamine (0.35 mL, 2.61 mmol) and a solution of 1-(4-aminophenyl)-3-(pyridin-3-yl)propan-1-one (0.354 g, 1.56 mmol) in DCM (1 mL) was added at 0° C. to the reaction mixture. The mixture was stirred at rt for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was quenched with saturated NaHCO3 solution and extracted with DCM. The organic layer was separated, washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford 5-cyclopropyl-N-(4-(3-(pyridin-3-yl)propanoyl)phenyl)isoxazole-3-carboxamide (0.4 g, 42%). LCMS: m/z=362.05 (M+H) +.
    • Step 4: Synthesis of N-(4-(1-amino-3-(pyridin-3-yl)propyl)phenyl)-5-cyclopropylisoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00515
  • To a stirred solution of 5-cyclopropyl-N-(4-(3-(pyridin-3-yl)propanoyl)phenyl)isoxazole-3-carboxamide (0.05 g, 0.13 mmol) in dry MeOH (10 mL) was added ammonium acetate (0.127 g, 1.66 mmol) and the reaction stirred at rt for 15 min. Sodium cyanoborohydride (0.034 g, 0.55 mmol) was then added. The reaction mixture was heated to reflux for 16 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with 0.5 M NaOH solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by prep HPLC to afford compound N-(4-(1-amino-3-(pyridin-3-yl)propyl)phenyl)-5-cyclopropylisoxazole-3-carboxamide (0.030 g, 12%). 1H NMR (400 MHz, Methanol-d4): δ 8.41-8.29 (m, 2H), 7.88-7.79 (m, 2H), 7.69-7.65 (m, 1H), 7.49-7.41 (m, 2H), 7.39-7.35 (m, 1H), 6.48 (s, 1H), 4.21 (dd, J=8.8, 6.3 Hz, 1H), 2.70-2.51 (m, 2H), 2.34-2.23 (m, 2H), 2.2-2.15 (m, 1H), 1.31 (d, J=18.9 Hz, 1H), 1.21-1.11 (m, 2H), 1.04-0.95 (m, 2H); LCMS: m/z=362.17 (M+1)−.
    • Example 11 Synthesis of N-(4-aminobutyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 254)
  • Figure US20200148650A1-20200514-C00516
    • Step 1: Synthesis of Tert-Butyl (4-(5-cyclopropylisoxazole-3-carboxamido) butyl)carbamate
  • Figure US20200148650A1-20200514-C00517
  • To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.5 g, 3.2 mmol) in DMF (3 mL) was added EDCI.HCl (0.93 g, 4.9 mmol), HOBt (0.66 g, 4.9 mmol) and triethylamine (1.41 mL, 9.8 mmol). The solution was stirred for 10 min at 0° C. After that tert-butyl (4-aminobutyl) carbamate (0.67 g, 3.5 mmol) was added and the reaction stirred at rt for 16 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford tert-butyl (4-(5-cyclopropylisoxazole-3-carboxamido)butyl)carbamate (0.25 g, 20%). LCMS: m/z=234.05 (M-Boc)+.
    • Step 2: Synthesis of N-(4-aminobutyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00518
  • To a stirred solution of tert-butyl (4-(5-cyclopropylisoxazole-3-carboxamido)butyl)carbamate (0.24 g, 0.74 mmol) in dioxane (2 mL), was added 4M dioxane:HCl (2 mL) at 0° C. and the reaction mixture was stirred at rt for 5 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a crude residue which was purified by Prep HPLC to obtain N-(4-aminobutyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.16 g, 96%). 1H NMR (400 MHz, DMSO-d6):δ 8.71 (t, J=5.9 Hz, 1H), 7.76 (s, 2H), 6.48 (s, 1H), 3.23 (q, J=6.0 Hz, 2H), 2.78 (q, J=6.1 Hz, 2H), 2.18 (td, J=8.6, 4.5 Hz, 1H), 1.54 (p, J=3.4 Hz, 4H), 1.1-1.08 (m, 2H), 0.96-0.87 (m, 2H); LCMS (method A, ESI): m/z=224.10 (M+H)+.
    • Example 12 Synthesis of (S)—N-(4-(2-aminopropanamido)butyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 249)
  • Figure US20200148650A1-20200514-C00519
    • Step 1: Synthesis of (S)-Tert-butyl (1-((4-(5-cyclopropylisoxazole-3-carboxamido)butyl) amino)-1-oxopropan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00520
  • To a stirred solution of (S)-2-((tert-butoxycarbonyl) amino)propanoic acid (0.08 g, 0.37 mmol) in DMF (2 mL) was added EDCI.HCl (0.098 g, 0.51 mmol), HOBt (0.069 g, 0.51 mmol), and triethylamine (0.14 mL, 1.0 mmol). The solution was stirred for 10 min at 0° C. N-(4-Aminobutyl)-5-cyclopropylisoxazole-3-carboxamide (0.065 g, 0.34 mmol) was added and the reaction stirred at it for 16 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford (S)-tert-butyl (1-((4-(5-cyclopropylisoxazole-3-carboxamido)butyl)amino)-1-oxopropan-2-yl)carbamate (0.08 g, 59%). LCMS: m/z=296.15 (M-Boc)+.
    • Step 2: Synthesis of (S)—N-(4-(2-aminopropanamido)butyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00521
  • To a stirred solution of (S)-tert-butyl (1-((4-(5-cyclopropylisoxazole-3-carboxamido)butyl)amino)-1-oxopropan-2-yl)carbamate (0.08 g, 0.20 mmol) in dioxane (2 mL) at 0° C. was added 4M dioxane:HCl solution (4 mL). The reaction mixture was stirred at rt for 5 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain a crude residue which was purified by repeated washing with ether and pentane to obtain (S)—N-(4-(2-aminopropanamido)butyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride (0.049 g, 83%). 1H NMR (400 MHz, DMSO-d6): δ 8.67 (t, J=5.9 Hz, 1H), 8.39 (t, J=5.6 Hz, 1H), 8.10 (s, 3H), 6.47 (s, 1H), 3.80-3.70 (m, 1H), 3.26-3.03 (m, 4H), 2.24-2.12 (m, 1H), 1.56-1.36 (m, 4H), 1.33 (d, J=6.9 Hz, 3H), 1.16-1.02 (m, 2H), 0.96-0.87 (m, 2H); LCMS (method A, ESI): m/z=295.15 (M+H)+.
    • Example 13 Synthesis of N-((1r,4r)-4-aminocyclohexyl)-5-(2-hydroxyethyl)isoxazole-3-carboxamide Hydrochloride (Cpd. No. 9)
  • Figure US20200148650A1-20200514-C00522
    • Step 1: Synthesis of Ethyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate
  • Figure US20200148650A1-20200514-C00523
  • To a stirred solution of but-3-yn-1-ol (2 g, 28.5 mmol) in ethanol (15 mL), was added ethyl nitro acetate (7.59 g, 57.06 mmol) and DABCO (0.32 g, 2.85 mmol). The reaction was heated in a sealed tube at 80° C. The progress of the reaction was monitored by TLC. After complete consumption of staring material the reaction was quenched with water and extracted with ethyl acetate, the organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to obtain ethyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate (3.1 g, 59%). LCMS: m/z=186 (M+H)+.
    • Step 2: Synthesis of 5-(2-hydroxyethyl)isoxazole-3-carboxylic Acid
  • Figure US20200148650A1-20200514-C00524
  • To a stirred solution of ethyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate (0.7 g, 3.78 mmol) in THF: MeOH: H2O (1:1:1, 15 ml) was added LiOH (0.317 g, 7.56 mmol). The reaction was stirred at rt for 16 hr. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure and the residue was acidified with dilute HCl to pH 2. The solid precipitated was collected by filtration and dried under reduced pressure to obtain 5-(2-hydroxyethyl)isoxazole-3-carboxylic acid (0.529 g, crude). 1H NMR (400 MHz, DMSO-d6): δ 11.0 (brs, 1H), 6.40 (s, 1H), 3.69-3.65 (m, 2H), 3.0-2.95 (m, 2H).
    • Step 3: Synthesis of Pentafluorophenyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate
  • Figure US20200148650A1-20200514-C00525
  • To a solution of 5-(2-hydroxyethyl)isoxazole-3-carboxylic acid (0.529 g, 1.27 mmol) in DMF (5 mL) at 0° C. under an N2 atmosphere was added DCC (0.26 g, 1.27 mmol) followed by pentafluorophenol (0.233 g, 1.27 mmol). The reaction was stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to give pentafluorophenyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate (0.26 g, 63%). 1H NMR (400 MHz, DMSO-d6): δ 6.40 (s, 1H), 3.7-3.65 (m, 2H), 3.0-2.96 (m, 2H).
    • Step 4: Synthesis of Tert-Butyl ((1r,4r)-4-(5-(2-hydroxyethyl)isoxazole-3-carboxamido)cyclohexyl)carbamate
  • Figure US20200148650A1-20200514-C00526
  • To a stirred solution of pentafluorophenyl 5-(2-hydroxyethyl)isoxazole-3-carboxylate (0.25 g, 0.77 mmol) in DMF (5 mL) was added tert-butyl ((1r, 4r)-4-aminocyclohexyl) carbamate (0.16 g, 0.77 mmol). The reaction was stirred at rt for 2 hr. and the progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to obtain tert-butyl ((1 r,4r)-4-(5-(2-hydroxyethyl)isoxazole-3-carboxamido)cyclohexyl)carbamate (0.130 g, 47%). LCMS: m/z=254 (M+H)+.
    • Step 5: Synthesis of N-((1r,4r)-4-aminocyclohexyl)-5-(2-hydroxyethyl)isoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00527
  • To a stirred solution of tert-butyl ((1 r,4r)-4-(5-(2-hydroxyethyl)isoxazole-3-carboxamido)cyclohexyl)carbamate (0.1 g, 0.28 mmol) in methanol (1 mL) at 0° C. was added 4 M methanol:HCl (10 mL). The reaction was at rt stirred for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure and the residue was purified by washings with diethyl ether and hexane to obtain compound N-((1r,4r)-4-aminocyclohexyl)-5-(2-hydroxyethyl)isoxazole-3-carboxamide hydrochloride (0.060 g, 83%). 1H NMR (400 MHz, DMSO-d5) δ 8.62-8.54 (m, 1H), 8.04 (d, J=5.6 Hz, 3H), 6.58 (s, 1H), 4.89 (s, 1H), 3.70 (t, J=6.3 Hz, 3H), 2.93 (t, J=6.3 Hz, 3H), 2.02-1.95 (m, 2H), 1.85 (d, J=7.1 Hz, 2H), 1.51-1.34 (m, 4H), LCMS: m/z=254 (M+H)+.
    • Example 14 Synthesis of N-((1r,4r)-4-aminocyclohexyl)-5-cyclopropyl-4-iodoisoxazole-3-carboxamide Hydrochloride (Cpd. No. 8
  • Figure US20200148650A1-20200514-C00528
    • Step 1: Synthesis of Ethyl 5-cyclopropyl-4-iodooxazole-3-carboxylate
  • Figure US20200148650A1-20200514-C00529
  • To the stirred solution of ethyl 5-cyclopropylisoxazole-3-carboxylate (1 g, 5.52 mmol) in TFA (16 ml), was added N-iodosuccinimide (1.48 g, 6.62 mmol) and reaction mixture stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and evaporated under reduced pressure. The material was purified by column chromatography to afford ethyl 5-cyclopropyl-4-iodoisoxazole-3-carboxylate (1.27 g, 75%).
    • Step 2: Synthesis of 5-cyclopropyl-4-iodoisoxazole-3-carboxylic Acid
  • Figure US20200148650A1-20200514-C00530
  • To a stirred solution of ethyl 5-cyclopropyl-4-iodoisoxazole-3-carboxylate (1.27 g, 4.14 mmol) in THF:MeOH:H2O (1:1:1, 9 ml) was added LiOH (1.04 g, 24.8 mmol). The solution was stirred at rt for 16 hr. After complete consumption of starting material, the residue was acidified to pH 2 with Amberlyst. The reaction mixture was filtration and concentrated under reduced pressure to obtain a compound 5-cyclopropyl-4-iodoisoxazole-3-carboxylic acid (1.01 g, 87%). LCMS: m/z=278.9 (M+H)+.
    • Step 3: Synthesis of Tert-Butyl ((1r,4r)-4-(5-cyclopropyl-4-iodoisoxazole-3-carboxamido)cyclohexyl)carbamate
  • Figure US20200148650A1-20200514-C00531
  • To a stirred solution of 5-cyclopropyl-4-iodoisoxazole-3-carboxylic acid (1.0 g, 3.59 mmol) in DMF (10 ml) was added EDCI (0.892 g, 4.66 mmol) and HOBT (0.533 g, 3.94 mmol). The solution was stirred for 10 min at 0° C. Next tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (0.769 g, 3.59 mmol) was added and the reaction was stirred at it for 2 hr. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and the solid precipitated was collected by filtration and dried under reduced pressure to obtain a residue. The material was purified by column chromatography to afford tert-butyl ((1 r,4r)-4-(5-cyclopropyl-4-iodoisoxazole-3-carboxamido)cyclohexyl)carbamate (0.48 g, 28%).
    • Step 4: Synthesis of N-((1r,4r)-4-aminocyclohexyl-5-cyclopropyl-4-iodoisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00532
  • To a stirred solution of tert-butyl ((1r,4r)-4-(5-cyclopropyl-4-iodoisoxazole-3-carboxamido)cyclohexyl)carbamate (0.1 g, 0.210 mmol) in methanol (3 ml) at 0° C. was added 4 M methanolic:HCl (3 ml). The reaction was stirred for at rt for 1 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure and the residue was purified by washing with diethyl ether to obtain N-((1r,4r)-4-aminocyclohexyl)-5-cyclopropyl-4-iodoisoxazole-3-carboxamide hydrochloride (0.008 g, 10%). 1H NMR (400 MHz. DMSO-d6) δ 8.70 (d, J=7.9 Hz, 1H), 7.92 (s, 3H), 3.67 (d, J=10.0 Hz, 1H), 2.96 (t, J=9.5 Hz, 1H), 2.20-2.17 (m, 1H), 1.97 (d, J=9.4 Hz, 2H), 1.87 (d, J 10.4 Hz, 2H), 1.39 (q, J=12.2, 11.2 Hz, 4H), 1.21-1.11 (m, 2H), 1.07-0.98 (m, 2H); LCMS (method C, ESI): m/z=375 (M+H)+.
    • Example 15 Synthesis of N3-((1 r,4r)-4-aminocyclohexyl)-5-cyclopropylisoxazole-3,4-dicarboxamide Hydrochloride (Cpd. No. 13)
  • Figure US20200148650A1-20200514-C00533
    • Step 1: Synthesis of 3-(((r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylic Acid
  • Figure US20200148650A1-20200514-C00534
  • To the stirred solution of tert-butyl ((1r,4r)-4-(5-cyclopropyl-4-iodoisoxazole-3-carboxamido)cyclohexyl)carbamate (1.6 g, 3.37 mmol) in DMF:H2O (4:1, 10 ml) was added Pd(OAc)2 (0.037 g, 0.168 mmol) and dppf (0.186 g, 0.337 mmol) and the reaction heated at 55° C. under CO balloon pressure overnight. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was filtered, diluted with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried using Na2SO4 and concentrated under reduced pressure to obtain a residue which was purified by column chromatography to obtain 3-(((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylic acid (0.350 g, 26%).
    • Step 2: Synthesis of Pentafluorophenyl 3-(((1r,4r)-4-((tert-butoxycarbonyl)amino) cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylate
  • Figure US20200148650A1-20200514-C00535
  • To the stirred solution of 3-(((1r,4r)-4-((tert-butoxycarbonyl)amino) cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylic acid (0.2 g, 0.508 mmol) in DMF (2 mL) at 0° C. was added pentafluorophenol (0.093 g, 0.508 mmol) and DCC (0.054 g, 0.508 mmol). The reaction was stirred at rt for 30 min. After complete consumption of starting material, the reaction was quenched with water and extracted with DCM; the organic layer was separated, washed with sodium bicarbonate solution, dried using Na2SO4 and concentrated under reduced pressure to obtain pentafluorophenyl 3-(((r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylate (0.250 g). The material was used without further purification LCMS: m/z=583.12 (M+Na) +.
    • Step 3: Synthesis of Tert-Butyl ((1r,4r)-4-(4-carbamoyl-5-cyclopropylisoxazole-3-carboxamido)cyclohexyl)carbamate
  • Figure US20200148650A1-20200514-C00536
  • Ammonia was bubbled through a stirred solution of pentafluorophenyl 3-(((1 r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)carbamoyl)-5-cyclopropylisoxazole-4-carboxylate (0.08 g, 0.143 mmol) in DCM (2 mL) at 0° C. for 30 min. The reaction was then stirred at rt for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was evaporated to complete dryness. The material was purified by trituration with hexane and diethyl ether to obtain tert-butyl ((1 r,4r)-4-4-carbamoyl-5-cyclopropylisoxazole-3-carboxamido)cyclohexyl) carbamate (0.040 g, 71%.).
    • Step 4: Synthesis of N3-((1r,4r)-4-aminocyclohexyl)-5-cyclopropylisoxazole-3,4-dicarboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00537
  • To a stirred solution of tert-butyl ((1r,4r)-4-(4-carbamoyl-5-cyclopropylisoxazole-3-carboxamido)cyclohexyl)carbamate (0.040 g, 0.101 mmol) in dioxane (2 mL) at 0° C. was added 4 M dioxane:HCl (3 mL). The reaction was stirred at rt for 1 h and progress monitored by TLC. After complete consumption of starting material, the solvent was removed under reduced pressure and the residue was purified by washing with diethyl ether to obtain N3-((1 r,4r)-4-aminocyclohexyl)-5-cyclopropylisoxazole-3,4-dicarboxamide hydrochloride (0.022 g, 75%). 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=7.8 Hz, 1H), 8.50-8.45 (m, 1H), 7.91 (s, 3H), 7.64 (s, 1H), 3.83 (brs, 1H), 3.0-2.97 (m, 2H), 1.96 (d, J=7.6 Hz, 2H), 1.91-1.84 (m, 2H), 1.49-136 (m, 4H), 1.24-1.21 (m, 2H), 1.15-1.10 (m, 2H); LCMS: m/z=293.15 (M+H)+.
    • Example 16 Synthesis of N-(6-((R)-3-aminobutanamido)bicyclo[3.3.1]nonan-2-yl)-5-cyclopropylisoxazole-3-carboxamide (Cpd. No. 293)
  • Figure US20200148650A1-20200514-C00538
    • Step 1: Synthesis of N2,N6-dibenzylbicyclo[3.3.1]nonane-2,6-diamine
  • Figure US20200148650A1-20200514-C00539
  • To a solution of bicyclo[3.3.1]nonane-2,6-dione (1.0 g, 6.5707 mmol) in THF (10 mL) was added benzyl amine (2.87 mL, 26.283 mmol) under N2 atmosphere at rt and stirred for 5 minutes. AcOH (0.8 mL, 1.3798 mmol) was added and mixture was cooled to 0° C. Sodium triacetoxy borohydride (5.57 g, 26.283 mmol) was added portionwise over 30 min. The reaction was allowed to stir at rt overnight. The reaction was diluted with water (20 mL) and neutralized with saturated aq. solution of NaHCO3 (80 mL). The mixture was extracted with DCM (40 mL×4). The combined organic layer was washed with saturated aq solution of NaHCOJ(50 mL), brine (50 mL), dried over Na2SO4 and concentrated under reduced pressure to give crude product, which was purified by column chromatography using mobile phase 0.3% methanol in DCM to obtain N2,N6-dibenzylbicyclo[3.3.1]nonane-2,6-diamine (1.3 g, yield 59.14%) LCMS: m/z=335.16 [M+H]+.
    • Step 2: Synthesis of bicyclo[3.3.1]nonane-2,6-diamine
  • Figure US20200148650A1-20200514-C00540
  • To a suspension of 10% Pd/C (dry) in MeOH (3 mL) was added solution of N2,N6-dibenzylbicyclo[3.3.1]nonane-2,6-diamine (1.3 g, 3.886 mmol) in MeOH (10 mL). The reaction was stirred overnight under a H2 atmosphere. The reaction was filtered through a celite pad and washed with MeOH (50 mL). The filtrate was concentrated under reduced pressure to obtain title compound (0.5 g, yield 83.4%). LCMS: m/z=155.20 [M+H]+.
    • Step 3: Synthesis of Tert-Butyl (6-aminobicyclo[3.3.1]nonan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00541
  • To a solution of bicyclo[3.3.1]nonane-2,6-diamine (500 mg, 3.241 mmol) in a mixture of MeOH (10 mL) and THF (20 mL) at 0° C. under N2 atmosphere was added a solution of Boc-anhydride (0.37 mL, 1.620 mmol) in mixture of MeOH (20 mL) and THF (50 mL) over a period of 6 hours. The reaction was allowed to stir at rt overnight. The reaction was concentrated under reduced pressure to give crude product which was purified by column chromatography using basic alumina as stationary phase and 0-4% MeOH in DCM as mobile phase to obtain title compound (290 mg, yield 35.17%). LCMS: m/z=255.25 [M+H]+.
    • Step 4: Synthesis of Tert-Butyl (6-(5-cyclopropylisoxazole-3-carboxamido)bicyclo[3.3.1]nonan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00542
  • To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (175 mg, 1.14 mmol) in DMF at 0° C. under N2 atmosphere was added HATU (650 mg, 1.71 mmol). The reaction stirred for 20 min. and then then tert-butyl (6-aminobicyclo[3.3.1]nonan-2-yl)carbamate (290 mg, 1.14 mmol) was added followed by addition of DIPEA (0.6 mL, 3.42 mmol). The reaction was brought to rt and stirred overnight. The reaction was diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4 and concentrated to give crude product which was purified by column chromatography using mobile phase to 0-12% ethyl acetate in hexane to obtain the title compound (300 mg, yield 75.5%). LCMS: m/z=334.36 [M−56]+.
    • Step 5: Synthesis of N-(6-aminobicyclo[3.3.1]nonan-2-yl)-5-cyclopropylisoxazole-3-carboxamide TFA Salt
  • Figure US20200148650A1-20200514-C00543
  • To a solution of tert-butyl (6-(5-cyclopropylisoxazole-3-carboxamido)bicyclo[3.3.1]nonan-2-yl)carbamate (300 mg, 0.7702 mmol) in DCM (3 mL) at 0° C. under N2 atmosphere was added TFA (1.5 mL). The reaction was allowed to stir at rt for 2 hours. The reaction was concentrated under reduced pressure and triturated with diethyl ether to obtain the title compound as the TFA salt (300 mg, yield 96.5%). LCMS: m/z=290.36 [M+H]+.
    • Step 6: Synthesis of Tert-Butyl ((2R)-4-((6-(5-cyclopropylisoxazole-3-carboxamido) bicyclo[3.3.1]nonan-2-yl)amino)-4-oxobutan-2-yl)carbamate
  • Figure US20200148650A1-20200514-C00544
  • To a solution of the TFA salt of (R)-3-((tert-butoxycarbonyl) amino)butanoic acid (50 mg, 0.246 mmol) in DMF (1.0 mL) at 0° C. was added HATU (140 mg, 0.369 mmol). After stirring for 15 minutes, the TFA salt of N-(6-aminobicyclo[3.3.1]nonan-2-yl)-5-cyclopropylisoxazole-3-carboxamide (100 mg, 0.246 mmol) was added followed by addition of DIPEA (0.126 mL, 0.738 mmol). The reaction was brought to rt and stirred overnight. The reaction was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to give crude product which was purified by column chromatography using mobile phase 0-70% ethyl acetate in hexane to obtain the title compound (80 mg, 67.9%). LCMS: m/z=475.16 [M+H]+.
    • Step 7: Synthesis of N-(6-((R)-3-aminobutanamido)bicyclo[3.3.]nonan-2-yl)-5-cyclopropylisoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00545
  • To a solution of tert-butyl ((2R)-4-((6-(5-cyclopropylisoxazole-3-carboxamido)bicyclo[3.3.1]nonan-2-yl)amino)-4-oxobutan-2-yl)carbamate (80 mg, 0.1686 mmol) in DCM (0.8 mL) at 0° C. under N2 atmosphere was added TFA (0.4 mL) dropwise. The reaction was allowed to stir at room temperature for 2 hours. The reaction was concentrated under reduced pressure to give crude product which was triturated with diethyl ether (10 mL) and hexanes (10 mL) to obtain the title compound as TFA salt (50 mg, 60.7%). 1H NMR (400 MHz, DMSO-d6) δ 8.667 (d, 1H), 8.180 (d, 111, 7.792 (s, 3H), 6.478 (s, 1H), 4.067 (s, 1H), 3.907 (s, 1H), 3.39 (s, 1H), 2.42 (s, 2H), 2.18 (s, 2H), 2.42 (s, 2H), 1.91-1.88 (m, 4H), 1.78-1.65 (m, 4H), 1.54-1.50 (m, 4H), 1.16-1.09 (m, 5H), 0.917 (s, 1H); LCMS: m/z=375.4 [M+1]−.
    • Example 17 Synthesis of N-(4-(3-aminopropanamido)phenyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride (Cpd. No. 325)
  • Figure US20200148650A1-20200514-C00546
    • Step 1: Synthesis of N-(4-aminophenyl)-5-cycloproplisoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00547
  • Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed dichloromethane (40 mL) and benzene-1,4-diamine (1.059 g, 9.79 mmol, 1.05 equiv); then 5-cyclopropyl-1,2-oxazole-3-carbonyl chloride (1.6 g, 9.33 mmol, 1.00 equiv) in 10 mL DCM was added dropwise. The resulting solution was stirred for 12 h at room temperature. The resulting mixture was concentrated under vacuum. The solids were filtered off. The filtrate was extracted with 2×100 mL of ethyl acetate and the organic layers combined and concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (10:1). This resulted in 750 mg (33%) of N-(4-aminophenyl)-5-cyclopropylisoxazole-3-carboxamide as a yellow solid. LCMS: rt=1.04 min, m/z=285.0 [M+CN]+.
    • Step 2: Synthesis of Tert-Butyl 3-(4-(5-cyclopropylisoxazole-3-carboxamido) phenylamino)-3-oxopropylcarbamate
  • Figure US20200148650A1-20200514-C00548
  • Into a 100-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed N-(4-aminophenyl)-5-cyclopropylisoxazole-3-carboxamide (170 mg, 0.70 mmol, 1.00 equiv), tetrahydrofuran (5 mL), dichloromethane (5 mL), EDCI (401 mg, 2.09 mmol, 2.99 equiv), DIEA (271 mg, 2.10 mmol, 3.00 equiv), HOBT (283 mg, 2.09 mmol, 3.00 equiv), and 3-[[(tert-butoxy)carbonyl]amino]propanoic acid (264 mg, 1.40 mmol, 2.00 equiv). The resulting solution was stirred for 6 h at room temperature. The mixture was concentrated under vacuum. The residue was diluted with 50 mL of H2O and extracted with DCM. The organic phase was collected and dried over anhydrous sodium sulfate. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (5:1). This resulted in 120 mg (41%) of tert-butyl 3-(4-(5-cyclopropylisoxazole-3-carboxamido)phenylamino)-3-oxopropylcarbamate as a light yellow solid. LCMS: m/z=437.1 [M+Na]+.
    • Step 3: Synthesis of N-(4-(3-aminopropanamido)phenyl)-5-cyclopropylisoxazole-3-carboxamide Hydrochloride
  • Figure US20200148650A1-20200514-C00549
  • Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl 3-(4-(5-cyclopropylisoxazole-3-carboxamido)phenylamino)-3-oxopropylcarbamate (120 mg, 0.29 mmol, 1.00 equiv) and 1,4-dioxane (5 mL). Then hydrogen chloride was introduced into the mixture. The resulting solution was stirred for 2 h at room temperature. The mixture was then concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with the following conditions (IntelFlash-1): Column, silica gel; mobile phase, detector, UV 254 nm. The result solution was acidified by dilute hydrochloric acid (1N), then concentrated and dried. This resulted in 21.4 mg (24%) of N-(4-(3-aminopropanamido)phenyl)-5-cyclopropylisoxazole-3-carboxamide hydrochloride as a white solid. 1H-NMR (300 MHz, D2O): δ 7.54-7.37 (m, 4H), 6.36 (s, 1H), 3.25 (t, J=6.6 Hz, 2H), 2.77 (t, J=6.6 Hz, 2H), 2.12-2.04 (m, 1H), 1.08-1.02 (m, 2H), 0.97-0.92 (m, 2H). LCMS: m/z=315.0 [M+H]+.
    • Example 18 Synthesis of N-(1-((1-(4-chlorobenzyl)-1H-pyrazol-4-yl)methyl)azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide (Cpd. No. 428)
  • Figure US20200148650A1-20200514-C00550
    • Step 1: Synthesis of Tert-Butyl 3-(5-cyclopropylisoxazole-3-carboxamido)azetidine-1-carboxylate
  • Figure US20200148650A1-20200514-C00551
  • To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (1.53 g) in DMF (20 mL) was added HATU (6.84 g, DIPEA (3.87 g) and tert-butyl 3-aminoazetidine-1-carboxylate (2.58 g). The resulting mixture was stirred at r.t. overnight. The reaction mixture was diluted with ethyl acetate (120 mL), washed with brine (30 mL×4), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (eluant petroleum ether: ethyl acetate gradient elution 100:0 to 50:50) to afford tert-butyl 3-(5-cyclopropylisoxazole-3-carboxamido)azetidine-1-carboxylate (2.55 g, 83%) as a pale yellow solid. ESI-LCMS (m/z): 330[M+Na]+.
    • Step 2: Synthesis of N-(azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00552
  • To a solution of tert-butyl 3-(5-cyclopropylisoxazole-3-carboxamido)azetidine-1-carboxylate (2.55 g) in DCM (10 mL) was added TFA (4 mL) drop-wise. The resulting mixture was stirred at r.t. overnight. The reaction mixture was concentrated under reduced pressure and the residue was treated with ammonia in MeOH (7N, 30 mL) and the solution concentrated under reduced pressure. The residue was purified by flash column chromatography (eluant: DCM:MeOH (MeOH:7N NH3 100:1) 10:1) to afford N-(azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide (1.35 g, 78%) as a white solid. ESI-LCMS (m/z): 208[M+H]+.
    • Step 3: Synthesis of N-(1-((1-(4-chlorobenzyl)-1H-pyrazol-4-yl)methyl)azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide
  • Figure US20200148650A1-20200514-C00553
  • Into the stirred solution of N-(azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide (400 mg, 1.9 mmol) and 1-(4-chlorobenzyl)-1H-pyrazole-4-carbaldehyde (425 mg, 1.9 mmol) in MeOH (10 mL) was added NaBH3CN (363 mg, 5.8 mmol). The mixture was stirred at 60° C. for 20 h. The product was purified by reversed phased pre-HPLC (NH4HCO3. CH3CN:H2O=5%-95%) to afford N-(l-((1-(4-chlorobenzyl)-1H-pyrazol-4-yl)methyl)azetidin-3-yl)-5-cyclopropylisoxazole-3-carboxamide as a white solid (70 mg, 8.8%). ESI-LCMS (m/z): 412 [M+H]−; 1HNMR (400 MHz, CD3OD) d ppm: 7.64 (s, 1H), 7.50 (s, 1H), 7.37-7.33 (m, 2H), 7.20 (d, J=8.81 Hz, 2H), 6.37 (s, 1H), 5.32 (s, 2H), 4.61-4.58 (m, 1H), 3.70-3.66 (m, 2H), 3.61 (s, 2H), 3.22-3.18 (m, 2H), 2.19-2.15 (m, 1H), 1.18-1.13 (m, 2H), 1.00-0.96 (m, 2H).
    • Example 19 SMYD3 Biochemical Assay General Materials
  • S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), Tris, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin (BSG), and Tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP) were purchased from Sigma-Aldrich at the highest level of purity possible. 3H-SAM was purchase from American Radiolabeled Chemicals with a specific activity of 80 Ci/mmol. 384-well opaque white OptiPlates and SPA beads (Perkin Elmer, catalog # RPNQ0013) were purchased from PerkinElmer.
    • Substrates
  • N-terminally GST-tagged MEKK2 (MAP3K2) protein corresponding to reference sequence AAF63496.3 was purchased from Life Technologies (catalog # PV4010). This protein was expressed in High Five insect cells and purified to >85% purity. Protein identity was confirmed by MS/MS analysis after proteolytic digestion. The protein sequence used was:
  • (SEQ ID No. 1).
    MAPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGL
    EFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVL
    DIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTH
    PDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIA
    WPLQGWQATFGGGDHPPKSDLVPRHNQTSLYKKAGTMDDQQALNSIMQDL
    AVLHKASRPALSLQETRKAKSSSPKKQNDVRVKFEHRGEKRILQFPRPVK
    LEDLRSKAKIAFGQSMDLHYTNNELVIPLTTQDDLDKALELLDRSIHMKS
    LKILLVINGSTQATNLEPLPSLEDLDNTVFGAERKKRLSIIGPTSRDRSS
    PPPGYIPDELHQVARNGSFTSINSEGEFIPESMEQMLDPLSLSSPENSGS
    GSCPSLDSPLDGESYPKSRMPRAQSYPDNHQEFSDYDNPIFEKFGKGGTY
    PRRYHVSYHHQEYNDGRKTFPRARRTQGNQLTSPVSFSPTDHSLSTSSGS
    SIFTPEYDDSRIRRRGSDIDNPTLTVMDISPPSRSPRAPTNWRLGKLLGQ
    GAFGRVYLCYDVDTGRELAVKQVQFDPDSPETSKEVNALECEIQLLKNLL
    HERIVQYYGCLRDPQEKTLSIFMEYMPGGSIKDQLKAYGALTENVTRKYT
    RQILEGVHYLHSNMIVHRDIKGANILRDSTGNVKLGDFGASKRLQTICLS
    GTGMKSVTGTPYWMSPEVISGQGYGRKADIWSVACTVVEMLTEKPPWAEF
    EAMAAIFKIATQPTNPKLPPHVSDYTRDFLKRIFVEAKLRPSADELLRHM
    FVHYH.
    • Molecular Biology
  • Full-length human SMYD3 isoform 1 (BAB86333) was inserted into a modified pET21 b plasmid containing a His6 tag and TEV and SUMO cleavage sites. Because two common variants of SMYD3 exist in the population, site directed mutagenesis was subsequently performed to change amino acid 13 from an asparagine to a lysine, resulting in plasmid pEPZ533. A lysine at position 13 conforms to the more commonly occurring sequence (NP_001161212).
    • Protein Expression
  • E. coli (BL21 codonplus RIL strain, Stratagene) were transformed with plasmid pEPZ553 by mixing competent cells and plasmid DNA and incubating on ice for 30 minutes followed by heat shock at 42° C. for 1 minute and cooling on ice for 2 minutes. Transformed cells were grown and selected on LB agar with 100 μg/mL ampicillin and 17 μg/mL chloramphenicol at 37° C. overnight. A single clone was used to inoculate 200 mL of LB medium with 100 g/mL ampicillin and 17 μg/mL chloramphenicol and incubated at 37° C. on an orbital shaker at 180 rpm. Once in log growth, the culture was diluted 1:100 into 2 L of LB medium and grown until OD600 was about 0.3 after which the culture was incubated at 15° C. and 160 rpm. Once OD600 reached about 0.4, IPTG was added to a final concentration of 0.1 mM and the cells were grown overnight at 15° C. and 160 rpm. Cells were harvested by centrifugation at 8000 rpm, for 4 minutes at 4° C. and stored at −80° C. for purification.
    • Protein Purification
  • Expressed full-length human His-tagged SMYD3 protein was purified from cell paste by Nickel affinity chromatography after equilibration of the resin with Buffer A (25 mM Tris, 200 mM NaCl, 5% glycerol, 5 mM β-mercaptoethanol, pH7.8). The column was washed with Buffer B (Buffer A plus 20 mM imidazole) and His-tagged SMYD3 was eluted with Buffer C (Buffer A plus 300 mM imidazole). The His tag, TEV and SUMO cleavage sites were removed generating native SMYD3 by addition of ULP1 protein at a ratio of 1:200 (ULP1:SMYD3). Imidazole was removed by dialysis overnight in Buffer A. The dialyzed solution was applied to a second Nickel column and the native SMYD3 protein was collected from the column flow-through. The flow-through was dialyzed in Buffer D (25 mM Tris, 5% glycerol, 5 mM β-mercaptoethanol, 50 mM NaCl, pH7.8) and ULP1 was removed using a Q sepharose fast flow column. SMYD3 was eluted in Buffer A and further purified using an S200 size-exclusion column equilibrated with Buffer A. SMYD3 was concentrated to 2 mg/mL with a final purity of 89%.
    • Predicted Translation:
  • SMYD3 (Q9H7B4)
    (SEQ ID No. 2).
    MEPLKVEKFATAKRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCD
    RCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPD
    SVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMT
    FQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPS
    ISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERR
    KQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHW
    KWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFY
    GTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIM
    RVTHGREHSLIEDLILLLEECDANIRAS.
    • General Procedure for SMYD3 Enzyme Assays on MEKK2 Protein Substrate
  • The assays were all performed in a buffer consisting of 25 mM Tris-Cl pH 8.0, 1 mM TCEP, 0.005% BSG, and 0.005% Tween 20, prepared on the day of use. Compounds in 100% DMSO (1 ul) were spotted into a 384-well white opaque OptiPlate using a Bravo automated liquid handling platform outfitted with a 384-channel head (Agilent Technologies). DMSO (1 ul) was added to Columns 11, 12, 23, 24, rows A-H for the maximum signal control and 1 ul of SAH, a known product and inhibitor of SMYD3, was added to columns 11, 12, 23, 24, rows I-P for the minimum signal control. A cocktail (40 ul) containing the SMYD3 enzyme was added by Multidrop Combi (Thermo-Fisher). The compounds were allowed to incubate with SMYD3 for 30 min at room temperature, then a cocktail (10 ul) containing SAM and MEKK2 was added to initiate the reaction (final volume=51 ul). The final concentrations of the components were as follows: SMYD3 was 0.4 nM, 3H-SAM was 8 nM, MEKK2 was 12 nM. SAH in the minimum signal control wells was 1 mM, and the DMSO concentration was 2%. The assays were stopped by the addition of non-radiolabeled SAM (10 ul) to a final concentration of 100 uM, which dilutes the 3H-SAM to a level where its incorporation into MEKK2 is no longer detectable. Radiolabeled MEKK2 was detected using a scintillation proximity assay (SPA). 10 uL of a 10 mg/mL solution of SPA beads in 0.5 M citric acid was added and the plates centrifuged at 600 rpm for 1 min to precipitate the radiolabeled MEKK2 onto the SPA beads. The plates were then read in a PerkinElmer TopCount plate reader to measure the quantity of 3H-labeled MEKK2 as disintegrations per minute (dpm) or alternatively, referred to as counts per minute (cpm).
    • % Inhibition Calculation
  • % inh = 100 - ( dpm cmpd - dpm m i n dpm ma x - dpm m i n ) × 100
  • Where dpm=disintegrations per minute, cmpd=signal in assay well, and min and max are the respective minimum and maximum signal controls.
    • Four-Parameter IC50 Fit
  • Y = Bottom + ( Top - Bottom ) ( 1 + ( X IC 50 ) Hill Coefficient
  • Where top and bottom are the normally allowed to float, but may be fixed at 100 or 0 respectively in a 3-parameter fit. The Hill Coefficient normally allowed to float but may also be fixed at 1 in a 3-parameter fit. Y is the % inhibition and X is the compound concentration.
  • SMYD3 biochemical assay data for representative Compounds of the Disclosure are presented in Table 1 in the column titled “SMYD3 Biochem IC50 (μM).”
    • Example 20 SMYD3 Cell Assay Trimethyl-MEKK2-in-Cell Western Assay
  • 293T/17 adherent cells were purchased from ATCC (American Type Culture Collection), Manassas, Va., USA. MEM/Glutamax medium, Optimem Reduced Serum medium, penicillin-streptomycin, 0.05% trypsin and 1×D-PBS were purchased from Life Technologies, Grand Island, N.Y., USA. PBS-10X was purchased from Ambion, Life Technologies, Grand Island. N.Y., USA. PBS with Tween 20 (PBST (10×)) was purchased from KPL, Gaithersburg, Md., USA. Tet System FBS— approved FBS US Source was purchased from Clontech. Mountain View, Calif., USA. Odyssey blocking buffer, 800CW goat anti-rabbit IgG (H+L) antibody, 680CW Goat anti-mouse IgG (H+L) and Licor Odyssey infrared scanner were purchased from Licor Biosciences. Lincoln, Nebr., USA. Tri-methyl-Lysine [A260]-MEKK2 antibody, MEKK2 and SMYD3 plasmids were made at Epizyne. Anti-flag monoclonal mouse antibody was purchased from Sigma, St. Louis, Mo., USA. Methanol was purchased from VWR. Franklin, Mass., USA. 10% Tween 20 was purchased from KPL, Inc., Gaithersburg, Md. USA. Fugene was purchased from Promega, Madison, Wis., USA. The Biotek ELx405 was purchased from BioTek, Winooski, Vt., USA. The multidrop combi was purchased from Thermo Scientific, Waltham, Mass., USA.
  • 293T/17 adherent cells were maintained in growth medium (MEM/Glutamax medium supplemented with 10% v/v Tet System FBS and cultured at 37° C. under 5% CO2.
  • Cell treatment, In Cell Western (ICW) for detection of trimethyl-lysine-MEKK2 and MEKK2.
  • 293T/17 cells were seeded in assay medium at a concentration of 33,333 cells per cm2 in 30 mL medium per T150 flask and incubated at 37° C. under 5% CO2. Plasmids were prepared for delivery to cells by first mixing 1350 μL Opti-MEM with Fugene (81 μL) in a sterile Eppendorf and incubated for five minutes at room temperature (RT). MEKK2-flag (13.6 ug/T150) MEKK2 p3XFlag-CMV-14 with C-3XFlag and SMYD3 (0.151 ug/T150) SMYD3 p3XFlag-CMV-14 without C-3XFlag plasmids were aliquotted to a 1.7 mL sterile microfuge tube. The gene ID for MEKK2 and SMYD3 is NM_006609.3 and Q9H7B4, respectively. Entire volume of Opti-MEM/Fugene mixture was then added to a microfuge tube containing DNA plasmid, mixed and then incubated×15 minutes at RT. The medium on the 293T/17 cells was refreshed, and the DNA/Fugene complex is added aseptically to each flask, rocked gently, and incubated at 37 C for 5 hours. Medium was then removed, and cells were washed once with PBS in the flask. Trypsin 0.05% (3 mL) was added and cells incubated for three minutes. Room temperature MEM+10% Tet system FBS was added and cells were mixed gently, and counted using the Vi-cell. Cells were seeded at 100,000 cells/mL in 50 μL MEM/10% Tet FBS/Pen/Strep to a 384 well black/clear poly-D-lysine coated plate containing test agent diluted in DMSO. The final top concentration of test compound was 40 μM. The total concentration of DMSO did not exceed 0.2% (v/v). Plates were incubated×30 minutes at RT in low-airflow area, followed by incubation at 37° C. under 5% CO2 for 24 hours. Medium was aspirated from all wells of assay plates prior to fixation and permeabilization with ice cold (−20° C.) methanol (90 μL/well) for ten minutes. Plates were rinsed with PBS three times on BioTek ELx405. PBS was removed with a final aspiration, and Odyssey blocking buffer (50 μL/well) was added to each well and incubated for one hour at RT. Primary antibody solution was prepared (anti-trimethyl-MEKK2 at 1:600 dilution plus mouse anti-flag antibody at 1:10,000 dilution in diluent (Odyssey Blocking buffer+0.1% Tween 20)) and 20 μL per well was dispensed using the Multidrop Combi. Assay plates were then sealed with foil, and incubated overnight at 4° C. Plates were washed five times with PBS-Tween (1X) on Biotek ELx405 and blotted on paper towel to remove excess reagent. Detection antibody solution (IRDye 800 CW goat anti-rabbit IgG diluted 1:400 in diluent (Odyssey Blocking buffer+0.1% Tween 20), plus IRDye 680CW goat anti-mouse IgG at 1:500 in diluent (Odyssey Blocking buffer+0.1% Tween 20) was added (20 μL/well) and incubated in dark for one hour at RT. Plates were then washed four times with PBS-T (1X) on ELx405. A final rinse with water was performed (115 μL/well×three washes on the ELx405). Plates were then centrifuged upside down, on paper towel, at 200×g to remove excess reagent. Plates were left to dry in dark for one hour. The Odyssey Imager was used to measure the integrated intensity of 700 and 800 wavelengths at resolution of 84 μm, medium quality, focus offset 4.0, 700 channel intensity=3.5 to measure the MEKK2-flag signal, 800 channel intensity=5 to measure the Trimethyl-MEKK2 signal of each well.
    • Calculations:
  • First, the ratio for each well was determined by:
  • ( Trimethyl MEKK 2 800 nm value flag tagged MEKK 2 700 nm value )
  • Each plate included fourteen control wells of DMSO only treatment (Minimum Inhibition) as well as fourteen control wells for maximum inhibition (Background). The average of the ratio values for each control type was calculated and used to determine the percent inhibition for each test well in the plate. Reference compound was serially diluted two-fold in DMSO for a total of nine test concentrations, beginning at 40 μM. Percent inhibition was calculated (below).
  • Percent Inhibition = 100 - ( ( ( individual Test Sample Ratio ) - ( Background Avg Ratio ) ( Minimum inhibition Ratio ) ( Background Average Ratio ) ) * 100 )
  • Non-linear regression curves were generated to calculate the IC50 and dose-response relationship using triplicate wells per concentration of compound.
  • SMYD3 cell assay data for representative Compounds of the Disclosure are presented in Table 1 in the column titled “SMYD3 Cell IC50 (μM).”
    • Example 21 SMYD2 Biochemical Assay General Materials
  • S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), bicine, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin (BSG), and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Sigma-Aldrich at the highest level of purity possible. 3H-SAM was purchase from American Radiolabeled Chemicals with a specific activity of 80 Ci/mmol. 384-well streptavidin Flashplates were purchased from PerkinElmer.
    • Substrates
  • Peptide was synthesized with a N-terminal linker-affinity tag motif and a C-terminal amide cap by 21st Century Biochemicals. The peptide was high high-performance liquid chromatography (HPLC) purified to greater than 95% purity and confirmed by liquid chromatography mass spectrometry (LC-MS). The sequence was ARTKQTARKSTGGKAPRKQLATKAARKSA(K-Biot)-amide. (SEQ ID No: 3)
    • Production of Recombinant SMYD2 Enzymes for Biochemical Enzyme Activity Assays
  • Full length SMYD2 (NP_064582.2) was cloned into a pFastbac-Htb-lic vector with an N-terminal His6 tag and FLAG tag, preceded by a TEV protease cleavage site. The protein was expressed in Sf9 insect cells. Cells were resuspended in lysis buffer (25 mM HEPES-NaOH, pH 7.5, 200 mM NaCl, 5% glycerol, and 5 mM β-ME) and lysed by sonication. The protein was purified by Ni-NTA (Qiagen), followed by TEV cleavage to remove the His6 tag, subtractive Ni-NTA (Qiagen), and gel filtration chromatography using an S200 column (GE Healthcare). Purified protein was stored in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. and 1 mM TCEP.
    • General Procedure for SMYD2 Enzyme Assays on Peptide Substrates
  • The assays were all performed in a buffer consisting of 20 mM Bicine (pH=7.6), 1 mM TCEP, 0.005% Bovine Skin Gelatin, and 0.002% Tween20, prepared on the day of use. Compounds in 100% DMSO (1 ul) were spotted into a polypropylene 384-well V-bottom plates (Greiner) using a Platemate Plus outfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) was added to Columns 11, 12, 23, 24, rows A-H for the maximum signal control and 1 ul of SAH, a known product and inhibitor of SMYD2, was added to columns 11, 12, 23, 24, rows I-P for the minimum signal control. A cocktail (40 ul) containing the SMYD2 enzyme was added by Multidrop Combi (Thermo-Fisher). The compounds were allowed to incubate with SMYD2 for 30 min at room temperature, then a cocktail (10 ul) containing 3H-SAM and peptide was added to initiate the reaction (final volume=51 ul). The final concentrations of the components were as follows: SMYD2 was 1.5 nM, 3H-SAM was 10 nM, and peptide was 60 nM, SAH in the minimum signal control wells was 1000 uM, and the DMSO concentration was 2%. The assays were stopped by the addition of non-radioactive SAM (10 ul) to a final concentration of 600 uM, which dilutes the 3H-SAM to a level where its incorporation into the peptide substrate is no longer detectable. 50 ul of the reaction in the 384-well polypropylene plate was then transferred to a 384-well Flashplate and the biotinylated peptides were allowed to bind to the streptavidin surface for at least 1 hour before being washed three times with 0.1% Tween20 in a Biotek ELx405 plate washer. The plates were then read in a PerkinElmer TopCount plate reader to measure the quantity of 3H-labeled peptide bound to the Flashplate surface, measured as disintegrations per minute (dpm) or alternatively, referred to as counts per minute (cpm).
    • % Inhibition Calculation
  • % inh = 100 - ( dpm ? - dpm ? dpm ? - dpm m i n ) × 100 ? indicates text missing or illegible when filed
  • Where dpm=disintegrations per minute, cmpd=signal in assay well, and min and max are the respective minimum and maximum signal controls.
    • Four-Parameter IC50 Fit
  • % inhibition = Bottom + Top - Bottom ( 1 + ( IC 50 / [ I ] ) Hill coefficient )
  • Where top and bottom are the normally allowed to float, but may be fixed at 100 or 0 respectively in a 3-parameter fit. The Hill Coefficient normally allowed to float but may also be fixed at 1 in a 3-parameter fit. I is the compound concentration.
  • SMYD2 biochemical assay data for representative Compounds of the Disclosure are presented in Tables 2 and 3 in the column titled “SMYD2 Biochem IC50 (μM).”
  • Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof.
  • Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
  • All patents and publications cited herein are fully incorporated by reference herein in their entirety.

Claims (27)

1. A compound having Formula I:
Figure US20200148650A1-20200514-C00554
or a pharmaceutically acceptable salt or hydrate thereof,
wherein:
R1 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-4 alkenyl, C1-4 haloalkyl, C3-6 cycloalkyl, and hydroxyalkyl;
R2 is selected from the group consisting of hydrogen, halo, and carboxamido;
A is selected from the group consisting of C1-10 alkylenyl, (cycloalkylenyl)alkyl, optionally substituted C3-12 cycloalkylenyl, optionally substituted C6-14 arylenyl, optionally substituted 5- to 14-membered heteroarylenyl, and —C(H)R3R4;
with the provisos:
a) when R1 is ethyl or cyclopropyl; R2 is hydrogen; and X is —N(R7)S(═O)2—N(R7)C(═O)—, or —N(R7)C(═O)C(R8)(H)—, then A is not optionally substituted 1,4-cyclohexylenyl; and
b) when R1 is ethyl or cyclopropyl; R2 is hydrogen; X is absent; and Z is amino, alkylamino, dialkylamino, or heterocycloamino, then A is not optionally substituted 1,4-cyclohexylenyl;
R3 is selected from the group consisting of hydrogen, C1-6 alkyl, (hydroxy)(aryl)alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, optionally substituted C3-12 cycloalkyl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted C6-14 aryl, aralkyl, alkoxycarbonyl, and —C(═O)N(R5)(R6);
R4 is selected from the group consisting of C1-6 alkyl, hydroxyalkyl, optionally substituted C3-12 cycloalkyl, optionally substituted C6-14 aryl, optionally substituted 5- to 14-membered heteroaryl, optionally substituted 4- to 14-membered heterocyclo, and (heteroaryl)alkyl;
R5 is selected from the from the group consisting of hydrogen and C1-4 alkyl;
R6 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, fluoroalkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(carboxamido)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl, (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —N(R7)S(═O)2—,—S(═O)2C(R8)(H)—, —C(═O)—, —C(═O)N(R7)—, —N(R7)C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)C(R8)(H)N(R7)—, —N(R7)C(═O)C(R8)(H)—, —C(R8)(H)C(═O)N(R7)—, —C(R8)(H)N(R7)C(═O)—, and —C(═O)C(R8)(H)—; or X is absent;
Z is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, fluoroalkyl, hydroxyalkyl, amino, alkylamino, dialkylamino, heterocycloamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (cycloalkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, (amino)(aryl)alkyl, (amino)(heteroaryl)alkyl (hydroxy)(aryl)alkyl, (aralkylamino)alkyl, (hydroxyalkylamino)alkyl, alkoxyalkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
wherein —X—Z is attached to any available carbon or nitrogen atom of A, R3, R4, or R6;
R7 is selected from the group consisting of hydrogen and C1-4 alkyl; and
R8 is selected from the group consisting of hydrogen, C1-4 alkyl, hydroxy, amino, alkylamino, dialkylamino, cycloalkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and hydroxyalkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein A is C1-10 alkylenyl.
3. The compound of claim 2, or a pharmaceutically acceptable salt or hydrate thereof, having Formula II:
Figure US20200148650A1-20200514-C00555
wherein:
R9a and R9b are independently selected from the group consisting of hydrogen and C1-4 alkyl;
R9c and R9d are independently selected from the group consisting of hydrogen and C1-4 alkyl; or
R9c and R9d taken together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
R9 is selected from the group consisting of hydrogen and C1-4 alkyl;
m is 0 or 1;
X is selected from the group consisting of —N(R7)C(═O)—, —N(R7)C(═O)C(R8)(H)—, and —N(R7)S(═O)2—;
R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
Z is selected from the group consisting of C1-6 alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, optionally substituted 4- to 14-membered heterocyclo, and optionally substituted C3-12 cycloalkyl.
4. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein A is optionally substituted C6-14 arylenyl.
5. The compound of claim 4, or a pharmaceutically acceptable salt or hydrate thereof, having Formula III:
Figure US20200148650A1-20200514-C00556
wherein:
R10a is selected from the group consisting of hydrogen, halo, C1-6 alkyl, alkoxy, hydroxyalkyl, and alkoxycarbonyl;
X is selected from the group consisting of —C(═O)N(R7)—, —N(R7)C(═O)—, —C(═O)C(R8)(H)N(R7)—, —C(R8)(H)C(═O)N(R7)— and —S(═O)2N(R7)—; or X is absent;
R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
Z is selected from the group consisting of hydrogen, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, heteroalkyl, (amino)(hydroxy)alkyl, (heterocyclo)alkyl, optionally substituted C3-12 cycloalkyl, and optionally substituted 4- to 14-membered heterocyclo.
6. The compound of claim 5, or a pharmaceutically acceptable salt or hydrate thereof, having Formula IV:
Figure US20200148650A1-20200514-C00557
7. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein A is optionally substituted C3-12 cycloalkylenyl.
8. The compound of claim 7, or a pharmaceutically acceptable salt or hydrate thereof, having Formula V:
Figure US20200148650A1-20200514-C00558
wherein:
R10a and R10b are independently selected from the group consisting of hydrogen and C1-4 alkyl;
X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —N(R7)C(═O)—, —C(═O)N(R7)—, —N(R7)S(═O)—, and —OC(═O)—; or X is absent;
Z is selected from the group consisting of amino, alkylamino, dialkylamino, heterocycloamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, and (hydroxyalkylamino)alkyl;
n is 0 or 1; and
p is 0 or 1.
9. (canceled)
10. (canceled)
11. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein A is —C(H)R3R4.
12-14. (canceled)
15. The compound of claim 11, or a pharmaceutically acceptable salt or hydrate thereof, having Formula VII, Formula VIII, or Formula IX:
Figure US20200148650A1-20200514-C00559
wherein:
R3 is selected from the group consisting of hydrogen, C1-4 alkyl, hydroxyalkyl, alkoxyalkyl, optionally substituted C6-14 aryl, aryloxyalkyl, and aralkyl
X is selected from the group consisting of —S(═O)2—, —S(═O)2N(R7)—, —S(═O)2C(R8)(H)—, —C(═O)—, —C(═O)N(R7)—, —C(═O)O—, —OC(═O)—, and —C(═O)C(R8)(H)—; or X is absent;
R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino; and
Z is selected from the group consisting of C1-6 alkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, hydroxyalkyl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl.
16. (canceled)
17. The compound of claim 11, or a pharmaceutically acceptable salt or hydrate thereof, having Formula X, Formula XI, or Formula XII:
Figure US20200148650A1-20200514-C00560
wherein R12 is selected from the group consisting of hydrogen, halo, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, hydroxyalkyl, (aralkyloxy)alkyl, alkoxyalkyl, heteroalkyl, (hydroxyalkylamino)alkyl, (heterocycloamino)alkyl, and carboxamido.
18. The compound of claim 17, or a pharmaceutically acceptable salt or hydrate thereof, wherein:
X is selected from the group consisting of —C(═O)N(R7)— and —S(═O)2N(R7)—;
Z is optionally substituted C1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl; and
R12 is hydrogen.
19. (canceled)
20. The compound of claim 11, or a pharmaceutically acceptable salt or hydrate thereof, having Formula XIII, Formula XIV, or Formula XV:
Figure US20200148650A1-20200514-C00561
wherein:
R6 is selected from the group consisting of optionally substituted C1-6 alkyl, hydroxyalkyl, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (heterocyclo)alkyl, (cycloalkyl)alkyl, (amino)(hydroxy)alkyl, optionally substituted C6-14 aryl, optionally substituted 4- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, optionally substituted C3-12 cycloalkyl, aralkyl, and (heteroaryl)alkyl;
X is selected from the group consisting of —C(═O)N(R7)—, —C(═O)C(R8)(H)—, and —S(═O)2N(R7)—; or
X is absent;
R8 is selected from the group consisting of C1-4 alkyl, amino, alkylamino, and dialkylamino;
Z is selected from the group consisting of C1-4 alkyl, amino, alkylamino, dialkylamino, (amino)alkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (amino)(heteroaryl)alkyl, and (amino)(hydroxy)alkyl.
21-24. (canceled)
25. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from the group consisting of C1-4 alkyl and C3-6 cycloalkyl.
26. The compound of claim 25, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is cyclopropyl.
27. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, selected from the group consisting of:
Figure US20200148650A1-20200514-C00562
Figure US20200148650A1-20200514-C00563
Figure US20200148650A1-20200514-C00564
Figure US20200148650A1-20200514-C00565
Figure US20200148650A1-20200514-C00566
Figure US20200148650A1-20200514-C00567
Figure US20200148650A1-20200514-C00568
Figure US20200148650A1-20200514-C00569
Figure US20200148650A1-20200514-C00570
Figure US20200148650A1-20200514-C00571
Figure US20200148650A1-20200514-C00572
Figure US20200148650A1-20200514-C00573
Figure US20200148650A1-20200514-C00574
Figure US20200148650A1-20200514-C00575
Figure US20200148650A1-20200514-C00576
Figure US20200148650A1-20200514-C00577
Figure US20200148650A1-20200514-C00578
Figure US20200148650A1-20200514-C00579
Figure US20200148650A1-20200514-C00580
Figure US20200148650A1-20200514-C00581
Figure US20200148650A1-20200514-C00582
Figure US20200148650A1-20200514-C00583
Figure US20200148650A1-20200514-C00584
Figure US20200148650A1-20200514-C00585
Figure US20200148650A1-20200514-C00586
Figure US20200148650A1-20200514-C00587
Figure US20200148650A1-20200514-C00588
Figure US20200148650A1-20200514-C00589
Figure US20200148650A1-20200514-C00590
Figure US20200148650A1-20200514-C00591
Figure US20200148650A1-20200514-C00592
Figure US20200148650A1-20200514-C00593
Figure US20200148650A1-20200514-C00594
Figure US20200148650A1-20200514-C00595
Figure US20200148650A1-20200514-C00596
Figure US20200148650A1-20200514-C00597
Figure US20200148650A1-20200514-C00598
Figure US20200148650A1-20200514-C00599
Figure US20200148650A1-20200514-C00600
Figure US20200148650A1-20200514-C00601
Figure US20200148650A1-20200514-C00602
Figure US20200148650A1-20200514-C00603
Figure US20200148650A1-20200514-C00604
Figure US20200148650A1-20200514-C00605
Figure US20200148650A1-20200514-C00606
Figure US20200148650A1-20200514-C00607
Figure US20200148650A1-20200514-C00608
Figure US20200148650A1-20200514-C00609
Figure US20200148650A1-20200514-C00610
Figure US20200148650A1-20200514-C00611
Figure US20200148650A1-20200514-C00612
Figure US20200148650A1-20200514-C00613
Figure US20200148650A1-20200514-C00614
Figure US20200148650A1-20200514-C00615
Figure US20200148650A1-20200514-C00616
Figure US20200148650A1-20200514-C00617
Figure US20200148650A1-20200514-C00618
Figure US20200148650A1-20200514-C00619
Figure US20200148650A1-20200514-C00620
Figure US20200148650A1-20200514-C00621
Figure US20200148650A1-20200514-C00622
Figure US20200148650A1-20200514-C00623
Figure US20200148650A1-20200514-C00624
Figure US20200148650A1-20200514-C00625
Figure US20200148650A1-20200514-C00626
Figure US20200148650A1-20200514-C00627
Figure US20200148650A1-20200514-C00628
Figure US20200148650A1-20200514-C00629
Figure US20200148650A1-20200514-C00630
28. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
29. A method of treating a patient comprising administering to the patient a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, wherein the patient has cancer.
30. The method of claim 29, wherein the cancer is selected from the group consisting of adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentigious melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogeous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, preimary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma periotonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor.
31-38. (canceled)
39. A method of treating a SMYD protein mediated disorder comprising administering to a subject in need thereof a compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof in an effective amount to treat the SMYD protein mediated disorder.
US16/588,209 2014-09-10 2019-09-30 Isoxazole carboxamide compounds Abandoned US20200148650A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/588,209 US20200148650A1 (en) 2014-09-10 2019-09-30 Isoxazole carboxamide compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US201562146794P 2015-04-13 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds
US201715510593A 2017-03-10 2017-03-10
US16/588,209 US20200148650A1 (en) 2014-09-10 2019-09-30 Isoxazole carboxamide compounds

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/049213 Division WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds
US15/510,593 Division US10428029B2 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (1)

Publication Number Publication Date
US20200148650A1 true US20200148650A1 (en) 2020-05-14

Family

ID=55459522

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/510,593 Active US10428029B2 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds
US16/588,209 Abandoned US20200148650A1 (en) 2014-09-10 2019-09-30 Isoxazole carboxamide compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/510,593 Active US10428029B2 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Country Status (6)

Country Link
US (2) US10428029B2 (en)
EP (1) EP3193603A4 (en)
JP (1) JP2017526706A (en)
AU (1) AU2015315167A1 (en)
CA (1) CA2960274A1 (en)
WO (1) WO2016040498A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
MX2017002985A (en) 2014-09-10 2017-11-17 Epizyme Inc Smyd inhibitors.
EP3193605A4 (en) * 2014-09-10 2018-04-18 Epizyme, Inc. Substituted piperidine compounds
CN107708420B (en) 2015-06-17 2020-05-01 住友化学株式会社 Reagents for controlling harmful arthropods
KR20210066848A (en) * 2018-09-21 2021-06-07 노파르티스 아게 Isoxazole carboxamide compounds and uses thereof
CN109879868B (en) * 2019-03-07 2022-04-22 南通大学 Preparation and Application of Pyrazole Amide Compounds Containing 2-Aryloxazole Structure

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (en) * 1999-06-30 2001-01-04 Bayer Ag New amino and amidosulfonamides as antiviral agents
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
JP2004537526A (en) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド NR2B receptor antagonist for treatment or prevention of migraine
DE10306250A1 (en) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006067446A1 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (en) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine derivatives.
WO2008040149A1 (en) 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
EP2183241B1 (en) 2007-05-03 2012-12-19 Pfizer Limited 2-pyridine carboxamide derivatives as sodium channel modulators
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
AU2011210116B2 (en) * 2010-01-29 2014-02-06 Catholic University Industry Academic Cooperation Foundation Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
US20130072470A1 (en) * 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
EP3868541A1 (en) * 2012-12-18 2021-08-25 Alcyone Lifesciences, Inc. Micro-molding device and system for making a catheter for reducing or preventing backflow in a delivery system
CN105228616B (en) * 2013-03-15 2019-05-03 实发生物医学公司 Anti-proprotein convertase subtilisin Kexin type 9 (anti-PCSK9) compounds and methods for their use in the treatment and/or prevention of cardiovascular disease
EP3193604B1 (en) * 2014-09-10 2021-06-16 Epizyme, Inc. Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds
MX2017002985A (en) 2014-09-10 2017-11-17 Epizyme Inc Smyd inhibitors.
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3193605A4 (en) 2014-09-10 2018-04-18 Epizyme, Inc. Substituted piperidine compounds

Also Published As

Publication number Publication date
WO2016040498A1 (en) 2016-03-17
EP3193603A4 (en) 2018-02-28
AU2015315167A1 (en) 2017-03-16
US10428029B2 (en) 2019-10-01
JP2017526706A (en) 2017-09-14
EP3193603A1 (en) 2017-07-26
US20170190676A1 (en) 2017-07-06
CA2960274A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US10266526B2 (en) Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
US10428029B2 (en) Isoxazole carboxamide compounds
EP3193604B1 (en) Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds
US10577363B2 (en) Substituted piperidine compounds
US10669243B2 (en) Isoxazole carboxamides as irreversible SMYD inhibitors
US20200048195A1 (en) Substituted pyrrolidine carboxamide compounds
US10106510B2 (en) Substituted isoxazoles for treating cancer
US20200123142A1 (en) Substituted Cyclohexylamine Compounds

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: EPIZYME, INC., MASSACHUSETTS

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848;ASSIGNOR:BIOPHARMA CREDIT PLC;REEL/FRAME:061165/0501

Effective date: 20220812